KOL | Charles L LoprinziMayo Clinic, Rochester, MN; | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA;, cloprinzi@mayo.edu | Department of Oncology, Mayo Clinic, Rochester, MN ... |
KOL简历 Charles L Loprinzi
| Year | |
|---|---|
| 2022 | Mayo Clinic, Rochester, MN; |
| 2021 | Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Mayo Clinic, Rochester, MN, USA |
| 2020 | Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, United States of America Division of Medical Oncology, Mayo Clinic, Rochester, USA North Central Cancer Treatment Group, Mayo Clinic, Rochester, Minnesota Mayo Clinic, Rochester, MN, United States. |
| 2019 | Department of Oncology; Mayo Clinic; Rochester, Minnesota Mayo Clinic Rochester, Florida, USA Medical Oncology |
| 2018 | Department of Medical Oncology, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA Division of Medical Oncology, Mayo Clinic, Rochester, MN |
| 2017 | Division of Medical Oncology, Mayo Clinic, Rochester, MN. Timothy Gilligan, Cleveland Clinic, Cleveland, OH ; Nessa Coyle, Memorial Sloan Kettering Cancer Center, New York; Ronald M. Epstein, University of Rochester School of Medicine, Rochester, NY; Richard M. Frankel, Regenstrief Institute, Indiana University School of Medicine, Indianapolis, IN; Donna L. Berry and Christopher S. Lathan, Dana-Farber Cancer Institute, Harvard Medical School; Vicki A. Jackson, Massachusetts General Hospital, Harvard Medical School, Boston; Carole Seigel, Patient/Advocacy Representative, Brookline, MA; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Esme Finlay, University of New Mexico School of Medicine, Albuquerque, NM; Charles L. Loprinzi, Mayo Clinic, Rochester, MN; and Lynne H. Nguyen and Walter F. Baile, The University of Texas MD Anderson Cancer Center, Houston, TX. Mayo Clinic Minnesota Department of Oncology Rochester Minnesota The Cancer Center |
| 2016 | Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN Mayo Clinic Cancer Center, Rochester, Minnesota |
| 2015 | Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA Mayo Clinic Division of Medical Oncology Rochester Minnesota |
| 2014 | Mayo Clinic Cancer Center Rochester MN |
| 2013 | From the Department of Oncology and Cancer Center Statistics, Mayo Clinic, Rochester, MN. Mayo Clinic Rochester, 200 First Street, SW, 55905, Rochester, MN, USA |
| 2012 | Department of Oncology, Mayo Clinic, 55905, Rochester, MN, USA Mayo Clinic, Rochester, MN, United States |
Charles L Loprinzi：影响统计
运行报告
| Concept | World rank |
|---|---|
| suggestion toxicity | #1 |
| agents cipn | #1 |
| patientreported outcomes balance | #1 |
| antineoplastic agents nrs | #1 |
| attribution percentage | #1 |
| reducing hot | #1 |
| tingling numbness | #1 |
| 2 study arms | #1 |
| methylphenidate cancer patients | #1 |
| placebo 15 glutathione | #1 |
| ulabtka | #1 |
| gabapentin arm | #1 |
| breakthrough nausea patients | #1 |
| gabapentin hot flashes | #1 |
| safety oestrogen | #1 |
| chemotherapy regimen type | #1 |
| data clinical histories | #1 |
| flashes androgen | #1 |
| paclitaxel weekly cryotherapy | #1 |
| hot flash data | #1 |
| residual hot flashes | #1 |
| 137 patients cycle | #1 |
| subsequent chemotherapy cycles | #1 |
| placebo oral mucositis | #1 |
| recommendation prevention | #1 |
| a151408 | #1 |
| judicious tpn | #1 |
| lymphedema hrqol outcomes | #1 |
| women megestrol acetate | #1 |
| paclitaxel acute | #1 |
| 8week observation period | #1 |
| recurrences clinical histories | #1 |
| life study arms | #1 |
| supportive cryotherapy | #1 |
| nonfluid weight | #1 |
| isaes | #1 |
| routine feces sensitivity | #1 |
| oral cryotherapy prevention | #1 |
| complete response authors | #1 |
| longitudinal continuation | #1 |
| cipn20 | #1 |
| tpn longterm survival | #1 |
| randomized study lymphedema | #1 |
| n01c9 | #1 |
| therapeutic targets cipn | #1 |
| flashes prostate | #1 |
| oral cryotherapy | #1 |
| rose geranium | #1 |
| chamomile mouthwash | #1 |
| shooting burning | #1 |
| burden alopecia | #1 |
| antibiotic lozenge placebo | #1 |
| relatedness treatment | #1 |
| accru trial | #1 |
| nonestrogenic management | #1 |
| prestudy hypothesis | #1 |
| dmc mutations | #1 |
| cipn data | #1 |
| preliminary promising data | #1 |
| prtmethodsdata | #1 |
| active nonhormonal | #1 |
| toxicity gabapentin | #1 |
| 5 methylphenidate | #1 |
| adjuvant numeracy calculators | #1 |
| compliance institutional guidelines | #1 |
| hormonal ablation andropause | #1 |
| dronabinol combination | #1 |
| estimated benefit dfs | #1 |
| understanding potential benefits | #1 |
| chemotherapy response rates | #1 |
| cipn adult | #1 |
| n06ca | #1 |
| paclitaxel favor | #1 |
| individuals impaired balance | #1 |
| antibiotic lozenge | #1 |
| hormone deprivation | #1 |
| arthralgia breast life | #1 |
| fluoxetine hot | #1 |
| oral cryotherapy management | #1 |
| mouthwash placebo | #1 |
| megestrol acetate nausea | #1 |
| eortc qlqcipn20 instrument | #1 |
| male megestrol megestrol | #1 |
| preceding 2 months | #1 |
| institutional guidelines patients | #1 |
| placebo anecdotal observations | #1 |
| ulabtka hfs | #1 |
| based chemotherapy isae | #1 |
| treatment hot flashes | #1 |
| cytotoxic chemotherapy supportive | #1 |
| testosterone improvements | #1 |
| 43 oral complications | #1 |
| nasal vestibulitis | #1 |
| numbness scores | #1 |
| phase iii evaluation | #1 |
| diphenhydraminelidocaineantacid | #1 |
| numeracy adjuvant | #1 |
| nonhormonal agent | #1 |
| acetate hot | #1 |
| anorexia antineoplastic agents | #1 |
| numbness tingling | #1 |
| qlq cipn20 | #1 |
| 5fuinduced stomatitis | #1 |
| reduction hot | #1 |
| symptoms feet | #1 |
| increased difficulty patients | #1 |
| acceptability ssc device | #1 |
| purposepaclitaxel | #1 |
| patient followup studies | #1 |
| patients 25 micrograms | #1 |
| placebo arm gabapentin | #1 |
| developed mucositis | #1 |
| cipn clinical trial | #1 |
| metastatic disease initiation | #1 |
| patients dfs predictions | #1 |
| phytotherapy vitamin | #1 |
| tpn female services | #1 |
| aps paclitaxel | #1 |
| vitamin cipn | #1 |
| oncology providers crci | #1 |
| flashes week | #1 |
| alliance study a221102 | #1 |
| study stool samples | #1 |
| prevention induced cipn | #1 |
| 2007 guidelines guideline | #1 |
| illness neuropathic symptoms | #1 |
| education lymphedema education | #1 |
| topic rectum surveys | #1 |
| women male megestrol | #1 |
| dmc assay | #1 |
| response relationship odc | #1 |
| sham acupuncture participants | #1 |
| supportive nsclc | #1 |
| subcutaneous testosterone improvements | #1 |
| agents antihypertensive agents | #1 |
| data hot | #1 |
| progestational agents patients | #1 |
| ganglion surveys humans | #1 |
| slight appetite stimulation | #1 |
| fourth treatment week | #1 |
| cachexia cyproheptadine | #1 |
| accru study | #1 |
| mascc isoo guidelines | #1 |
| prominent toxicity | #1 |
| cachexia studies | #1 |
| trial n00cb | #1 |
| oil nasal | #1 |
| toxicity agent | #1 |
| suggestion oral cryotherapy | #1 |
| n08cb alliance | #1 |
| antidepressant gabapentin | #1 |
| baseline prognosis | #1 |
| cyproheptadine appetite | #1 |
| baseline fsfi score | #1 |
| symptoms hormone deprivation | #1 |
| olanzapine arm emesis | #1 |
| 5 weeks device | #1 |
| survivors genitourinary syndrome | #1 |
| hec cisplatin therapy | #1 |
| daily hot | #1 |
| bridging editorial | #1 |
| dfs 5fu | #1 |
| eortc cipn20 | #1 |
| cachexia carcinoma life | #1 |
| antidepressants gabapentin | #1 |
| 1year survival trials | #1 |
| treatment symptom intervention | #1 |
| regional hypothermia burden | #1 |
| fsfi 95 | #1 |
| receiving fluorouracil | #1 |
| prevent oxaliplatin | #1 |
| weight loss investigation | #1 |
| cipn agents | #1 |
| time publication attitude | #1 |
| hot flashes treatment | #1 |
| deprivation symptoms | #1 |
| revisitation doc | #1 |
| flashes treatment | #1 |
| dfs predictions adjuvant | #1 |
| control hot flashes | #1 |
| dronabinol megestrol acetate | #1 |
| impaired postural control | #1 |
| patients highdose interferon | #1 |
| cipn methods | #1 |
| life qlqcipn20 | #1 |
| cancer hot | #1 |
| peripheral neuropathy paclitaxel | #1 |
| patients placebo pellet | #1 |
| alleviating hot | #1 |
| overview crci | #1 |
| patients cancer anorexia | #1 |
| nonhormonal | #1 |
| oncologists prognostic | #1 |
| items positive indication | #1 |
| current trial | #1 |
| backgrounddehydroepiandrosterone | #1 |
| agents cyclohexanecarboxylic | #1 |
| alliance n08ca | #1 |
| purpose hot | #1 |
| cipn nervous diseases | #1 |
| flaxseed bar lignans | #1 |
| myalgias arthralgias | #1 |
| newer antidepressants | #1 |
| 1 month appetite | #1 |
| hot flashes acceptability | #1 |
| week tamoxifen | #1 |
| trust oncologists competence | #1 |
| placebo 30 points | #1 |
| score baseline values | #1 |
| bellergal | #1 |
| aes relatedness | #1 |
| therapy numbness | #1 |
| cachexia trial | #1 |
| pilot evaluation | #1 |
| alopecia ocular toxicity | #1 |
| natural postural instability | #1 |
| head therapeutic equivalency | #1 |
| cipnsummarythere | #1 |
| peripheral neuropathy | #1 |
| patients 10 range | #1 |
| attribution clinical trials | #1 |
| overview oncology providers | #1 |
| − fsfi | #1 |
| underdescribers | #1 |
| association arhgef10 | #1 |
| oral mucositisrelated pain | #1 |
| management hot | #1 |
| neuronal uptake transporters | #1 |
| antiemetic prescribing | #1 |
| replacement testosterone andropause | #1 |
| neuropathy randomized | #1 |
| items uncertain gbu | #1 |
| 12 months anticoagulation | #1 |
| cachexia megestrol | #1 |
| patients ulabtka | #1 |
| outcomes study points | #1 |
| ncctg trial n06ca | #1 |
| dmc samples | #1 |
| cinv day | #1 |
| recommended colorectal | #1 |
| nonhormonal hot | #1 |
| neuropathy 20 | #1 |
| bakplo placebo | #1 |
| hot flash | #1 |
| stomatitis scores | #1 |
| motor subscales | #1 |
| aminobutyric acid hec | #1 |
| historical placebo response | #1 |
| middle aged minocycline | #1 |
| hot flashes day | #1 |
| megestrol acetate patients | #1 |
| compliance institutional guideline | #1 |
| postural instability chemotherapy | #1 |
| sensory neuropathy symptoms | #1 |
| cipnmethodspatients | #1 |
| lenolidamide | #1 |
| flashes stellate | #1 |
| treatment hot | #1 |
| arhgef10 cipn | #1 |
| treatment attribution | #1 |
| placebo drowsiness | #1 |
| oncologists competence | #1 |
| suggestion pregabalin | #1 |
| magnesium oxaliplatininduced neurotoxicity | #1 |
| cipn common | #1 |
| flash scores | #1 |
| taxane infusion | #1 |
| placebo 15 points | #1 |
| gene arhgef10 | #1 |
| therapy hot | #1 |
| hfs ulabtka | #1 |
| weeks hot flashes | #1 |
| suggested gabapentin | #1 |
| cipn trials | #1 |
| positive indication prognosis | #1 |
| burning pain | #1 |
| adt cyclohexanecarboxylic acids | #1 |
| ambulatory patients opioids | #1 |
| individuals cipn | #1 |
| nonfluid | #1 |
| study dmc assay | #1 |
| hormone deprivation cancer | #1 |
| nociceptors putative mechanism | #1 |
| ocular ice packs | #1 |
| life megestrol acetate | #1 |
| 20 data patients | #1 |
| humans ganglion surveys | #1 |
| acute pain syndrome | #1 |
| prominent clinical problem | #1 |
| n08ca association | #1 |
| creatine placebo groups | #1 |
| anorexia appetite | #1 |
| topical cannabinoids patients | #1 |
| bothersome hot | #1 |
| crc patients 95 | #1 |
| lymphedemafree rates groups | #1 |
| agents humans clinicians | #1 |
| flashes gabapentin | #1 |
| leap rom | #1 |
| bothersome hot flashes | #1 |
| weeks hot | #1 |
| cancers prevalence | #1 |
| numeracy benefit | #1 |
| acute symptoms cycle | #1 |
| rs17683288 | #1 |
| centrally active agent | #1 |
| joints syndrome | #1 |
| 22 nonestrogenic management | #1 |
| patientcompleted questionnaires | #1 |
| hot flash frequency | #1 |
| paclitaxel study arms | #1 |
| patientreported nasal symptoms | #1 |
| patients nasal vestibulitis | #1 |
| glutathione cipn | #1 |
| oral mucositis alopecia | #1 |
| oncologists competence 95ci | #1 |
| rs9657362 | #1 |
| ocular ice | #1 |
| difference cipn20 scores | #1 |
| underdescribing | #1 |
| cipn paps | #1 |
| nonhormonal agents treatment | #1 |
| ncctg n08c1 | #1 |
| acetate doses | #1 |
| disease patient factors | #1 |
| favor placebo | #1 |
| hot flash scores | #1 |
| nonfluid weight gain | #1 |
| anthracycline data | #1 |
| gait testing patients | #1 |
| evidence cipn | #1 |
| management genital symptoms | #1 |
| placebo pilot trials | #1 |
| udi scores baseline | #1 |
| n08ca patients | #1 |
| authors 115 patients | #1 |
| tingling | #1 |
| flashes common | #1 |
| acetate anorexia | #1 |
| pharmacological targeting oct2 | #1 |
| tpn initiation death | #1 |
| iii double | #1 |
| vte recurrence enoxaparin | #1 |
| altered sensory organization | #1 |
| chemotherapy neuropathy | #1 |
| topic peripheral neuropathy | #1 |
| neuropathy data | #1 |
| women 65 day | #1 |
| adam vte trial | #1 |
| hot flash score | #1 |
| megestrol acetate | #1 |
| cancerrelated fatigue interventions | #1 |
| hot flash mechanism | #1 |
| acetate appetite | #1 |
| qolresultsfrom | #1 |
| cipn postural control | #1 |
| balance gait testing | #1 |
| flashes pilot | #1 |
| chemotherapy treatment chemotherapy | #1 |
| qolconclusionsthe | #1 |
| week hot | #1 |
| isae anthracycline | #1 |
| mouthwash diphenhydramine | #1 |
| pilot trial hands | #1 |
| infliximab cancer | #1 |
| fsfi udi | #1 |
| numbness hands | #1 |
| 30 points 95 | #1 |
| hfs trial | #1 |
| neoplasms placebos | #1 |
| neoplasms climacteric | #1 |
| papsmethodspatients | #1 |
| oxybutynin hot flashes | #1 |
| compounded topical gel | #1 |
| n08ca | #1 |
| individual patients understanding | #1 |
| ganglion surveys | #1 |
| hot flash control | #1 |
| alliance a151724 | #1 |
| sensory subscale | #1 |
| cipn20 questionnaire | #1 |
| aimss life | #1 |
| paclitaxel polyneuropathy | #1 |
| guidelineendorsed treatment | #1 |
| uniscale qol baseline | #1 |
| duloxetine response patients | #1 |
| attribution treatment | #1 |
| patients subcutaneous testosterone | #1 |
| tools oncologists | #1 |
| neuropathic symptoms breast | #1 |
| extreme phenotyping | #1 |
| skin dermatitis trials | #1 |
| male megestrol life | #1 |
| purposehot | #1 |
| n00cb | #1 |
| patients hot flashes | #1 |
| patients paclitaxel polyneuropathy | #1 |
| points diphenhydramine | #1 |
| difficulty neuropathic pain | #1 |
| bupropion nicotine dependence | #1 |
| neuropathy prevention | #1 |
| patients gabapentin | #1 |
| vaginal cytology women | #1 |
| acetate versus | #1 |
| uncertain gbu | #1 |
| treating institution intervention | #1 |
| cvte rivaroxaban | #1 |
| inadequate control antidepressant | #1 |
| lidocaine antacid | #1 |
| antacid mouthwash | #1 |
| darbepoetin alfa head | #1 |
| patients megestrol acetate | #1 |
| leap lymphedema | #1 |
| lymphedema incidence intervention | #1 |
| resected cutaneous melanomas | #1 |
| drug humans interferons | #1 |
| life cipn | #1 |
| flaxseed bar | #1 |
| anecdotal observations | #1 |
| isae | #1 |
| balance patientreported outcomes | #1 |
| venous toxicity fosaprepitant | #1 |
| decrease hot | #1 |
| background hot | #1 |
| paclitaxel coasting phenomenon | #1 |
| 95 doxepin mouthwash | #1 |
| rom leap | #1 |
| relatedness treatment arms | #1 |
| 2007 guidelines suggestion | #1 |
| cinv neoplasms vomiting | #1 |
| alleviate hot | #1 |
| tools hypothetical scenarios | #1 |
| flash therapies | #1 |
| pain chemotherapy | #1 |
| symptom intervention | #1 |
| hot flashes women | #1 |
| conducted studies hrt | #1 |
| a151408 study data | #1 |
| discrepancies clinicians assessment | #1 |
| safety progestational agents | #1 |
| stomatitis administration | #1 |
| pilot trials venlafaxine | #1 |
| records adult patients | #1 |
| underdescribers weeks | #1 |
| toxicities opioids | #1 |
| survival tpn initiation | #1 |
| δ − 95 | #1 |
| hours nighttime sleep | #1 |
| benefit 5fu | #1 |
| nonhormonal agents | #1 |
| flaxseed hot flashes | #1 |
| oral cryotherapy patients | #1 |
| nonfluid bodyweights | #1 |
| duloxetine response | #1 |
| rs9657362 previous study | #1 |
| n08cb | #1 |
| purposehot flashes | #1 |
| efficacy gabapentin | #1 |
| hot flashes gabapentin | #1 |
| cipn20 sensory | #1 |
| education lymphedema prevention | #1 |
| placebo mouthwash | #1 |
| compassionate honesty | #1 |
| lymphedemafree rates | #1 |
| management hot flashes | #1 |
| ru221408i | #1 |
| effects hot flashes | #1 |
| single snv rs9657362 | #1 |
| cryotherapy auc | #1 |
| points doxepin | #1 |
| leucovorin breast cancer | #1 |
| glutamine toxicity | #1 |
| preliminary evidence improvement | #1 |
| women inadequate control | #1 |
| 81 patients patients | #1 |
| ulabtka arm | #1 |
| deprivation therapy patients | #1 |
| acetate dexamethasone | #1 |
| doubleblinded manner | #1 |
| physical consequences cipn | #1 |
| neoplasm recurrence apixaban | #1 |
| or1 year patients | #1 |
| supportive cytotoxic chemotherapy | #1 |
| magnesium camg | #1 |
| baseline prognosis values | #1 |
| treatment cipn | #1 |
| isae data | #1 |
| efficacy agent | #1 |
| topical cannabinoids | #1 |
| prognosis items | #1 |
| flash score | #1 |
| oestrogen survivors | #1 |
| antiemetic prescribing practices | #1 |
| prevention cipn | #1 |
| established cipn | #1 |
| leucovorin breast | #1 |
| oestrogen hot flashes | #1 |
| cyclohexanols female | #1 |
| weight megestrol acetate | #1 |
| induced neurotoxicity oct2 | #1 |
| adjuvant numeracy | #1 |
| doxepin mouthwash | #1 |
| painful oxaliplatininduced cipn | #1 |
| flashes patients | #1 |
| udi δ − | #1 |
| induced cipn | #1 |
| incurable cancer records | #1 |
| modalities cancer patients | #1 |
| rest psychostimulants | #1 |
| cisplatin therapy cinv | #1 |
| bortezomib alters | #1 |
| 95 neuropathic pain | #1 |
| flashes prospective | #1 |
| 5fu adjuvant | #1 |
| premenopause radiotherapy | #1 |
| toxicity anecdotal observations | #1 |
| severe stomatitis | #1 |
| pregenplus | #1 |
| ulabtka placebo cream | #1 |
| vaginal dehydroepiandrosterone dhea | #1 |
| pregabalin paps | #1 |
| pharmacologic therapeutics | #1 |
| initiation tpn | #1 |
| flashes objective | #1 |
| doxepin mouthwash patients | #1 |
| leap 12 months | #1 |
| rs2294039 | #1 |
| symptoms cipn | #1 |
| cancerassociated anorexia cachexia | #1 |
| neuropathic pain difficulty | #1 |
| accru study ru221408i | #1 |
| flashes breast | #1 |
| cryotherapy hands | #1 |
| gabapentin aminobutyric acid | #1 |
| uncertain gbu gbu | #1 |
| aminobutyric acid adt | #1 |
| pilot trials citalopram | #1 |
| alliance trial | #1 |
| flashes quality | #1 |
| adam vte | #1 |
| doxepin mouthwash placebo | #1 |
| drowsiness doxepin mouthwash | #1 |
| alliance n08c1 | #1 |
| studies cyproheptadine | #1 |
| female services tpn | #1 |
| mascc isoo evidence | #1 |
| hot flashes patients | #1 |
| day cisplatin therapy | #1 |
| hot flashes weeks | #1 |
| cipn phase iii | #1 |
| pregabalin paclitaxel | #1 |
| bakplo symptoms | #1 |
| hot flash relief | #1 |
| populations neurologic humans | #1 |
| ctcae grade | #1 |
| bakplo | #1 |
| fluorouracilinduced stomatitis | #1 |
| intervention leap | #1 |
| antiserotonergic drug | #1 |
| cryotherapy mucositis | #1 |
| 5fuinduced ocular toxicity | #1 |
| treating hot | #1 |
| megestrol acetate weeks | #1 |
| discrepancies women | #1 |
| lymphedema prevention education | #1 |
| managing hot flashes | #1 |
| daily questionnaires | #1 |
| effects limited efficacy | #1 |
| baseline week followup | #1 |
| amines antidepressive | #1 |
| gabapentin baseline week | #1 |
| differences neuropathy syndromes | #1 |
| numerical analogue scale | #1 |
| hot flashes quality | #1 |
| ssc device prototype | #1 |
| grade peripheral neuropathy | #1 |
| benefit fluoxetine | #1 |
| n08c1 | #1 |
| 95 increased difficulty | #1 |
| minocycline cipn | #1 |
| cipn20 data | #1 |
| newer antidepressants gabapentin | #1 |
| eortc cipn | #1 |
| highdose melphalan intervention | #1 |
| digital melt curve | #1 |
| paresthesia peripheral | #1 |
| taxane treatment development | #1 |
| topical keratolytic | #1 |
| hormone deprivation symptoms | #1 |
| cachexia cancer anorexia | #1 |
| median δ qs | #1 |
| managing hot | #1 |
| vaginal dehydroepiandrosterone | #1 |
| n08c3 | #1 |
| nonhormonal therapies paroxetine | #1 |
| 65 day | #1 |
| pilot study minocycline | #1 |
| isae patients | #1 |
| diseases pilot | #1 |
| chamomile mouthwash toxicity | #1 |
| balance impairments patients | #1 |
| qol reported difficulty | #1 |
| prevention paps | #1 |
| postsurgical neuropathic pain | #1 |
| oxybutynin doses | #1 |
| feet oxaliplatin | #1 |
| cipn topical gel | #1 |
| aes placebo arm | #1 |
| patients underdescribers | #1 |
| toxicity prospective trial | #1 |
| nsclc response rate | #1 |
| olanzapine projects vomiting | #1 |
| snv rs9657362 | #1 |
| patients spray product | #1 |
| patients dosing guidelines | #1 |
| hot flash activity | #1 |
| device 5 weeks | #1 |
| life leap | #1 |
| treatment alteration | #1 |
| baseline neuropathic pain | #1 |
| prevention oral cryotherapy | #1 |
| pilot trials efficacy | #1 |
| anecdotal observations gabapentin | #1 |
| placebos pregabalin quality | #1 |
| polyneuropathy allelic variability | #1 |
| treatments modalities | #1 |
| effects cipn | #1 |
| cachexia dexamethasone | #1 |
| appetite stimulation patients | #1 |
| lignans 6 weeks | #1 |
| fractures infertility | #1 |
| cipn function | #1 |
| improvements hot flashes | #1 |
| tested interventions lymphedema | #1 |
| sae δ − | #1 |
| tpn death | #1 |
| infliximab lung | #1 |
| paps fatigue | #1 |
| oral mucosa study | #1 |
| gsm fsfi | #1 |
| extensive animal data | #1 |
| combination chemotherapy hec | #1 |
| enoxaparin cvte | #1 |
| gabapentin hot | #1 |
| hot flashes | #1 |
| cipn development severity | #1 |
| loe prevention | #1 |
| placebo arms percentage | #1 |
| symptoms hands | #1 |
| baseline week gabapentin | #1 |
| fosaprepitant isae | #1 |
| gabapentin antidepressant | #1 |
| coasting phenomenon | #1 |
| flashes women | #1 |
| gas menopause patient | #1 |
| antidepressive agents gamma | #1 |
| cancer anorexia cachexia | #1 |
| authors 30 minutes | #1 |
| cyclohexanecarboxylic acids gamma | #1 |
| small cell continuity | #1 |
| flashes venlafaxine | #1 |
| ncctg n08c3 | #1 |
| auc cryotherapy | #1 |
| baseline assessment week | #1 |
| stellate ganglion block | #1 |
| patients physical examinations | #1 |
| inadequate hot | #1 |
| drowsiness unpleasant taste | #1 |
| hfs symptoms patients | #1 |
| toxicity ocular | #1 |
| randomized receive | #2 |
| cold items 71 | #2 |
| treatment baseline week | #2 |
| standard arm rate | #2 |
| receiving megestrol | #2 |
| circulating concentrations npy | #2 |
| nonhormonal management | #2 |
| anorexia severity | #2 |
| women hot flashes | #2 |
| cancerassociated wasting | #2 |
| 34—vitamin | #2 |
| skindex16 ctcae | #2 |
| starting tamoxifen women | #2 |
| pa outcomes pros | #2 |
| nutrition scores physicians | #2 |
| treatment breakthrough cinv | #2 |
| oxaliplatin hands | #2 |
| cck8 anorexia severity | #2 |
| life illness tetracycline | #2 |
| 120 arm | #2 |
| hot flashes humans | #2 |
| hot flashes aprepitant | #2 |
| treatment aprepitant | #2 |
| life 4week intervention | #2 |
| nutrition score disagreement | #2 |
| appetite dissent disputes | #2 |
| arms conclusions | #2 |
| mometasone time | #2 |
| breast cancer venlafaxine | #2 |
| previous hot flashes | #2 |
| ecog nutrition score | #2 |
| leucovorin women | #2 |
| versus megestrol | #2 |
| placebo combination therapy | #2 |
| postmenopausal women previous | #2 |
| stomatitis sex | #2 |
| appetite dissent | #2 |
| ctcae differences | #2 |
| decreasing stomatitis | #2 |
| patients black cohosh | #2 |
| dhea vaginal symptoms | #2 |
| vitamin hot flashes | #2 |
| prevent radiation | #2 |
| hemoccultsensa hemoccult | #2 |
| fsfi score baseline | #2 |
| kps nutrition scores | #2 |
| oxaliplatin doses trends | #2 |
| hemoccultsensa sdt1 | #2 |
| study arms | #2 |
| scrambler therapy treatment | #2 |
| vitamin hot | #2 |
| humans postmenopause pregabalin | #2 |
| life venlafaxine | #2 |
| clinical trials n9741 | #2 |
| weight concerns 26 | #2 |
| receive parenteral | #2 |
| substantial hot flashes | #2 |
| fatigue improvement methylphenidate | #2 |
| 120k arm patients | #2 |
| hot flash management | #2 |
| sensitivity cold items | #2 |
| dronabinol versus | #2 |
| magnesium oxaliplatin | #2 |
| suggested agents | #2 |
| cycle chronic neurotoxicity | #2 |
| appearing pilot data | #2 |
| phytogenic female humans | #2 |
| chemotherapy peripheral neuropathy | #2 |
| 15 points 95 | #2 |
| patients daily mmf | #2 |
| dna markers participants | #2 |
| chemotherapyassociated anemia caa | #2 |
| coriat | #2 |
| treatment target doses | #2 |
| pregabalin treatments placebo | #2 |
| study arms conclusions | #2 |
| cipn prevention trials | #2 |
| moderate correlations ≤ | #2 |
| therapy hot flashes | #2 |
| poor qol 95 | #2 |
| older age bupropion | #2 |
| increased risk cipn | #2 |
| smokers nicotine inhaler | #2 |
| palliative communications | #2 |
| treatment minority smokers | #2 |
| anabolic corticosteroid | #2 |
| tens global impression | #2 |
| chronic chemotherapy | #2 |
| ncctg trial | #2 |
| patients treating institution | #2 |
| breakthrough cinv | #2 |
| mometasone surveys | #2 |
| megestrol acetate dexamethasone | #2 |
| time ncctg alliance | #2 |
| questionnaires antineoplastic agents | #2 |
| pregabalin arms | #2 |
| intervention 18 months | #2 |
| inadequate benefit | #2 |
| lmwh arms 7 | #2 |
| vte recurrence doacs | #2 |
| hemoccultsensa sensitivity | #2 |
| control arms rate | #2 |
| adjuvant 5fu models | #2 |
| anthrapyrazoles piroxantrone | #2 |
| placebo bar | #2 |
| neoplasms double | #2 |
| worse survivorship | #2 |
| lamotrigine neuropathic symptoms | #2 |
| kps nutrition score | #2 |
| hot flash diary | #2 |
| flashes citalopram | #2 |
| tamoxifen percentage reduction | #2 |
| acttionconsortium | #2 |
| cipn | #2 |
| desipramine hot flashes | #2 |
| 40000 40k arm | #2 |
| oxaliplatin induced neurotoxicity | #2 |
| improvement hot flashes | #2 |
| cipn cancer treatment | #2 |
| sdt2 hemoccult | #2 |
| paclitaxel induced | #2 |
| life treatment weeks | #2 |
| stat itching | #2 |
| incidence severity stomatitis | #2 |
| differences mometasone | #2 |
| flashes placebo | #2 |
| patients olanzapine arm | #2 |
| trial baseline week | #2 |
| conceppt | #2 |
| rash incidence severity | #2 |
| 01 mmf | #2 |
| week breast cancer | #2 |
| pilocarpine vaginal | #2 |
| patients receiving fluorouracil | #2 |
| induced arthralgias | #2 |
| time toxt approach | #2 |
| longitudinal studies postmenopause | #2 |
| treatment alterations | #2 |
| conclusions sunscreen | #2 |
| qol hb increment | #2 |
| cachexia acetate | #2 |
| hemoccultsensa sdt2 | #2 |
| physicians kps | #2 |
| patients monthly intervals | #2 |
| scrambler | #2 |
| 800 liquid suspension | #2 |
| cisplatin polymerase inhibitors | #2 |
| patients 120k arm | #2 |
| participants 3 stools | #2 |
| hot flash trials | #2 |
| dosing zoledronic | #2 |
| week baseline week | #2 |
| declining qol | #2 |
| data relative benefits | #2 |
| females cessation treatment | #2 |
| numeracy prognosis | #2 |
| cipn interventions | #2 |
| cipn antineoplastic agents | #2 |
| n06c4 | #2 |
| postural instability individuals | #2 |
| management genitourinary symptoms | #2 |
| gabapentin venlafaxine hydrochloride | #2 |
| global impression life | #2 |
| ctcae pruritus | #2 |
| patients cipn | #2 |
| 432 smokers treatment | #2 |
| cachexia decision | #2 |
| ductal mometasone furoate | #2 |
| weekly epoetin | #2 |
| single snv | #2 |
| eortc qlqcipn20 | #2 |
| tamoxifenassociated hot flashes | #2 |
| nonestrogenic hot | #2 |
| oral iron 46 | #2 |
| positive doseresponse | #2 |
| egfr inhibitor tetracycline | #2 |
| lmwh arms | #2 |
| woman quality | #2 |
| outcome measures ctcae | #2 |
| lvef 1000 | #2 |
| folfox alliance | #2 |
| life venlafaxine hydrochloride | #2 |
| cohosh treatment | #2 |
| stomatitis women | #2 |
| postchemotherapy rheumatism | #2 |
| anthraquinones agents breast | #2 |
| hot flashes bupropion | #2 |
| hot flashes dehydroepiandrosterone | #2 |
| patients chemotherapyassociated anemia | #2 |
| symptoms surveys | #2 |
| levetiracetam 4 weeks | #2 |
| prevent paclitaxel | #2 |
| stage disease 5fu | #2 |
| aprepitant 4 weeks | #2 |
| real patients treatment | #2 |
| pilocarpine arms | #2 |
| 120k arm | #2 |
| 16 sdt2 | #2 |
| piroxantrone women | #2 |
| patients shark cartilage | #2 |
| subject global impression | #2 |
| folfox auc analysis | #2 |
| thiophenes treatment life | #2 |
| time randomized study | #2 |
| cipn20 scores | #2 |
| illness tetracycline egfr | #2 |
| historic controls npy | #2 |
| flash diary | #2 |
| tingling patients | #2 |
| detection screenrelevant neoplasms | #2 |
| 150 groups patients | #2 |
| sulfate prevent | #2 |
| patients difluoromethylornithine | #2 |
| central cancer | #2 |
| citalopram hot flashes | #2 |
| lessons cipn | #2 |
| depomedroxyprogesterone | #2 |
| hf frequency placebo | #2 |
| disagreement increased risk | #2 |
| nicotine inhaler bupropion | #2 |
| 5fuinduced mucositis | #2 |
| life aimss | #2 |
| cipn peripheral neuropathy | #2 |
| cdf score | #2 |
| n0993 | #2 |
| shark cartilage patients | #2 |
| advanced cancer anorexia | #2 |
| placebo breast radiotherapy | #2 |
| stat erythema | #2 |
| prevalence weight concerns | #2 |
| treatment cycles cycle | #2 |
| placebo situ carcinoma | #2 |
| humans citalopram cyclohexanols | #2 |
| pregabalin hot flashes | #2 |
| original report time | #2 |
| tetracycline rash incidence | #2 |
| antidepressants hot | #2 |
| 95 oral placebo | #2 |
| real real patients | #2 |
| advancedstage cancer | #2 |
| 95 indirect estimates | #2 |
| alternative treatment regimen | #2 |
| trial acetate doses | #2 |
| feet 18 months | #2 |
| glutamine placebo preparation | #2 |
| placebo pregabalin treatments | #2 |
| dalteparin lowest risk | #2 |
| autonomic scales | #2 |
| life cipn20 | #2 |
| paclitaxel chronic neuropathy | #2 |
| infliximab 5 day | #2 |
| appetite improvement | #2 |
| subsequent mucositis | #2 |
| detection dna markers | #2 |
| injections hot flashes | #2 |
| failure prior chemotherapy | #2 |
| clinically deficient fatigue | #2 |
| usual breathing | #2 |
| hot flash quality | #2 |
| descriptive manner | #2 |
| months randomized | #2 |
| efficacy scrambler therapy | #2 |
| cipn cohort | #2 |
| tamoxifen medications | #2 |
| 40k arm 120000 | #2 |
| alliance folfox | #2 |
| mometasone cream | #2 |
| supplementary n03cb | #2 |
| peripheral neuropathy cipn | #2 |
| sensitivity screenrelevant neoplasms | #2 |
| hot flashes efficacy | #2 |
| placebo vaginal dryness | #2 |
| cipn clinical | #2 |
| pilocarpine vaginal dryness | #2 |
| hot flash studies | #2 |
| ≤ moderate correlations | #2 |
| flash studies | #2 |
| dermatitis symptom evolution | #2 |
| venlafaxine oxaliplatin neurotoxicity | #2 |
| induced peripheral | #2 |
| average stomatitis sex | #2 |
| hot flashes data | #2 |
| cycle folfox | #2 |
| 7 control arms | #2 |
| placebo arms women | #2 |
| life scrambler therapy | #2 |
| design considerations recommendations | #2 |
| women rom | #2 |
| venlafaxine gabapentin | #2 |
| middle aged survivors | #2 |
| cpmp scrambler therapy | #2 |
| 49 venlafaxine | #2 |
| pruritus pros | #2 |
| trials newer antidepressants | #2 |
| survival 3915 patients | #2 |
| study n08cb alliance | #2 |
| monthly intervals appetite | #2 |
| established chemotherapy | #2 |
| starting tamoxifen | #2 |
| 5fubased chemotherapy mucositis | #2 |
| methylphenidate cancer | #2 |
| guaninemethyltransferase | #2 |
| shark cartilage product | #2 |
| conclusions original report | #2 |
| trial suggestion | #2 |
| scrambler therapy management | #2 |
| oxybutynin women | #2 |
| women stomatitis | #2 |
| 16 hemoccult | #2 |
| cachexia pentoxifylline | #2 |
| 75 49 venlafaxine | #2 |
| anabolic corticosteroid appetite | #2 |
| sdt2 | #2 |
| tingling shooting | #2 |
| nutrition scores 95 | #2 |
| hemoccultsensa detection | #2 |
| evaluate weight | #2 |
| screenrelevant neoplasms 16 | #2 |
| npy levels groups | #2 |
| 135±19 | #2 |
| irox folfox auc | #2 |
| folfox symptoms | #2 |
| dronabinol combination therapy | #2 |
| folfox auc p0·0001 | #2 |
| anemia caa | #2 |
| pilot citalopram | #2 |
| vte recurrence dalteparin | #2 |
| week black cohosh | #2 |
| dhea 4 weeks | #2 |
| fosaprepitant patients | #2 |
| tens 2 weeks | #2 |
| topical aged antimetabolites | #2 |
| hot flash frequencies | #2 |
| symptoms skin toxicity | #2 |
| colonoscopically normal patients | #2 |
| provider assessed | #2 |
| cipn primary outcomes | #2 |
| ferric gluconate darbepoetin | #2 |
| allopurinol mouthwash | #2 |
| placebo oxybutynin doses | #2 |
| treating chemotherapy | #2 |
| sdt1 hemoccult | #2 |
| cipn cancer survivors | #2 |
| trials suggested | #2 |
| induced peripheral neuropathy | #2 |
| baseline week day | #2 |
| epoetin alfa 40000 | #2 |
| daily mmf radiotherapy | #2 |
| mmf itching | #2 |
| data gabapentin | #2 |
| qol crc | #2 |
| surveys repeated measures | #2 |
| evaluating gabapentin | #2 |
| citalopram cyclohexanols humans | #2 |
| patients oxybutynin doses | #2 |
| randomized study mometasone | #2 |
| skindex16 itching | #2 |
| 14 hot flashes | #2 |
| venlafaxine treatment 75 | #2 |
| acknowledged loss | #2 |
| hot flashes pregabalin | #2 |
| preventive therapies cipn | #2 |
| neuropathy paclitaxel | #2 |
| locoregional event | #2 |
| infliximab docetaxel | #2 |
| day average pain | #2 |
| 40k arm | #2 |
| screenrelevant neoplasms | #2 |
| doses megestrol | #2 |
| duloxetine hydrochloride humans | #2 |
| study treatment citalopram | #2 |
| coumarin placebo | #2 |
| toxicity profiles time | #2 |
| study arms quality | #2 |
| life cancerrelated fatigue | #2 |
| 3 months bupropion | #2 |
| local antineoplastic agents | #2 |
| placebo hf frequency | #2 |
| sunscreen arms | #2 |
| evaluating venlafaxine | #2 |
| glutathione prevention | #2 |
| antidepressant hot flashes | #2 |
| gabapentin 4 weeks | #2 |
| aprepitan | #2 |
| oral megestrol | #2 |
| cipn cases | #2 |
| rcts preventive therapies | #2 |
| natural paps | #2 |
| anabolic corticosteroid treatment | #2 |
| bupropion nicotine inhaler | #2 |
| mucositis 5fubased chemotherapy | #2 |
| n03cb | #2 |
| 46 adenomas 1 | #2 |
| reducing chemotherapy | #2 |
| iii randomized | #2 |
| experience hot flashes | #2 |
| docetaxel serum concentrations | #2 |
| dronabinoltreated patients | #2 |
| nonestrogenic therapies | #2 |
| cipn20 factor analysis | #2 |
| target doses placebo | #2 |
| 108±11 | #2 |
| indirect comparison apixaban | #2 |
| fluoxymesterone treatment | #2 |
| guidelines recommendation | #2 |
| ncctg n10c1 | #2 |
| tamoxifen metabolism evidence | #2 |
| type chemotherapy drug | #2 |
| treatment arm mmf | #2 |
| topic estrogen | #2 |
| 46 screenrelevant neoplasms | #2 |
| neuropathy caused | #2 |
| 80 anorexia | #2 |
| improvement hot | #2 |
| n01c4 | #2 |
| 4 treatment weeks | #2 |
| manuscript “use | #2 |
| npy anorexia cholecystokinin | #2 |
| sdt2 sdt1 | #2 |
| intermediate term efficacy | #2 |
| oxybutynin doses placebo | #2 |
| scrambler therapy tens | #2 |
| cancerassociated anorexia | #2 |
| singleagent megestrol acetate | #2 |
| venlafaxine control | #2 |
| hot flashes citalopram | #2 |
| original report mometasone | #2 |
| gabapentin symptoms | #2 |
| newer antidepressants trials | #2 |
| treatment smoking abstinence | #2 |
| disagreement patients | #2 |
| study arms tetracycline | #2 |
| patients 40k arm | #2 |
| reduce hot | #2 |
| scrambler therapy | #2 |
| day baseline week | #2 |
| shark cartilage placebo | #2 |
| neuropathy cipn | #2 |
| cipn paclitaxel | #2 |
| pain ≥4 10 | #2 |
| symptomatic cipn | #2 |
| patient‐physician disagreement | #2 |
| dexamethasone fluoxymesterone | #2 |
| product hot flashes | #2 |
| “use vitamin | #2 |
| treatment week placebo | #2 |
| time toxt analysis | #2 |
| 1 oral megestrol | #2 |
| predictors disagreement | #2 |
| appetite cachexia | #2 |
| weekly hf score | #2 |
| day study week | #2 |
| infertility ovarian failure | #2 |
| patients adjuvant 5fu | #2 |
| 979254 | #2 |
| 120000 epoetin alfa | #2 |
| anorexia antineoplastic | #2 |
| purposeoxaliplatin | #3 |
| placebo breast | #3 |
| hot flashes trial | #3 |
| 10 weeks therapy | #3 |
| qlqcipn20 scores | #3 |
| crossover methodology | #3 |
| chemotherapy gabapentin | #3 |
| mouthwash patients | #3 |
| neuropathy trials | #3 |
| methylphenidate patients | #3 |
| median δ | #3 |
| egfr inhibitor patients | #3 |
| measures peripheral | #3 |
| eightyone randomized women | #3 |
| recommendations dietary counseling | #3 |
| controls singleton snv | #3 |
| patients chemotherapy cycle | #3 |
| mcbdr primary endpoint | #3 |
| incurable cancers | #3 |
| aminobutyric acid gabapentin | #3 |
| snv charcotmarietooth disease | #3 |
| chlorhexidine mouthwash | #3 |
| advanced cancer standard | #3 |
| cipn n08cx population | #3 |
| chemotherapy increases | #3 |
| dalteparin vte | #3 |
| apixaban lowest risk | #3 |
| gwas mayo clinic | #3 |
| fasting chemotherapy | #3 |
| data pilot trials | #3 |
| feet 15 | #3 |
| epoetintreated patients incidence | #3 |
| bacterial agents life | #3 |
| oxaliplatininduced neuropathy | #3 |
| baseline treatment day | #3 |
| patients scrambler therapy | #3 |
| cyclohexanecarboxylic acids | #3 |
| patients cancerassociated wasting | #3 |
| longitudinal adverse | #3 |
| data ginseng | #3 |
| asco guideline management | #3 |
| hemoccult hemoccultsensa | #3 |
| experts cipn | #3 |
| ssc device | #3 |
| oxaliplatinbased therapy | #3 |
| oral megestrol acetate | #3 |
| acute neuropathy | #3 |
| male megestrol | #3 |
| hormonal ablation | #3 |
| mfsisf 4 weeks | #3 |
| n08ca n08cb study | #3 |
| cmt gene | #3 |
| burning pain patients | #3 |
| “use | #3 |
| epoetin alfa hgb | #3 |
| survival epa | #3 |
| patients antiemetic | #3 |
| thirdline hormonal therapy | #3 |
| blind trial | #3 |
| classic sums | #3 |
| selfreport ctcae grading | #3 |
| completed diaries | #3 |
| neoplasms vomiting | #3 |
| patients cyproheptadine | #3 |
| patients lidocaine patch | #3 |
| patients upfront arm | #3 |
| survival cancerassociated wasting | #3 |
| rash prevention | #3 |
| cvte | #3 |
| vitamin prevention | #3 |
| delayed zoledronic | #3 |
| hgb rbc transfusions | #3 |
| methodologic lessons | #3 |
| patients baseline week | #3 |
| weekly arm differences | #3 |
| bivariate construct | #3 |
| hgpin chemoprevention trial | #3 |
| ” numbness | #3 |
| topic mayo clinic | #3 |
| middle aged pilot | #3 |
| tingling burning pain | #3 |
| management cancer cachexia | #3 |
| numeracy patients | #3 |
| combinationtreated arms survival | #3 |
| relationship numbness | #3 |
| questionnaires syndrome paclitaxel | #3 |
| bit hands | #3 |
| upfront arm | #3 |
| corticosteroid medications | #3 |
| neurotoxic chemotherapy cipn | #3 |
| asco surveillance | #3 |
| genetic factors patients | #3 |
| epoetintreated patients study | #3 |
| cancer patients drugs | #3 |
| oxaliplatin cipn | #3 |
| eventual sensory patients | #3 |
| controlled double | #3 |
| pros differences | #3 |
| epa combinationtreated arms | #3 |
| patient completed | #3 |
| general subscale mfsisf | #3 |
| inhibitorinduced rash | #3 |
| neurotoxic chemotherapies | #3 |
| qol placebotreated patients | #3 |
| ctcae grading arms | #3 |
| toxicity agents | #3 |
| neuropathy chemotherapy | #3 |
| undergoing androgen ablation | #3 |
| n05c4 | #3 |
| rash conclusions | #3 |
| carboplatin gwas | #3 |
| starting letrozole | #3 |
| 1 month cytokines | #3 |
| n08cx | #3 |
| ginseng crf | #3 |
| cumulative neurotoxicity oxaliplatin | #3 |
| paps scores dose | #3 |
| evidence prostate adenocarcinoma | #3 |
| ctpm experts | #3 |
| iii evaluation | #3 |
| rash study arms | #3 |
| cold items | #3 |
| prevent epidermal | #3 |
| genetic predictors paclitaxel | #3 |
| flutamide hgpin | #3 |
| trial bmd | #3 |
| qol hgb | #3 |
| preventing peripheral | #3 |
| ginseng arm | #3 |
| n08ca paclitaxel | #3 |
| cipn evidence | #3 |
| chemotherapy‐associated anemia | #3 |
| 51 female age | #3 |
| stomatitis sucralfate | #3 |
| additional 4 weeks | #3 |
| acetate treated | #3 |
| receive placebo | #3 |
| radiation‐induced mucositis | #3 |
| cipn mcbdr population | #3 |
| hemoccultsensa | #3 |
| cartilage shark | #3 |
| rash symptoms | #3 |
| qlqcipn20 | #3 |
| cipn ctpm | #3 |
| week venlafaxine therapy | #3 |
| life antineoplastic agents | #3 |
| pilot evaluation gabapentin | #3 |
| paps dose | #3 |
| 40000 units | #3 |
| cipn biological targets | #3 |
| etanercept current trial | #3 |
| 3 weeks 80k | #3 |
| cachexia decision humans | #3 |
| female gabapentin | #3 |
| placebo prostate adenocarcinoma | #3 |
| physiologic pilot | #3 |
| life dronabinol | #3 |
| life hospice patients | #3 |
| ≤−20 | #3 |
| mastectomy rates | #3 |
| n03cc | #3 |
| cmtassociated genes | #3 |
| toxicities selfreport | #3 |
| reported rash | #3 |
| delayed treatment arm | #3 |
| osteoporosis osteopenia letrozole | #3 |
| average severity | #3 |
| repeated measures analyses | #3 |
| trials n9741 | #3 |
| centrally active agents | #3 |
| survivors gsm | #3 |
| combinationtreated arms | #3 |
| traditional ctcae | #3 |
| baseline general subscale | #3 |
| follow fsfi | #3 |
| mucositis scores | #3 |
| snv cmtassociated genes | #3 |
| cipn snv | #3 |
| placebo preparation | #3 |
| hot flashes placebo | #3 |
| treatment bother | #3 |
| ctcae pros | #3 |
| months bupropion | #3 |
| oncology colorectal | #3 |
| vaginal dhea | #3 |
| mcbdr | #3 |
| projects prospective | #3 |
| experience greater | #3 |
| cmt genes oxaliplatin | #3 |
| genetic predictors cipn | #3 |
| pts stage iii | #3 |
| paps scores | #3 |
| hands burning pain | #3 |
| minocycline prevention | #3 |
| relationship response rate | #3 |
| shooting burning pain | #3 |
| primary endpoint gwas | #3 |
| upfront treatment arm | #3 |
| iii controlled | #3 |
| purposefosaprepitant | #3 |
| gabapentin management | #3 |
| prophylactic tetracycline | #3 |
| cyproheptadine patients | #3 |
| depression somnolence | #3 |
| anorexia anorexia appetite | #3 |
| frequency hot | #3 |
| centric decision | #3 |
| chronic neuropathy patients | #3 |
| qlqcipn20 traditional ctcae | #3 |
| sham acupuncture week | #3 |
| oxaliplatin primary endpoint | #3 |
| tamoxifen fluoxetine | #3 |
| mpa single dose | #3 |
| thromboembolism secondary | #3 |
| clonidine randomized trials | #3 |
| canada collaborative effort | #3 |
| 20 calories | #3 |
| real day | #3 |
| interventions cancerrelated fatigue | #3 |
| fluoxetine arm | #3 |
| week chemotherapy dose | #3 |
| dhea hot flashes | #3 |
| pilot trial pregabalin | #3 |
| patients paps scores | #3 |
| subcutaneous weekly | #3 |
| 95 40 points | #3 |
| drug toxicity patients | #3 |
| chemotherapy induced | #3 |
| life eortc qlq | #3 |
| study population mcbdr | #3 |
| trials newer | #3 |
| study antidepressive agents | #3 |
| topical ceramides | #3 |
| egfr inhibitorinduced rash | #3 |
| epoetintreated patients | #3 |
| cipn cmtassociated genes | #3 |
| ctcae grades patients | #3 |
| baseline hot | #3 |
| intravenous calcium magnesium | #3 |
| chemotherapyassociated anemia | #3 |
| alfa compared | #3 |
| 95 udi | #3 |
| treatment cancer anorexia | #4 |
| secondary vte prevention | #4 |
| parenteral iron | #4 |
| weight loss syndrome | #4 |
| hot flashes therapy | #4 |
| odx ctx | #4 |
| day paroxetine | #4 |
| cancer acute vte | #4 |
| aged mouthwashes | #4 |
| toxt analysis | #4 |
| rash study | #4 |
| hec cisplatin | #4 |
| outcomes olanzapine | #4 |
| odc activity mice | #4 |
| anorexia weight | #4 |
| oxybutynin placebo | #4 |
| topic survivors | #4 |
| control hot | #4 |
| women greater toxicity | #4 |
| controls imbalance | #4 |
| therapy aimss | #4 |
| doxepin female head | #4 |
| hgpin antineoplastic agents | #4 |
| symptoms individual patients | #4 |
| hemoccult | #4 |
| suggested efficacy | #4 |
| tpn initiation | #4 |
| anorexia cholecystokinin | #4 |
| nsclc trials | #4 |
| placebo arms | #4 |
| paced breathing | #4 |
| surgery lymphedema | #4 |
| therapy oncologists | #4 |
| receive oral | #4 |
| gabapentin day | #4 |
| nonestrogenic | #4 |
| predictors duloxetine response | #4 |
| apr dex | #4 |
| recommended endorsement | #4 |
| calgb 70305 | #4 |
| inhibitor induced | #4 |
| egfr inhibitor rash | #4 |
| loss syndrome | #4 |
| ais biomarkers | #4 |
| oral cryotherapy mucositis | #4 |
| additional meta analysis | #4 |
| backgroundhistorically | #4 |
| recommendation ctx | #4 |
| arm breast neoplasms | #4 |
| breast medical oncologists | #4 |
| daily baseline | #4 |
| treatment ncctg | #4 |
| intrapatient difference | #4 |
| administration parp inhibitor | #4 |
| guidelines oral | #4 |
| doubleblind manner | #4 |
| oral cavity mucosa | #4 |
| general subscale | #4 |
| based chemotherapy severity | #4 |
| logistic regression incidence | #4 |
| qol performance score | #4 |
| qol baseline fatigue | #4 |
| anorectic cancer patients | #4 |
| placebo hot | #4 |
| 40000 | #4 |
| or1 year | #4 |
| based chemotherapy women | #4 |
| major doselimiting toxicity | #4 |
| iron arm | #4 |
| cutaneous electrostimulation | #4 |
| bupropion 3 | #4 |
| nonabsorbable antibiotic | #4 |
| measurable metastatic disease | #4 |
| weekly toxicity | #4 |
| severe stomatitis leukopenia | #4 |
| aimss | #4 |
| ctx odx | #4 |
| cachexia purpose | #4 |
| chemotherapy‐induced peripheral | #4 |
| chronic neuropathy | #4 |
| fluorouracilbased chemotherapy | #4 |
| endorsed treatment | #4 |
| bupropion 3 months | #4 |
| hot flashes week | #4 |
| single dose venlafaxine | #4 |
| 95 oral iron | #4 |
| publication antiemetics humans | #4 |
| trpa1 cisplatin | #4 |
| flaxseed placebo | #4 |
| survivors hot | #4 |
| cipn20 ctcae | #4 |
| addition letrozole | #4 |
| mastectomy rates patients | #4 |
| numbness toes | #4 |
| 3915 patients | #4 |
| vaginal assessment scale | #4 |
| risk reduction therapy | #4 |
| 6 months bupropion | #4 |
| hfs quality | #4 |
| severity sexes | #4 |
| rash incidence | #4 |
| dietician | #4 |
| to100 | #4 |
| 900 dose | #4 |
| achievements ncctg | #4 |
| appetite quality | #4 |
| prominent problem | #4 |
| flash frequency | #4 |
| colorectal cancer asco | #4 |
| cco guideline followup | #4 |
| doac dalteparin | #4 |
| followup surveillance protocol | #4 |
| baseline fatigue survival | #4 |
| 1093 women | #4 |
| appetite stimulation | #4 |
| odc odc activity | #4 |
| benefits adjuvant | #4 |
| gabapentin patients | #5 |
| trials cytotoxic chemotherapy | #5 |
| flashes data | #5 |
| race ttr | #5 |
| genetic quality life | #5 |
| rectal cancer surveillance | #5 |
| ongoing clinical trial | #5 |
| bone loss osteopenia | #5 |
| major outcome measure | #5 |
| vasomotor hot flashes | #5 |
| groups leptin concentrations | #5 |
| women 5fu | #5 |
| libido | #5 |
| 3 patients 4 | #5 |
| pain scores dose | #5 |
| cancerrelated fatigue patients | #5 |
| numeracy online clinical | #5 |
| cipn effects | #5 |
| cumulative neurotoxicity | #5 |
| kps ecog | #5 |
| treating postmenopausal | #5 |
| aapro | #5 |
| cipn participants | #5 |
| ajcc version staging | #5 |
| patient outcomes numeracy | #5 |
| crc cancer types | #5 |
| epa supplement | #5 |
| nodal status stage | #5 |
| fiftynine percent | #5 |
| ttr ajcc | #5 |
| life lmwh | #5 |
| cisplatin ganglia | #5 |
| physicians predictive ttr | #5 |
| additional 8 weeks | #5 |
| trial developed | #5 |
| higher drug doses | #5 |
| acetate neoplasms | #5 |
| crc cancers | #5 |
| oxantrazole | #5 |
| study dmc | #5 |
| colorectal cancer surveillance | #5 |
| progestational agent | #5 |
| cipnrelated symptoms | #5 |
| cipn numbness | #5 |
| patients lmwh injections | #5 |
| life epa | #5 |
| induced stomatitis | #5 |
| neuropeptide leptin | #5 |
| ttr variables | #5 |
| cancer anorexia | #5 |
| combination electroacupuncture | #5 |
| fluoxymesterone patients | #5 |
| trial gabapentin | #5 |
| cyclohexanecarboxylic | #5 |
| disputes female humans | #5 |
| impaired postural | #5 |
| neoplasm diagnostic tests | #5 |
| questionnaires pregabalin | #5 |
| receiving paclitaxel | #5 |
| 5fu trials | #5 |
| grade model estimates | #5 |
| intravenous calcium | #5 |
| medical oncology outpatients | #5 |
| acetate neoplasms quality | #5 |
| digital melt | #5 |
| editor manuscript | #5 |
| treatment benefits sex | #5 |
| ajcc external validation | #5 |
| sham real | #5 |
| placebo exposed | #5 |
| centrally active | #5 |
| appetite enhancement | #5 |
| reported hot | #5 |
| 3 stools | #5 |
| tools numeracy | #5 |
| gabapentin trial | #5 |
| reduce chemotherapy | #5 |
| nodal status grade | #5 |
| cachexia anorexia | #5 |
| iron oral | #5 |
| postsurgical neuropathic | #5 |
| subsets treatment benefits | #5 |
| cancer survivors symptoms | #5 |
| difference control arm | #5 |
| cindices ajcc | #5 |
| agents basis | #5 |
| fosaprepitant prevention | #5 |
| neuropathic pain qol | #5 |
| discontinuation aimss | #5 |
| mucositis caused | #5 |
| mucositis allopurinol | #5 |
| ttr cindices | #5 |
| current trial patients | #5 |
| numeracy tools | #5 |
| physicianreported | #5 |
| death communication humans | #5 |
| colorectal cancer society | #5 |
| hb increment | #5 |
| nutrition scores | #5 |
| acetate placebo | #5 |
| olanzapine arm | #5 |
| models ttr | #5 |
| ajcc tools | #5 |
| neoplasms compared | #5 |
| trials lessons | #5 |
| trial hot | #5 |
| odx | #5 |
| neuropathy acute | #5 |
| megestrol | #6 |
| breakthrough nausea | #6 |
| 5fubased chemotherapy | #6 |
| 500 mcg | #6 |
| flashes humans | #6 |
| sadenosyllmethionine treatment | #6 |
| background chemotherapy | #6 |
| 4week intervention | #6 |
| north central | #6 |
| daily diary questionnaires | #6 |
| neurological safety | #6 |
| olanzapine prevention | #6 |
| bf qol | #6 |
| agents breast | #6 |
| methylo | #6 |
| participants sham acupuncture | #6 |
| 71 sensitivity | #6 |
| nci ctcae | #6 |
| imidazoles letrozole | #6 |
| predictive illness surveys | #6 |
| nonanthracycline chemotherapy | #6 |
| staging patient outcomes | #6 |
| alliance clinical | #6 |
| inhaler bupropion | #6 |
| mri trends | #6 |
| life toxicity | #6 |
| paclitaxel peripheral neuropathy | #6 |
| cipn treatment | #6 |
| cancerrelated fatigue life | #6 |
| rs11572080 | #6 |
| placebo arm patients | #6 |
| hrqol breast neoplasms | #6 |
| wisconsin ginseng | #6 |
| apixaban cancer patients | #6 |
| highly emetogenic chemotherapy | #6 |
| fatigue pilot study | #6 |
| severity data | #6 |
| nicotine inhaler | #6 |
| medical acupuncture | #6 |
| data supporting | #6 |
| severity neuropathic symptoms | #6 |
| her2directed therapy | #6 |
| placebo hot flashes | #6 |
| sensory scale | #6 |
| smoking abstinence rates | #6 |
| active malignancy | #6 |
| loe guidelines | #6 |
| pharmaceutic aged aged | #6 |
| death kps | #6 |
| selective poly | #6 |
| intervention lymphedema | #6 |
| 5fu folfox | #6 |
| hospitalized oncology patients | #6 |
| depomedroxyprogesterone acetate | #6 |
| induced sensory | #6 |
| longacting methylphenidate | #6 |
| therapy 10 weeks | #6 |
| versus combination | #6 |
| studies vomiting | #6 |
| placebo hfs | #6 |
| proportion aes | #6 |
| study arms difference | #7 |
| model estimates survival | #7 |
| sensitivity fecal | #7 |
| hemoquant | #7 |
| fuinduced | #7 |
| neuropathy oxaliplatin | #7 |
| cancer patients anorexia | #7 |
| letrozole differences | #7 |
| pain cipn | #7 |
| 5fu based chemotherapy | #7 |
| accru | #7 |
| citalopram cyclohexanols | #7 |
| 1week baseline period | #7 |
| venlafaxine therapy | #7 |
| prevalence moderatetosevere | #7 |
| cmt genes | #7 |
| lymphedema education | #7 |
| follow year | #7 |
| nausea cancer patients | #7 |
| patients product | #7 |
| uniscale | #7 |
| throat discomfort | #7 |
| 12 treatment arms | #7 |
| induced rash | #7 |
| 20 percent placebo | #7 |
| study drug trial | #7 |
| appetites | #7 |
| weekly epoetin alfa | #7 |
| scheduled receive | #7 |
| venlafaxine day | #7 |
| toxic polyneuropathy | #7 |
| outcomes primary outcomes | #7 |
| chronic postmastectomy pain | #7 |
| rs10509681 | #7 |
| induced neuropathy | #7 |
| incidence rbc transfusion | #7 |
| patients hb response | #7 |
| mpa arm | #7 |
| symptom subscale | #7 |
| intermediate odx | #7 |
| venlafaxine versus | #7 |
| menopause hot | #7 |
| odx score | #7 |
| skindex16 | #7 |
| patient anthracycline | #7 |
| pregabalin prevention | #7 |
| cyclophosphamidedoxorubicin | #7 |
| transdermal clonidine | #7 |
| mucositis placebo | #7 |
| patients oral cryotherapy | #7 |
| placebocontrolled trial | #7 |
| paclitaxel peripheral | #7 |
| intervention lymphedema status | #7 |
| nutrition score | #7 |
| blind study | #7 |
| cryotherapy arm | #7 |
| lower extremity symptoms | #7 |
| weight concerns smokers | #7 |
| stage nodal status | #7 |
| cream versus | #7 |
| bupropion relapse | #7 |
| week followup | #7 |
| vte recurrence doac | #7 |
| smoking 3 | #7 |
| adjuvant interferon patients | #7 |
| minority smokers | #7 |
| illness antimetabolites | #7 |
| hemoccult hemoquant | #7 |
| fluoxetine clinical trials | #7 |
| uniscale qol | #7 |
| serum concentrations cytokines | #7 |
| recurrence colon cancer | #8 |
| smokers weight concerns | #8 |
| cancer survivors cipn | #8 |
| tamoxifeninduced hot flashes | #8 |
| agents newer | #8 |
| placebo suggestion | #8 |
| sdt1 | #8 |
| chronic neurotoxicity | #8 |
| 18 months symptoms | #8 |
| efficacy newer antidepressants | #8 |
| topic antineoplastic | #8 |
| libido women | #8 |
| epa survival | #8 |
| oral placebo | #8 |
| opioids moderate pain | #8 |
| cycle capecitabine | #8 |
| odx risk | #8 |
| flutamide placebo | #8 |
| pros aes | #8 |
| evidence pharmacologic interventions | #8 |
| prior chemotherapy exposure | #8 |
| venous toxicity | #8 |
| placebo pilot study | #8 |
| neuropathic symptoms | #8 |
| greater toxicity | #8 |
| raw data trials | #8 |
| 1355 | #8 |
| treatment cinv | #8 |
| cpmp | #8 |
| neuropathy scale | #8 |
| women hfs | #8 |
| nonhormonal treatments | #8 |
| 70305 | #8 |
| series clinical trials | #8 |
| fecal blood | #8 |
| progestational | #8 |
| oxaliplatin paclitaxel | #8 |
| oxaliplatin neuropathy | #8 |
| antidepressant patients | #8 |
| anecdotal | #8 |
| paclitaxel severity | #8 |
| induced painful | #8 |
| mouth sores | #8 |
| paclitaxel pain | #8 |
| life antibodies | #8 |
| administered systemically | #8 |
| neuropathy pain | #8 |
| venlafaxine hot flashes | #8 |
| symptoms neuropathy | #8 |
| direct oral factor | #8 |
| folfox dfs | #8 |
| stomatitis patients | #8 |
| oral iron placebo | #8 |
| severe hot flashes | #8 |
| factors cipn | #8 |
| 43 trials | #9 |
| study treatment arm | #9 |
| 5 nausea | #9 |
| hot flashes tamoxifen | #9 |
| flashes hot | #9 |
| cutaneous aged anesthetics | #9 |
| aged pilot | #9 |
| fosaprepitant | #9 |
| neuropathic symptoms patients | #9 |
| medications evidence | #9 |
| appetite weight | #9 |
| flash control | #9 |
| trial paroxetine | #9 |
| disease receive | #9 |
| incurable disease | #9 |
| cancer patients cipn | #9 |
| prevention vomiting | #9 |
| lymphedema prevention | #9 |
| baseline week week | #9 |
| incidence colorectal adenomas | #9 |
| genistein tumor growth | #9 |
| topical antimetabolites | #9 |
| follow tests | #9 |
| ambulatory analgesics | #9 |
| apixaban lower rate | #9 |
| questionnaires syndrome | #9 |
| radiationinduced esophagitis | #9 |
| letrozole day | #9 |
| sensory axonopathy | #9 |
| mometasone furoate placebo | #9 |
| lymphedema hrqol | #9 |
| cipn patients | #9 |
| surgical year | #9 |
| vitality subscale | #9 |
| skindex16 scores | #9 |
| antiemetic properties | #9 |
| dose dfmo | #9 |
| fatigue methylphenidate | #9 |
| lmwh injections | #9 |
| mucositis pain | #9 |
| acid amines | #9 |
| patients provided | #9 |
| disease recurrence recurrence | #9 |
| oxaliplatin placebo | #9 |
| lamotrigine pain | #9 |
| relapse relapse prevention | #9 |
| numbness fingers | #9 |
| patients hot | #9 |
| antineoplastic agents humans | #10 |
| nonhormonal therapies | #10 |
| trials demonstrated | #10 |
| recommendations general population | #10 |
| advanced cancer life | #10 |
| data relatedness | #10 |
| frequency hot flashes | #10 |
| cancerrelated fatigue fatigue | #10 |
| phase iii | #10 |
| differences 5 years | #10 |
| nonhormonal treatment | #10 |
| asco guideline | #10 |
| neoplasms neuralgia | #10 |
| shark cartilage | #10 |
| patients treatment period | #10 |
| scrambler therapy patients | #10 |
| life topic reproducibility | #10 |
| randomized placebo | #10 |
| combination therapy relapse | #10 |
| gabapentin | #10 |
| patients neurotoxic chemotherapy | #10 |
| flash data | #10 |
| sensitivity cancer | #10 |
| pain medications patients | #10 |
| doses citalopram | #10 |
| qol total | #10 |
| controlled randomized | #10 |
| chemotherapy‐induced | #10 |
| vaginal dryness | #10 |
| inhibit cyp2d6 | #10 |
| minocycline reduction | #10 |
| 40 arm | #10 |
| ecog kps | #10 |
| δ − | #10 |
| cognitive chemotherapy | #10 |
| ctcae grades | #10 |
| megestrol acetate quality | #10 |
| anorexia cachexia | #10 |
| incidence stomatitis | #10 |
| folfox 5fu | #10 |
| cancerassociated anemia | #10 |
| oxaliplatin peripheral | #10 |
| factes | #10 |
| adult cancers | #10 |
| symptomatic malignant ascites | #10 |
| life dietary supplements | #10 |
| qol anemia | #10 |
| venlafaxine arm | #10 |
| physical consequences | #10 |
| aprepitant treatment | #10 |
| oxaliplatin trpa1 | #10 |
| humans megestrol | #10 |
| electroanalgesia | #11 |
| institutional guideline | #11 |
| differences study arms | #11 |
| cancer undergoing | #11 |
| qol uniscale | #11 |
| promising data | #11 |
| vomiting cancer patients | #11 |
| hydrazine sulfate | #11 |
| dalteparin major bleeding | #11 |
| physicians increased risk | #11 |
| olanzapine chemotherapy | #11 |
| erythropoietic response | #11 |
| curve assay | #11 |
| gbu | #11 |
| fsfi female | #11 |
| reported incidences | #11 |
| ginseng placebo | #11 |
| sensory neurotoxicity | #11 |
| diphenhydramine lidocaine | #11 |
| flashes | #11 |
| ativan | #11 |
| combination treated | #11 |
| anastrozole 10 | #11 |
| nicotine patch therapy | #11 |
| prevalence neuropathic pain | #11 |
| melt curve | #11 |
| efficacy black cohosh | #11 |
| difficulty patients | #11 |
| translational component | #11 |
| antiemetic guidelines | #11 |
| cycles drugs | #12 |
| individuals advanced adenomas | #12 |
| cachexia clinical trials | #12 |
| irox folfox | #12 |
| probability prospective studies | #12 |
| venlafaxine hydrochloride | #12 |
| oxaliplatin induced | #12 |
| adjuvant communication decision | #12 |
| apixaban dalteparin | #12 |
| reported peripheral | #12 |
| completed daily | #12 |
| decreased libido | #12 |
| hb response | #12 |
| pluronic lecithin organogel | #12 |
| cipn development | #12 |
| ctpm | #12 |
| −307 | #12 |
| hot flashes 95 | #12 |
| capsaicin cream | #12 |
| neurotoxic chemotherapy | #12 |
| breast cancer letrozole | #12 |
| toxicities groups | #12 |
| pilot trial levetiracetam | #12 |
| toxicity 4 weeks | #12 |
| patients cipn symptoms | #12 |
| gait testing | #12 |
| leptin cck8 | #12 |
| valerian placebo | #12 |
| recurrence comparisons | #12 |
| venlafaxine women | #12 |
| rash quality | #12 |
| autonomic scale | #13 |
| bmd 1 year | #13 |
| treatment advanced cancer | #13 |
| 2000 update | #13 |
| median hb | #13 |
| adjuvant benefit | #13 |
| life neoplasm recurrence | #13 |
| acute treatment vte | #13 |
| life investigation | #13 |
| neuropathy outcome | #13 |
| weight cachexia | #13 |
| education clinical practice | #13 |
| incident exposure | #13 |
| troubling | #13 |
| rs3213619 | #13 |
| patients diphenhydramine | #13 |
| venlafaxine paroxetine | #13 |
| major bleeding doac | #13 |
| common toxicity | #13 |
| estimates prognosis | #13 |
| patients breakthrough cinv | #13 |
| andropause | #13 |
| adjuvant colon cancer | #13 |
| 40 points 95 | #13 |
| trial support | #13 |
| paroxetine hot flashes | #13 |
| ncctg | #13 |
| hot flashes baseline | #13 |
| adenomas aspirin | #13 |
| months smoking | #13 |
| megestrol acetate therapy | #13 |
| troublesome symptoms | #13 |
| nausea patients | #13 |
| abh gel | #13 |
| therapy benefits | #13 |
| neuropathic pain surgery | #13 |
| severity hot flashes | #13 |
| initial 3 months | #13 |
| venlafaxine life | #13 |
| patients advancedstage cancer | #13 |
| 10 range | #13 |
| valerian sleep | #13 |
| improve cancer | #13 |
| newer antidepressants placebo | #13 |
| flashes day | #13 |
| ais women | #13 |
| oral anesthetics | #13 |
| anemia life | #13 |
| prophylactic agent | #14 |
| fluoxymesterone | #14 |
| genital symptoms | #14 |
| based topical | #14 |
| benefit toxicity | #14 |
| phase 3 months | #14 |
| 5fu surgery | #14 |
| life anemia | #14 |
| flash activity | #14 |
| smokers placebo | #14 |
| patients pain scores | #14 |
| provided data | #14 |
| diagnosis localized disease | #14 |
| stool dna | #14 |
| palliate | #14 |
| marked toxicity | #14 |
| oral iron | #14 |
| oxaliplatin vivo | #14 |
| recurrences patients | #14 |
| biomarkers bone formation | #14 |
| aes treatment | #15 |
| academic oncologists | #15 |
| evidence treatment options | #15 |
| syndromes peripheral | #15 |
| therapy nicotine | #15 |
| adjuvant aromatase | #15 |
| androgen ablation therapy | #15 |
| bfq | #15 |
| duloxetine cipn | #15 |
| trials gabapentin | #15 |
| monoclonal carcinoma antibodies | #15 |
| advanced cancer methods | #15 |
| acute diarrhea patients | #15 |
| folfox irox | #15 |
| advanced malignant disease | #15 |
| 16–28 | #15 |
| agents life | #15 |
| oxaliplatininduced neurotoxicity | #15 |
| suggestion guideline | #15 |
| week baseline | #15 |
| week darbepoetin | #15 |
| persistent incisional pain | #15 |
| grade age | #15 |
| mastectomy irradiation | #15 |
| vaginal dryness dyspareunia | #15 |
| prognosis quality life | #15 |
| highly emetogenic | #15 |
| acceptability device | #15 |
| triazoles zoledronic | #15 |
| treatment weeks patients | #15 |
| clinician perception | #15 |
| life life survivors | #15 |
| sternal skin conductance | #15 |
| taste alterations | #15 |
| lidocaine patch | #15 |
| vte apixaban | #16 |
| premenopausal women chemotherapy | #16 |
| loss appetite | #16 |
| patients venlafaxine | #16 |
| female cancer survivors | #16 |
| induced hot | #16 |
| product time | #16 |
| treatment cancer vte | #16 |
| venlafaxine patients | #16 |
| advancedstage cancer patients | #16 |
| tingling pain | #16 |
| symptoms numbness | #16 |
| randomized trial aspirin | #16 |
| antiemetic agent | #16 |
| breast gynecologic cancer | #16 |
| mfsi | #16 |
| diarrhoea time | #16 |
| stool dna test | #16 |
| dalteparin 95 | #16 |
| rash pruritus | #16 |
| paclitaxel oxaliplatin | #16 |
| findings education | #16 |
| patch therapy | #16 |
| measurable evaluable disease | #16 |
| endpoints baseline | #16 |
| reduction fatigue | #17 |
| recommendation suggestion | #17 |
| fractional co2 | #17 |
| adenomas 1 | #17 |
| flashes tamoxifen | #17 |
| 786 patients | #17 |
| venlafaxine | #17 |
| study tetracycline | #17 |
| dfs folfox | #17 |
| screen detection | #17 |
| device women | #17 |
| cancer menopause | #17 |
| crc patients patients | #17 |
| rs11849538 | #17 |
| inadequate control | #17 |
| institute common | #17 |
| leptin concentrations groups | #17 |
| arthralgias | #17 |
| breast cancer oestrogen | #17 |
| 18 months women | #17 |
| women metastatic | #17 |
| oxaliplatin doses | #17 |
| leap study | #17 |
| vaginal symptoms | #17 |
| arhgef10 | #17 |
| oxaliplatin treated | #17 |
| secondary endpoint analysis | #18 |
| intervention guidelines | #18 |
| sigmoidoscopy tomography | #18 |
| severity cipn | #18 |
| patients overview | #18 |
| flash frequencies | #18 |
| randomized trials women | #18 |
| sternal skin | #18 |
| patients informed decisions | #18 |
| data followup | #18 |
| subsets age | #18 |
| oral dronabinol | #18 |
| menopausal problems | #18 |
| baseline 4 | #18 |
| patients hb | #18 |
| 5 adjuvant | #18 |
| standard prognostic | #18 |
| symptoms hormone | #18 |
| mri mastectomy | #18 |
| oncology providers patients | #18 |
| placebo 04 | #18 |
| receiving head | #18 |
| patients irox | #18 |
| severity hot | #18 |
| postmenopausal women letrozole | #18 |
| treatment osteopenia | #18 |
| prophylactic antiemetic therapy | #18 |
| 120000 | #18 |
| folfox fluorouracil | #19 |
| life gabapentin | #19 |
| induced mucositis | #19 |
| groups infliximab | #19 |
| physician reported | #19 |
| mastectomy methotrexate | #19 |
| oxaliplatin carboplatin | #19 |
| previous colorectal | #19 |
| rs7349683 | #19 |
| neoplasms peripheral | #19 |
| panax quinquefolius | #19 |
| ncdf | #19 |
| double blinded | #19 |
| unpleasant taste | #19 |
| evidence status | #19 |
| acute cancer | #19 |
| treatment mastectomy | #19 |
| oxaliplatin neurotoxicity | #19 |
| n6 n5 | #19 |
| minimal adverse effects | #19 |
| 95 46 | #19 |
| bmd neoplasms chemotherapy | #19 |
| 7 outcomes | #19 |
| flash reduction | #19 |
| patients based chemotherapy | #19 |
| diseases randomized | #20 |
| revisitation | #20 |
| therapeutic options treatment | #20 |
| pilot trials | #20 |
| numbness | #20 |
| moderate pain patients | #20 |
| study ginseng | #20 |
| baseline week | #20 |
| fecal occult | #20 |
| life skindex16 | #20 |
| advanced cancer study | #20 |
| fatigue 4 | #20 |
| reducing pain | #20 |
| emetogenic chemotherapy | #20 |
| major bleeding treatment | #20 |
| placebo smokers | #20 |
| palliating | #20 |
| placebo cream | #20 |
| cancer cancer therapy | #20 |
| surveillance protocol | #20 |
| appetite nutritional status | #20 |
| receiving pelvic | #20 |
| progestational agents | #20 |
| crossover analysis | #21 |
| receptorpositive breast cancer | #21 |
| acetate patients | #21 |
| radiationinduced dermatitis | #21 |
| treatment options women | #21 |
| studies methylphenidate | #21 |
| cancer starting | #21 |
| oral mucositis pain | #21 |
| metastatic breast carcinoma | #21 |
| substantial problem | #21 |
| routine test | #21 |
| management cachexia | #21 |
| cipn symptoms | #21 |
| therapy adverse effects | #21 |
| female menopause | #21 |
| chemotherapy agents | #21 |
| trial 12 months | #21 |
| refractory cachexia | #21 |
| subcutaneous testosterone | #22 |
| optumlabs | #22 |
| scores ≤ | #22 |
| 150 groups | #22 |
| guideline intervention | #22 |
| severity adverse events | #22 |
| asco panel | #22 |
| doc time | #22 |
| patients 5 weeks | #22 |
| median time initiation | #22 |
| gain patients | #22 |
| n9741 | #22 |
| crossover phase | #22 |
| npy leptin | #22 |
| patients testosterone | #22 |
| projects quality | #22 |
| location stage | #22 |
| emetogenic | #22 |
| candidate single | #22 |
| pharmacokinetics infliximab | #22 |
| stool dna testing | #23 |
| acetate middle | #23 |
| fsdsr | #23 |
| detecting recurrence | #23 |
| potential toxicities | #23 |
| aes qol | #23 |
| decision adjuvant | #23 |
| 5 pounds | #23 |
| mcf7 cells genistein | #23 |
| acupuncture hot | #23 |
| sucralfate patients | #23 |
| life ascites | #23 |
| mascc isoo | #23 |
| versus delayed | #23 |
| followup tests | #23 |
| prevention chemotherapy | #24 |
| replacement testosterone | #24 |
| female hot | #24 |
| ortho biotech | #24 |
| aged anorexia | #24 |
| mirtazapine patients | #24 |
| adjuvant decision making | #24 |
| hrt survival | #24 |
| day chemotherapy | #24 |
| topic design severity | #24 |
| apixaban treatment | #24 |
| abstract5fluorouracil | #24 |
| weeks primary | #24 |
| pilot clinical | #24 |
| every3 | #24 |
| randomized 1 | #24 |
| design rcts | #24 |
| aged amines | #24 |
| n56 | #24 |
| tamoxifen octreotide | #24 |
| neoplasia screening | #25 |
| lymphedema incidence | #25 |
| vte trial | #25 |
| placebo arm treatment | #25 |
| nausea olanzapine | #25 |
| mmf placebo | #25 |
| doses schedules | #25 |
| severe nausea vomiting | #25 |
| bpisf | #25 |
| prevention nausea | #25 |
| cancerassociated weight loss | #25 |
| recommendations basis | #25 |
| antiepileptic agent | #25 |
| women adjuvant tamoxifen | #25 |
| criteria adverse | #25 |
| institutional guidelines | #25 |
| qol tools | #25 |
| cco guideline | #25 |
| trial pilot | #25 |
| oncology journals | #26 |
| irradiation mastectomy | #26 |
| trial evaluate | #26 |
| undergoing adjuvant | #26 |
| mfsisf | #26 |
| regional breast | #26 |
| neoplasms estrogens | #26 |
| treatment arms | #26 |
| combination weight loss | #26 |
| agents prevention | #26 |
| receiving oxaliplatin | #26 |
| 2005 update | #26 |
| prior week | #26 |
| colorectal adenomas patients | #26 |
| cachexia carcinoma | #26 |
| nci ctc | #26 |
| induced musculoskeletal | #26 |
| aiinduced | #26 |
| clinical trials chemotherapy | #26 |
| dose gabapentin | #26 |
| joints muscles | #26 |
| syndrome menopause | #26 |
| fubased | #27 |
| neuropathy symptoms | #27 |
| events ctcae | #27 |
| antiemetic | #27 |
| series trials | #27 |
| valerian | #27 |
| smoking bupropion | #27 |
| hot flashes hf | #27 |
| lmwh survival | #27 |
| adjuvant 5fu | #27 |
| patients short term | #27 |
| nurse survey | #27 |
| recommendations trials | #27 |
| lymphedema arm | #27 |
| prophylactic antiemetic | #27 |
| mastectomy rate | #28 |
| prevent colorectal adenomas | #28 |
| lidocaine patches | #28 |
| muscles joints | #28 |
| chest rays | #28 |
| fluoxetine citalopram | #28 |
| treatment hot flushes | #28 |
| matched general population | #28 |
| newer | #28 |
| describers | #28 |
| primary endpoint proportion | #28 |
| intractable palliative | #28 |
| standard prognostic factors | #28 |
| alliance | #28 |
| definitively | #28 |
| gynecologic cancer survivors | #28 |
| citalopram placebo | #29 |
| patients paclitaxel | #29 |
| blood screening | #29 |
| placebo arm | #29 |
| statistical controversies | #29 |
| difluoromethylornithine dfmo | #29 |
| smokers bupropion | #29 |
| mucositis study | #29 |
| taxanebased chemotherapy | #29 |
| pain cancer survivors | #29 |
| points study | #29 |
| vitamin incidence | #29 |
| survival arms | #29 |
| paclitaxel cipn | #29 |
| biological predictors | #29 |
| chemotherapy cipn | #29 |
| efficacy venlafaxine | #29 |
| feet hands | #29 |
| asco guideline update | #29 |
| twoyear followup | #30 |
| development cipn | #30 |
| alfa darbepoetin | #30 |
| management oral mucositis | #30 |
| benadryl | #30 |
| cipn pain | #30 |
| anthrapyrazoles | #30 |
| month duration | #30 |
| postmenopause predictive | #30 |
| mild nausea | #30 |
| pain oral | #30 |
| middle aged postmenopause | #30 |
| diseases peripheral | #30 |
| contralateral axillary | #30 |
| phase iii comparison | #30 |
| loss postmenopausal | #30 |
| usual oncology | #30 |
| small pilot | #30 |
| treatment acute vte | #31 |
| patients races | #31 |
| pain quality life | #31 |
| benefit dfs | #31 |
| calcium magnesium | #31 |
| symptomatic ascites | #31 |
| middle aged perimenopause | #31 |
| efficacy methylphenidate | #31 |
| prevention oral mucositis | #31 |
| management menopausal symptoms | #31 |
| patients secondary analysis | #31 |
| sixtysix patients | #31 |
| treatment paclitaxel | #31 |
| term rectal | #31 |
| ixabepilone patients | #31 |
| mastectomy mri | #31 |
| arms placebo | #31 |
| oncologist patients | #32 |
| female services | #32 |
| vera gel | #32 |
| guideline endorsement | #32 |
| women lymphedema | #32 |
| rash severity | #32 |
| breast cancer symptoms | #32 |
| doubleblind trial | #32 |
| receiving highly | #32 |
| evidencebased guidance | #32 |
| delayed chemotherapy | #32 |
| camg | #32 |
| neuropathy patients | #33 |
| isoo | #33 |
| smokers randomized | #33 |
| hands feet | #33 |
| questionnaires total | #33 |
| sensitivity polyps | #33 |
| survival advanced cancer | #33 |
| patients taxol | #33 |
| increased difficulty | #33 |
| aloe vera gel | #33 |
| week treatment | #33 |
| toxicity breast | #33 |
| therapy bupropion | #33 |
| instruments life | #33 |
| patients cinv | #33 |
| painful cipn | #33 |
| neoplasms carboplatin | #33 |
| pursuant | #33 |
| chemotherapeutic regimens | #33 |
| blind manner | #33 |
| dose megestrol | #33 |
| fingers hands | #33 |
| acupuncture hot flashes | #33 |
| 4week followup | #33 |
| breast neoplasms life | #33 |
| chemotherapy hec | #34 |
| toxicity fluorouracil | #34 |
| patients acitretin | #34 |
| continuation study | #34 |
| patients nausea | #34 |
| united states hrqol | #35 |
| levels week | #35 |
| dawley statistics | #35 |
| prevention chemotherapyinduced nausea | #35 |
| primary outcomes trials | #35 |
| treating cancer | #35 |
| trial designed | #35 |
| cipn severity | #35 |
| carcinoembryonic antigen levels | #35 |
| patients tools | #35 |
| 4 week | #35 |
| cancer international society | #35 |
| inhibitors venlafaxine | #35 |
| stomatitis | #35 |
| major bleeding lmwh | #35 |
| formal consensus process | #35 |
| moderatetosevere patients | #35 |
| pyrexia patients | #36 |
| tnfα study | #36 |
| pain pilot | #36 |
| cohosh | #36 |
| head neck radiotherapy | #36 |
| mometasone placebo | #36 |
| doxepin | #36 |
| lymphedema treatment | #36 |
| myalgias | #36 |
| secondary prevention measures | #36 |
| nk1ras | #36 |
| stages colorectal cancer | #36 |
| global impression | #37 |
| survival supportive | #37 |
| alleviation | #37 |
| mc5 | #37 |
| ctcae | #37 |
| topic humans life | #37 |
| planned sample size | #37 |
| topic stomatitis | #37 |
| study intravenous | #37 |
| symptoms cancer | #37 |
| nausea neoplasms | #37 |
| early integrated | #37 |
| cancerrelated fatigue | #37 |
| chronic nausea | #37 |
| p00052 | #37 |
| illness purpose | #38 |
| oncology providers | #38 |
| individual item | #38 |
| patients taxanes | #38 |
| tests controlled trials | #38 |
| women metastatic disease | #38 |
| patients highdose melphalan | #38 |
| relationships populations | #38 |
| sensitization nociceptors | #38 |
| trial conducted | #38 |
| fluorouracil based | #38 |
| 5ht3ras | #38 |
| crushed ice | #39 |
| cohort type | #39 |
| chi2 tests | #39 |
| arm placebo | #39 |
| arm difference | #39 |
| menopause gsm | #39 |
| 3 agents | #39 |
| european organisation cancer | #39 |
| blind crossover | #39 |
| treatment breakthrough | #39 |
| qol clinical trials | #39 |
| trials oncology | #39 |
| acids drug | #39 |
| grade 2 toxicity | #39 |
| study double | #39 |
| topic reproducibility surveys | #40 |
| arthralgia breast | #40 |
| initial mastectomy | #40 |
| appetite patients | #40 |
| mastectomy chemotherapy | #40 |
| single dose placebo | #40 |
| cachexia clinical | #40 |
| difluoromethylornithine | #40 |
| patients lamotrigine | #40 |
| terminology criteria | #40 |
| prevent colorectal | #40 |
| method fatigue | #40 |
| treatment analyses | #40 |
| bupropion smokers | #41 |
| symptoms 12 months | #41 |
| drug evaluation studies | #41 |
| treatment period | #41 |
| undergoing androgen | #41 |
| zoledronic acid bmd | #41 |
| gabapentin placebo | #41 |
| smokers weight | #41 |
| relapse 3 months | #41 |
| united states guidelines | #41 |
| cure recurrence | #41 |
| trial performed | #41 |
| neuronal protection | #42 |
| oral gabapentin | #42 |
| placebo venlafaxine | #42 |
| location age | #42 |
| nortriptyline placebo | #42 |
| patients incurable | #42 |
| randomized doubleblind trial | #42 |
| patients completed | #42 |
| appetite body | #42 |
| treating institution | #42 |
| chemotherapy day | #42 |
| transdermal gel | #42 |
| highdose interferon | #43 |
| baseline fatigue | #43 |
| sex location | #43 |
| preliminary insights | #43 |
| desipramine patients | #43 |
| postsurgical | #43 |
| median weight | #43 |
| dietary supplements life | #43 |
| 5 induced | #43 |
| nonpain | #44 |
| bupropion placebo | #44 |
| weeks efficacy | #44 |
| trial benefit | #44 |
| chemotherapyinduced nausea vomiting | #44 |
| vaginal moisturizer | #44 |
| disagreement | #44 |
| collaborative effort | #44 |
| outcome gamma | #44 |
| pain reduction patients | #44 |
| risk cipn | #44 |
| surveillance united states | #44 |
| sensory symptoms | #44 |
| conclusion trial | #45 |
| survivors colorectal cancer | #45 |
| humans peripheral | #45 |
| piroxantrone | #45 |
| ginseng panax quinquefolius | #45 |
| genitourinary syndrome menopause | #45 |
| fisher tests | #45 |
| 5 years incidence | #45 |
| menogaril | #45 |
| objective tumor regression | #45 |
| rash grade | #45 |
| acute pain patients | #45 |
| historic controls | #45 |
| vaccines melanoma | #46 |
| iii colon cancer | #46 |
| radiationinduced oral mucositis | #46 |
| middle aged patient | #46 |
| adverse symptoms | #46 |
| current manuscript | #46 |
| megestrol acetate treatment | #46 |
| cisplatin neuropathy | #46 |
| study gaba | #46 |
| putative mechanism | #46 |
| item measures | #46 |
| randomized comparison | #46 |
| radiotherapy randomized | #46 |
| longitudinal methods | #46 |
| nonpharmacological therapy | #46 |
| chemotherapy antineoplastic | #46 |
| factor prognostic | #46 |
| patients advanced adenomas | #46 |
| acute skin toxicity | #46 |
| epoetin alfa placebo | #46 |
| phase iii life | #46 |
| clinical problem | #46 |
| genetic predictors | #47 |
| neoplasms parenteral nutrition | #47 |
| differences pros | #47 |
| darbepoetin alfa patients | #47 |
| twopart | #47 |
| mascc | #47 |
| screening setting | #47 |
| dose paclitaxel | #47 |
| bipn | #47 |
| aged mometasone | #47 |
| average pain | #47 |
| cachexia female | #47 |
| genitourinary symptoms | #48 |
| oxybutynin | #48 |
| stratification factor | #48 |
| qol female humans | #48 |
| neck radiotherapy | #48 |
| menopause life | #48 |
| placebo gabapentin | #48 |
| nausea day | #48 |
| physical examinations | #48 |
| chemotherapy nausea | #49 |
| female cancer | #49 |
| patientclinician communication | #49 |
| sham arm | #49 |
| flie | #49 |
| cachexia | #50 |
| models stage | #50 |
| hot flashes hfs | #50 |
| replens | #50 |
| pain numbness | #50 |
| antiserotonergic | #50 |
| receiving androgen | #50 |
| placebos randomized | #50 |
| cancer survivors fatigue | #50 |
| time conclusions | #50 |
| mastectomy pain | #50 |
| regional hypothermia | #51 |
| patients cancer pain | #51 |
| vomiting chemotherapy | #51 |
| cisplatin humans | #51 |
| blinded placebo | #51 |
| transdermal testosterone | #51 |
| effective treating | #51 |
| genitourinary syndrome | #51 |
| patients 8 weeks | #51 |
| metaanalysis incidence | #52 |
| risk bone loss | #52 |
| management chemotherapy | #52 |
| treatment adt | #52 |
| differences treatment arms | #52 |
| aged orchiectomy | #52 |
| trastuzumab orr | #52 |
| 80k | #52 |
| black cohosh | #52 |
| control nausea | #53 |
| purposepatients | #53 |
| nervous peripheral | #53 |
| cancer venous | #53 |
| receiving radiotherapy | #53 |
| potential adjuvant | #53 |
| toxicity time | #53 |
| tamoxifen antineoplastic agents | #53 |
| double‐blind trial | #54 |
| 20 data | #54 |
| recurrent disease | #54 |
| levetiracetam treatment | #54 |
| treatment months | #54 |
| severe hot | #54 |
| blood testing | #54 |
| antiemetics antineoplastic | #54 |
| pilot trial | #54 |
| standard placebo | #54 |
| life topic humans | #54 |
| acupuncture cancer | #55 |
| bupropion treatment | #55 |
| cancerdirected therapy | #55 |
| treatment tobacco dependence | #55 |
| symptoms therapy | #55 |
| serial levels | #55 |
| scalp cooling | #55 |
| cachexia therapy | #55 |
| fatigue inventory | #55 |
| undergoing chemotherapy | #56 |
| diseases antineoplastic | #56 |
| time placebo | #56 |
| carboplatin female humans | #56 |
| adjuvant endocrine treatment | #56 |
| symptoms hot | #56 |
| xaliproden | #56 |
| adjuvant colon | #57 |
| recurrence symptoms | #57 |
| common terminology | #57 |
| 12 courses | #57 |
| placebo solution | #57 |
| benefit scale | #57 |
| points placebo | #58 |
| topical gel | #58 |
| limited degree | #58 |
| skin dermatitis | #58 |
| major bleeding enoxaparin | #58 |
| undergoing treatment | #58 |
| cachexia weight loss | #58 |
| compared oral | #58 |
| pain peripheral | #58 |
| ferric gluconate | #58 |
| completion adjuvant chemotherapy | #58 |
| quality life questionnaire | #58 |
| osteopaenia | #59 |
| placebo citalopram | #59 |
| weight appetite | #59 |
| patients hec | #59 |
| safety rivaroxaban | #59 |
| coprescription | #59 |
| chemotherapyinduced nausea | #59 |
| chemotherapy cognitive | #59 |
| ocular irritation | #59 |
| data understanding | #59 |
| patients mirtazapine | #60 |
| anticonvulsants antidepressive | #60 |
| colonoscopically | #60 |
| study medication | #60 |
| serotonergic effects | #60 |
| hb baseline | #60 |
| cancer patients study | #61 |
| 3 randomized | #61 |
| doubleblind | #61 |
| caregivers pain | #61 |
| lymphedema women | #61 |
| standard dosing | #61 |
| topic surveys life | #61 |
| 1 week treatment | #61 |
| emla cream | #61 |
| paroxetine fluoxetine | #61 |
| tamoxifen metabolism | #61 |
| bleomycin patients | #61 |
| pipn | #61 |
| sensitivity individuals | #61 |
| recurrent disease patients | #62 |
| ocular toxicity | #62 |
| dermatological toxicities | #62 |
| efficacy fluoxetine | #62 |
| alpha weight | #62 |
| venlafaxine placebo | #62 |
| chemotherapy dose | #62 |
| fluorouracil induced | #62 |
| induced taste | #62 |
| pain bleeding | #62 |
| anorexia patients | #63 |
| integrative oncology | #63 |
| ncictc | #63 |
| antibodies monoclonal carcinoma | #63 |
| 105 months | #63 |
| lessen | #63 |
| patients disease recurrence | #63 |
| aged placebos | #63 |
| prior chemotherapy regimen | #63 |
| patients cancer types | #64 |
| incidence rash | #64 |
| allelic variability | #64 |
| versus placebo | #64 |
| treatment chemotherapy | #64 |
| cyclohexanols | #64 |
| improvement sexual function | #64 |
| carboplatin oxaliplatin | #64 |
| cyproheptadine | #64 |
| painful peripheral neuropathy | #64 |
| alleviate | #64 |
| aged nausea | #64 |
| bupropion nicotine | #64 |
| rivaroxaban enoxaparin | #64 |
| efficacy toxicity | #65 |
| validated patient | #65 |
| appetite weight loss | #65 |
| patients comparisons | #65 |
| patients minocycline | #65 |
| 75 daily | #65 |
| survivorship issues | #65 |
| dalteparin treatment | #65 |
| agents double | #65 |
| 4 weeks week | #65 |
| administration paclitaxel | #65 |
| diseases neoplasms | #66 |
| nicotine nasal | #66 |
| food intake patients | #66 |
| acetate therapy | #66 |
| study gabapentin | #66 |
| oncology clinical | #66 |
| placebo months | #66 |
| life topic | #67 |
| qol fatigue | #67 |
| estrogen suppression | #67 |
| target doses | #67 |
| clinician training | #67 |
| induced dermatitis | #68 |
| patients randomized | #68 |
| prevention smoking | #68 |
| cachexia weight | #68 |
| pilocarpine treatment | #68 |
| subcutaneous dalteparin | #68 |
| baseline study | #68 |
| hec | #68 |
| hormonal therapies | #68 |
| 46 95 | #68 |
| vasomotor symptoms women | #69 |
| ongoing loss | #69 |
| skin surveys | #69 |
| gained weight | #69 |
| fsfi score | #69 |
| debilitating | #69 |
| induced ovarian | #70 |
| chemotherapy anemia | #70 |
| multifactorial syndrome | #70 |
| item score | #70 |
| development severity | #70 |
| surgery cancer | #70 |
| women ais | #70 |
| nonsignificant trends | #70 |
| major bleeding apixaban | #71 |
| life referral | #71 |
| week percentage | #71 |
| infliximab combination | #71 |
| anthrapyrazole | #71 |
| incidence severity | #71 |
| weight compared | #71 |
| trials planning | #72 |
| effects ginseng | #72 |
| placebo patches | #72 |
| cisplatin treated | #72 |
| patients pilot | #72 |
| oral drug administration | #72 |
| humans lignans | #72 |
| systemic retinoids | #72 |
| chemoprevention trial | #73 |
| stage primary | #73 |
| ergotamines | #73 |
| weeks placebo | #73 |
| prospective pilot trial | #73 |
| ginseng treatment | #73 |
| chemotherapy supportive | #73 |
| placebo | #73 |
| receiving chemotherapy | #74 |
| rcts systematic reviews | #74 |
| anemia antineoplastic | #74 |
| dronabinol | #74 |
| trial evaluating | #74 |
| women estrogen therapy | #74 |
| fractional co2 laser | #74 |
| rash | #74 |
| qli | #74 |
| 353 patients | #75 |
| nervous diseases | #75 |
| prevention | #75 |
| cancerrelated fatigue crf | #75 |
| acid supplement | #75 |
| weekly arm | #76 |
| acute skin | #76 |
| cycles cycle | #76 |
| inhibitors tamoxifen | #76 |
| blind clinical | #76 |
| anorexia weight loss | #77 |
| breast cancer paclitaxel | #77 |
| hospice staff | #77 |
| dose 90 | #77 |
| 95 01 | #77 |
| alliance patients | #77 |
| week p005 | #77 |
| cancer randomized | #77 |
| tamoxifen postmenopausal | #77 |
| anemia darbepoetin | #77 |
| tamoxifen postmenopausal women | #78 |
| values data | #78 |
| 3 arm | #78 |
| female humans insurance | #78 |
| patients zoledronic acid | #78 |
| vte recurrence | #79 |
| pain syndrome | #79 |
| week schedule | #79 |
| serum concentrations infliximab | #79 |
| surgery year | #79 |
| patients darbepoetin alfa | #79 |
| efficacy lamotrigine | #79 |
| therapy antineoplastic | #79 |
| symptoms sensitivity | #79 |
| foot syndrome | #80 |
| week 4 | #80 |
| vomiting antiemetics | #80 |
| zoledronic acid treatment | #80 |
| time mastectomy | #80 |
| isoflavone supplements | #80 |
| life phase iii | #80 |
| oral oncology | #81 |
| guideline recommendation | #81 |
| period crossover | #81 |
| study march | #81 |
| lowmolecular weight heparin | #81 |
| patients treatment arms | #81 |
| patient qol | #81 |
| bupropion smoking | #82 |
| greater weight gain | #82 |
| suggestion | #82 |
| standard clinical | #82 |
| paroxetine patients | #82 |
| backgroundchemotherapy | #82 |
| patients participating | #83 |
| orbital stability | #83 |
| trpv1 trpa1 | #83 |
| day weeks | #83 |
| recommendations article | #83 |
| method female | #84 |
| trpm8 trpa1 | #84 |
| cinv patients | #84 |
| zinc sulfate | #84 |
| cancer weight | #85 |
| systematic reviews rcts | #85 |
| ice pack | #85 |
| neoplasm metastasis neoplasms | #85 |
| ttf survival | #86 |
| cryotherapy patients | #86 |
| receiving placebo | #86 |
| treatment nicotine dependence | #86 |
| mayo clinic | #86 |
| therapyinduced | #87 |
| baseline arms | #87 |
| pilot study safety | #87 |
| methodspatients | #87 |
| incidence osteoporosis | #87 |
| frequency severity | #87 |
| nicotine nasal spray | #87 |
| primary symptom | #87 |
| serum hepcidin levels | #87 |
| week 5 | #87 |
| life cachexia | #87 |
| integrative therapies | #88 |
| anecdotal reports | #88 |
| acp documentation | #88 |
| iu daily | #89 |
| cancer vte | #89 |
| putative mediator | #89 |
| treatment fatigue | #89 |
| clinical oncology asco | #90 |
| morphine pharmacokinetics | #90 |
| outcome venlafaxine | #90 |
| male chemotherapy | #90 |
| scores placebo | #91 |
| endoxifen concentrations | #91 |
| delayed cinv | #91 |
| tolerated patients | #91 |
| iii efficacy | #91 |
| ncorp | #91 |
| arm treatment | #91 |
| symptoms including | #91 |
| completion chemotherapy | #92 |
| patients paroxetine | #92 |
| nerve pain | #92 |
| cisplatin oxaliplatin | #92 |
| trials treatment | #92 |
| patients upfront | #92 |
| ameliorating | #93 |
| neoplasms quality life | #94 |
| duloxetine hydrochloride | #94 |
| apixaban dose | #94 |
| questionnaires survival | #94 |
| arm 3 | #94 |
| 1 primary | #94 |
| breast cancer survivors | #94 |
| mometasone | #94 |
| quiet stance | #94 |
| anemic patients | #94 |
| patients appetite | #95 |
| alfa patients | #95 |
| common symptoms | #95 |
| cancerrelated pain | #95 |
| prevention management | #96 |
| ccop | #96 |
| 0 10 | #96 |
| failure chemotherapy | #96 |
| hlaa2 patients | #96 |
| mayo clinic rochester | #96 |
| udi | #96 |
| patients completion | #96 |
| pyrexia | #97 |
| paclitaxel patient | #97 |
| adjuvant therapy survival | #97 |
| acute vte | #97 |
| oral mucositis patients | #97 |
| painful area | #98 |
| identical placebo | #98 |
| text review | #98 |
| treatment tolerability | #98 |
| crnmb | #98 |
| preliminary data | #98 |
| completed study | #98 |
| 15 points | #98 |
| alleviating | #98 |
| agents paclitaxel | #98 |
| induced esophagitis | #99 |
| 5fu leucovorin | #99 |
| 4 weeks baseline | #99 |
| patient questionnaires | #99 |
| bcca | #99 |
| 5fluorouracil oxaliplatin | #99 |
| patient medical | #99 |
| pregnadienediols | #99 |
| topic cyclophosphamide | #99 |
| fatigue insomnia | #99 |
| difference incidence | #99 |
| qlq | #100 |
| 10 doses | #100 |
| clinician communication | #100 |
| oncology outpatients | #100 |
| survival nsclc | #100 |
| male sex factors | #100 |
| postresection | #101 |
| oncology asco | #101 |
| lung cancer chemoprevention | #101 |
| oncology clinicians | #101 |
| antineoplastic agents life | #101 |
| humans life | #101 |
| lidocaine lidocaine | #101 |
| 275 patients | #101 |
| nortriptyline | #101 |
| 5 based | #101 |
| methods trial | #102 |
| placebo 1 year | #102 |
| variance clinical trials | #103 |
| reported effects | #103 |
| purposeprevious | #104 |
| races ethnicities | #104 |
| patients anorexia | #104 |
| 3106 | #104 |
| quality life data | #104 |
| diseases treatment | #105 |
| patients 150 | #105 |
| phytogenic clinical trials | #105 |
| chemotherapy cycle | #105 |
| leap | #105 |
| 12 24 months | #105 |
| dfmo | #106 |
| infusion site | #106 |
| stool samples patients | #106 |
| months relapse | #106 |
| trial studies | #106 |
| neuropathy | #106 |
| compounds oxaliplatin | #106 |
| nutritional determinants | #106 |
| dalteparin patients | #106 |
| humans menopause | #107 |
| versus dexamethasone | #107 |
| valeriana officinalis | #107 |
| pain intensity ratings | #107 |
| anastrozole letrozole | #107 |
| cycle cycles | #107 |
| urogenital diseases | #107 |
| epoetin alfa patients | #107 |
| women experience | #108 |
| time toxicity | #108 |
| breast cancer tamoxifen | #108 |
| week study | #108 |
| relapse prevention | #108 |
| life topic severity | #108 |
| strong prognostic factor | #109 |
| levocarnitine | #109 |
| female urogenital | #109 |
| patients guideline | #109 |
| treatment cancer pain | #109 |
| mouthwash | #109 |
| women vasomotor symptoms | #109 |
| patients cancer treatment | #110 |
| clinic rochester | #110 |
| combined paclitaxel | #110 |
| life adverse events | #110 |
| oxaliplatin therapy | #110 |
| egfr inhibitor | #111 |
| vomiting adult | #111 |
| prevention bone loss | #111 |
| cmf chemotherapy | #111 |
| insomnia pain | #112 |
| function suppression | #112 |
| dosing schedules | #112 |
| vaginal diseases | #113 |
| adverse events ctcae | #113 |
| functional iron deficiency | #113 |
| patients arms | #113 |
| colorectal neoplasia | #113 |
| visits patient | #113 |
| reassess | #113 |
| –iii | #113 |
| treatment arms patients | #113 |
| agents hormonal | #113 |
| vestibulitis | #113 |
| patients olanzapine | #114 |
| dietary lignans | #114 |
| diseases breast | #114 |
| single nucleotide variants | #114 |
| months 3 | #114 |
| therapy induced | #114 |
| hfsd | #114 |
| cachexia humans | #114 |
| acitretin | #114 |
| alopecia patients | #114 |
| qol patient | #114 |
| laser therapy lasers | #115 |
| crci | #115 |
| studies randomized | #115 |
| combination nicotine | #115 |
| rivaroxaban venous | #115 |
| letrozole tamoxifen | #115 |
| patients anthracycline | #115 |
| placebo postmenopausal women | #116 |
| treatment arm | #116 |
| nk1 receptor antagonist | #117 |
| symptoms chemotherapy | #117 |
| 2007 guidelines | #117 |
| induction ornithine decarboxylase | #117 |
| oral factor | #117 |
| patients peripheral neuropathy | #117 |
| oral antineoplastic agents | #118 |
| appetite stimulant | #118 |
| recurrence diagnosis | #118 |
| diseases pain | #119 |
| noradrenaline reuptake | #119 |
| trials conducted | #119 |
| trpa1 trpv1 | #119 |
| preventive therapies | #119 |
| patients weekly paclitaxel | #119 |
| 3915 | #119 |
| treatment weeks | #120 |
| resultswhile | #120 |
| original report | #120 |
| participants arms | #120 |
| clinical histories | #120 |
| definition classification | #120 |
| olanzapine placebo | #120 |
| 750 day | #120 |
| placebo double | #121 |
| patients cancers | #121 |
| hormonal agents | #121 |
| induced ocular | #121 |
| fullerton | #121 |
| untoward | #121 |
| postmenopausal postmenopause | #121 |
| nervous agents | #122 |
| oxaliplatin folfox | #122 |
| cancer multiple | #122 |
| skin pain | #123 |
| objective review | #123 |
| rolapitant | #123 |
| weeks 4 | #123 |
| acute oral | #123 |
| stable dose | #123 |
| cancer quality | #123 |
| surgery analysis | #123 |
| netupitant | #123 |
| rivaroxaban compared | #124 |
| pros baseline | #124 |
| neuropathic pain patients | #124 |
| patients diploid tumors | #124 |
| treatment letrozole | #124 |
| survivors breast cancer | #124 |
| isoflavones genistein | #124 |
| 1 month patients | #125 |
| week dose | #125 |
| 90 dose | #125 |
| factors odds | #126 |
| neurotoxic agents | #126 |
| resultsfour | #126 |
| patients physicians | #127 |
| recurrent adenomas | #127 |
| diagnosis metastatic disease | #127 |
| anorexia | #127 |
| hormonal breast | #127 |
| fsfi | #127 |
| genetic quality | #127 |
| promising agents | #127 |
| cancerassociated vte | #128 |
| weight concerns | #128 |
| alfa erythropoietin | #128 |
| uncommon variants | #128 |
| arms patients | #128 |
| belladonna | #128 |
| postural instability | #129 |
| vomiting cinv | #129 |
| agents neoplasms | #129 |
| clinical trial patients | #129 |
| resultsforty | #129 |
| 5 leucovorin | #129 |
| neoplasms quality | #129 |
| serum baseline | #130 |
| control arms | #130 |
| problem patients | #130 |
| patientreported outcome | #130 |
| cancer fatigue | #131 |
| 150 iu | #131 |
| prognostic variables | #131 |
| function fsfi | #131 |
| bmd tscore | #131 |
| treatment toxicities | #131 |
| pilot data | #132 |
| onycholysis | #132 |
| relapse smoking | #132 |
| efficacy vitamin | #132 |
| cancerrelated symptoms | #132 |
| neurotoxicity syndromes | #132 |
| assessable | #133 |
| cachexia patients | #133 |
| topical treatment | #133 |
| progress report | #133 |
| ginseng panax | #134 |
| 5 placebo | #134 |
| symptom control | #134 |
| ganglion block | #134 |
| endodermal sinus tumor | #134 |
| chemotherapy 5 | #135 |
| cancers patients | #135 |
| toxt | #135 |
| cold hyperalgesia | #135 |
| 150 women | #135 |
| agents generation | #135 |
| common adverse effects | #135 |
| bmd postmenopausal women | #135 |
| patientlevel pooled analysis | #136 |
| painful neuropathy | #136 |
| symptomatic benefit | #136 |
| npy levels | #136 |
| bothersome | #136 |
| weekly therapy | #136 |
| substantial benefit | #137 |
| poor qol | #137 |
| life physical function | #137 |
| percentage reduction | #137 |
| agents bortezomib | #137 |
| severe fatigue | #137 |
| stage cancer | #137 |
| intrapatient | #137 |
| study trials | #137 |
| grade stage | #138 |
| zoledronic | #138 |
| hfs patients | #138 |
| accrued | #138 |
| advanced lung | #139 |
| therapy breast | #139 |
| underwent mastectomy | #139 |
| chemoprevention studies | #139 |
| incurable cancer | #139 |
| factbr | #139 |
| patients advanced cancer | #140 |
| breast chest wall | #140 |
| liquid suspension | #140 |
| oxaliplatin chemotherapy | #141 |
| paclitaxel weekly | #141 |
| patients placebo | #141 |
| financial concerns | #142 |
| tamoxifen placebo | #142 |
| patients levetiracetam | #142 |
| disclose | #142 |
| fluorouracil 5 | #143 |
| medicine clinical | #143 |
| protocols breast | #143 |
| snv | #144 |
| european organisation | #144 |
| preoperative magnetic | #144 |
| allopurinol placebo | #144 |
| agents bone | #145 |
| evidence loe | #145 |
| debilitating condition | #145 |
| fluorouracil humans | #145 |
| eortc qlq | #145 |
| vaginal cytology | #145 |
| surgery type | #146 |
| eligible women | #146 |
| backgroundwomen | #148 |
| dietary counselling | #148 |
| volatile plants | #148 |
| oral olanzapine | #148 |
| desipramine treatment | #149 |
| numeracy | #149 |
| predict recurrence | #150 |
| adjuvant systemic | #150 |
| n201 | #150 |
| venlafaxine treatment | #150 |
| daily diaries | #151 |
| prior chemotherapy regimens | #151 |
| patients receive | #151 |
| multinational association | #151 |
| women estrogen | #151 |
| methodologic | #151 |
| intravenous access | #151 |
| response rate survival | #151 |
| 14 week | #152 |
| groups symptoms | #152 |
| ovarian function suppression | #152 |
| balance impairments | #152 |
| tumor recurrence patients | #152 |
| caa patients | #152 |
| oral mucositis | #152 |
| cramping | #153 |
| carboplatin trastuzumab | #154 |
| 80 dose | #154 |
| adjuvant systemic therapy | #155 |
| dermatomes | #155 |
| cindices | #155 |
| vinblastine bleomycin | #156 |
| infliximab 5 | #156 |
| mangafodipir | #156 |
| life randomized | #156 |
| methods randomized | #156 |
| combination chemotherapy cisplatin | #156 |
| fsds | #156 |
| integrated palliative | #156 |
| hyperalimentation | #156 |
| common terminology criteria | #157 |
| gait stability | #157 |
| women breast carcinoma | #157 |
| racially diverse | #157 |
| breast cancer trastuzumab | #157 |
| oncology study | #158 |
| arm versus | #158 |
| vomiting nausea | #158 |
| study initiation | #158 |
| chemotherapy breast cancer | #159 |
| survivors colorectal | #159 |
| iii clinical | #159 |
| weekly doses | #159 |
| induced nausea | #159 |
| physicians patients | #159 |
| cancer pain patients | #160 |
| stellate ganglion | #160 |
| major problem | #160 |
| paclitaxel taxol | #160 |
| european organisation treatment | #160 |
| chemotherapy quality | #160 |
| treatment postmenopausal women | #160 |
| risk infertility | #161 |
| validity life | #161 |
| estrogen depletion | #161 |
| women hormone therapy | #161 |
| data efficacy | #163 |
| efficacy women | #164 |
| neoplasms pain | #164 |
| mometasone furoate | #165 |
| current project | #165 |
| cisplatin vinblastine | #165 |
| skeletal events | #166 |
| pharmacokinetic analyses | #166 |
| patients 1 month | #166 |
| life topic surveys | #167 |
| illness surveys questionnaires | #167 |
| osteoporosis prevention | #167 |
| anthracycline | #168 |
| chemotherapy‐induced nausea | #168 |
| direct inhibitors | #168 |
| chemotherapy groups | #168 |
| patients data | #169 |
| dosing patients | #169 |
| menopause symptoms | #169 |
| 432 patients | #169 |
| patients adenomas | #169 |
| ixabepilone | #170 |
| management chronic pain | #170 |
| global quality | #171 |
| disease cmt | #171 |
| rochester | #171 |
| daily placebo | #171 |
| prospective clinical trials | #171 |
| prestudy | #172 |
| chemotherapy completion | #172 |
| hot flushes | #173 |
| 1 year therapy | #173 |
| impaired balance | #173 |
| label pilot | #173 |
| placebos | #173 |
| lamotrigine placebo | #173 |
| judicious | #173 |
| prospective evaluation | #174 |
| methylphenidate placebo | #174 |
| phase iii trial | #174 |
| diarrhoea patients | #174 |
| pilot feasibility study | #174 |
| cancer cancer treatment | #175 |
| physician order | #175 |
| arthralgia | #175 |
| male breast cancer | #175 |
| decreased quality | #175 |
| baseline weight | #176 |
| weeks women | #177 |
| life assessments | #177 |
| treatment 14 | #177 |
| bodyweights | #178 |
| thirty percent | #178 |
| treatmentrelated toxicity | #179 |
| bothered | #179 |
| life baseline | #179 |
| expected benefits | #179 |
| bolus fluorouracil | #179 |
| sufferer | #180 |
| phase evaluation | #181 |
| gain weight | #182 |
| oxaliplatin 5fluorouracil | #182 |
| escalations | #182 |
| darbepoetin | #182 |
| ginseng | #182 |
| peri postmenopausal women | #183 |
| organisation treatment | #183 |
| toxicity criteria | #183 |
| biostatisticians | #184 |
| acute pain | #184 |
| received oral | #184 |
| acetyll | #184 |
| tube primary | #184 |
| effects chemotherapy | #184 |
| white smokers | #184 |
| infliximab antibodies | #184 |
| prognostic criteria | #184 |
| reported sexual | #185 |
| additional chemotherapy | #185 |
| outcome measures life | #185 |
| arm volume | #186 |
| treatment 4 weeks | #187 |
| cinv | #187 |
| delayed nausea | #187 |
| patients drug | #187 |
| treating | #187 |
| strong prognostic | #188 |
| management breast cancer | #188 |
| tamoxifen letrozole | #188 |
| reduction therapy | #188 |
| lessened | #188 |
| week follow | #188 |
| adjuvant decision | #188 |
| troublesome | #188 |
| oxaliplatin dose | #189 |
| neoplasia female humans | #189 |
| aching | #189 |
| antiemetic regimens | #190 |
| protocol therapy | #190 |
| survivors breast | #190 |
| placebo study | #190 |
| aged nitriles | #190 |
| week 1 | #190 |
| cancer cancer survivors | #191 |
| twentyfive patients | #191 |
| completed baseline | #191 |
| patients increases | #192 |
| manuscript | #192 |
| fortysix patients | #192 |
| chronic lymphedema | #192 |
| aspirin incidence | #192 |
| treatment cancer patients | #192 |
| toxicity patients | #192 |
| aches | #192 |
| humans isoflavones | #193 |
| assigned receive | #193 |
| cimicifuga racemosa | #193 |
| 25 women | #194 |
| effective agents | #194 |
| weekly trastuzumab | #194 |
| weight loss patients | #195 |
| ornithine decarboxylase activity | #195 |
| 3 fatty | #195 |
| pain breast | #195 |
| acids double | #196 |
| resultsdata | #196 |
| trial designs | #197 |
| palonosetron dexamethasone | #197 |
| pituitaryadrenal axis | #197 |
| toxicity profiles | #198 |
| resultstwo | #198 |
| surveillance strategy | #198 |
| postmenopausal patients | #198 |
| nicotine patch | #199 |
| organization treatment | #199 |
| patients letrozole | #199 |
| delayed emesis | #199 |
| women menopause | #199 |
| accent | #199 |
| culminates | #199 |
| adjuvant interferon | #200 |
| percent reduction | #200 |
| menopause premature | #201 |
| oral glutamine | #201 |
| primary goal | #202 |
| greater 5 | #202 |
| treatment bmd | #202 |
| item responses | #202 |
| treatment week | #202 |
| imiquimod | #202 |
| hormonal treatments | #203 |
| bmd postmenopausal | #203 |
| cancer anemia | #203 |
| composition cachexia | #204 |
| plo | #204 |
| treated placebo | #204 |
| pelvic radiation therapy | #204 |
| induced oral | #205 |
| dalteparin | #206 |
| udi6 | #206 |
| unwilling | #206 |
| placebo 8 | #206 |
| leucovorin patients | #206 |
| chemotherapy drugs | #206 |
| pharmacologic interventions | #207 |
| heat hyperalgesia | #207 |
| mice cisplatin | #207 |
| incurable | #208 |
| humans leucovorin | #208 |
| reduced food intake | #208 |
| 4 8 weeks | #208 |
| 5 daily | #209 |
| chemotherapy | #209 |
| hands patients | #209 |
| estrogen receptor modulators | #210 |
| methotrexate 5 | #210 |
| controlled evaluation | #210 |
| lamotrigine | #210 |
| gel application | #211 |
| initials | #212 |
| methodsthis | #212 |
| regionally advanced | #212 |
| vomiting patients | #212 |
| diagnosis recurrence | #212 |
| charcotmarietooth disease | #213 |
| trial vitamin | #213 |
| docetaxel cyclophosphamide | #213 |
| oncology practices | #214 |
| patient weight | #214 |
| placebo 6 weeks | #214 |
| dexamethasone control | #214 |
| 15 minutes | #215 |
| olanzapine 5 | #215 |
| december patients | #215 |
| oxaliplatin | #215 |
| antiemetic therapy | #215 |
| neoplasms cross | #216 |
| prostate cancer survivors | #216 |
| patients duloxetine | #217 |
| women tamoxifen | #217 |
| tamoxifen users | #217 |
| women breast cancer | #217 |
| gabapentin humans | #217 |
| purposethe purpose | #218 |
| 10 daily | #218 |
| nonmajor | #218 |
| aprepitant | #218 |
| placebo weeks | #218 |
| hot | #218 |
| current management | #218 |
| —reply | #218 |
| palliative oncology | #219 |
| nmscs | #219 |
| transdermal fentanyl | #219 |
| life humans | #219 |
| sexual symptoms | #220 |
| sublingual administration | #220 |
| nonabsorbable | #220 |
| painful peripheral | #221 |
| moderate pain | #221 |
| pregabalin patients | #221 |
| ornithine decarboxylase odc | #221 |
| society clinical oncology | #221 |
| methylphenidate modafinil | #222 |
| neoplasms palliative | #222 |
| ginkgo biloba egb | #222 |
| prospective study women | #222 |
| primary breast cancer | #222 |
| lymphedema patients | #222 |
| relieving | #222 |
| treatment postmenopausal | #222 |
| furoate | #223 |
| randomized doubleblind study | #223 |
| prevention patients | #224 |
| quinquefolius | #225 |
| 99 months | #225 |
| computerized physician | #225 |
| vaginal estrogen | #226 |
| partial mastectomy | #226 |
| agent patients | #226 |
| pain presence | #227 |
| turmoil | #227 |
| bupropion | #227 |
| trial | #228 |
| clinical situation | #228 |
| nondiploid | #229 |
| 200 iu | #229 |
| secondary endpoint | #229 |
| anthracycline cardiotoxicity | #230 |
| akt inhibitor | #230 |
| antidepressive | #230 |
| placebo 10 | #230 |
| editorials | #230 |
| hospice patients | #230 |
| physicians quality | #230 |
| eating disorders humans | #230 |
| cancer recommendations | #230 |
| based adjuvant | #231 |
| rashes | #231 |
| vitamin effects | #231 |
| conclusionsthe | #232 |
| time study | #232 |
| cachexia cytokines | #232 |
| handfoot syndrome | #232 |
| lightheadedness | #232 |
| fluoxetine paroxetine | #233 |
| nonpharmacologic | #233 |
| treatment vte | #234 |
| thirty women | #234 |
| 4 doses | #234 |
| acute symptoms | #234 |
| women hot | #234 |
| tamoxifen neoplasms chemotherapy | #235 |
| arm 95 | #235 |
| relieve | #235 |
| day response | #235 |
| sucralfate | #235 |
| 375 day | #235 |
| effective treatments | #236 |
| premenopausal patients | #237 |
| placebo gel | #237 |
| incidence grade | #238 |
| flash | #238 |
| letrozole patients | #238 |
| antiemetics | #238 |
| survivors treatment | #238 |
| postoperative monitoring | #238 |
| chemotherapy placebo | #239 |
| nonpharmacologic interventions | #239 |
| overexpressing metastatic | #239 |
| improved bioavailability | #239 |
| methodswomen | #239 |
| adjuvant 5 | #239 |
| oncology clinic | #239 |
| menopause middle | #239 |
| treatment breast cancer | #240 |
| cachexia syndrome | #240 |
| neoadjuvant therapy surgery | #240 |
| oral complications | #240 |
| independent tests | #241 |
| participants randomized | #242 |
| stinging | #242 |
| aged paclitaxel | #243 |
| small doses | #243 |
| tetracycline | #244 |
| 3 arms | #245 |
| epoetin alfa | #245 |
| common practice | #246 |
| appetite stimulants | #246 |
| adjuvant oxaliplatin | #246 |
| efficacy placebo | #247 |
| cachexia cancer | #248 |
| mouthwashes | #248 |
| 800 iu | #249 |
| dysgeusia | #249 |
| survivors adult | #250 |
| loss bmd | #250 |
| randomized sham | #250 |
| item scores | #250 |
| 689 | #251 |
| patients physical | #251 |
| major problems | #251 |
| menopause women | #252 |
| coasting | #252 |
| topic vitamin | #252 |
| primary point | #253 |
| randomised studies | #253 |
| armodafinil | #253 |
| average intensity | #254 |
| nasal spray | #254 |
| moderate degree | #254 |
| recurrence registries | #255 |
| chemotherapy breast | #255 |
| longitudinal followup | #256 |
| prospective clinical | #256 |
| therapy women | #257 |
| cancer treatment | #257 |
| antidepressant | #257 |
| neoplasms randomized | #257 |
| pretreatment levels | #258 |
| new therapeutic approaches | #258 |
| women treated | #258 |
| dyspareunia | #258 |
| rigors | #259 |
| hydrochloride | #259 |
| tube cancer | #260 |
| inhibitors treatment | #260 |
| opioid doseresponse relationship | #260 |
| 1 baseline | #261 |
| common problem | #261 |
| patients cancer | #261 |
| repeated measures | #261 |
| patients ovarian cancer | #262 |
| citalopram treatment | #262 |
| chronic post | #262 |
| months treatment | #263 |
| dosage levels | #263 |
| management options | #263 |
| decision framework | #263 |
| duloxetine placebo | #264 |
| hematinics | #264 |
| phytogenic | #264 |
| treatment oxaliplatin | #264 |
| outcome administration | #265 |
| recommendations quality | #265 |
| preoperative mri | #266 |
| treatmentrelated deaths | #266 |
| placebo 8 weeks | #267 |
| paresthesia | #267 |
| individual items | #267 |
| surgery adjuvant | #267 |
| substantiation | #267 |
| treatment cancer | #267 |
| impact quality | #268 |
| adult cancer survivors | #268 |
| 208 patients | #269 |
| nausea | #270 |
| signaled | #270 |
| ginkgo biloba | #270 |
| patients rash | #270 |
| estrogen antagonists | #271 |
| patients octreotide | #271 |
| moderate correlations | #271 |
| 80 90 | #271 |
| treatment 95 | #272 |
| bridged ring | #272 |
| performance status patients | #272 |
| weekly | #272 |
| distressing | #272 |
| control trials | #272 |
| dna test | #272 |
| score baseline | #272 |
| abstinence rates | #273 |
| placebo‐controlled trial | #273 |
| oncology clinical trials | #274 |
| dryness | #274 |
| sham treatment | #274 |
| valeriana | #275 |
| gross disease | #275 |
| induced cisplatin | #275 |
| patients caa | #276 |
| chemoprevention trials | #277 |
| treatment breast | #278 |
| perspiration | #278 |
| biomarkers disease humans | #279 |
| patients symptoms | #279 |
| therapeutic options | #279 |
| patients hospice | #279 |
| prominent | #279 |
| cimicifuga | #279 |
| cholinergic antagonists | #280 |
| individual patient | #280 |
| breast cancer outcomes | #280 |
| cartilage patients | #280 |
| patients frequency | #280 |
| doxorubicin cyclophosphamide | #281 |
| psychometric testing | #281 |
| zoledronic acid patients | #281 |
| chamomile | #282 |
| stage colon | #282 |
| antidepressive agents | #282 |
| greater severity | #284 |
| completed questionnaires | #284 |
| women effects | #284 |
| smoking abstinence | #285 |
| gabapentin treatment | #285 |
| early discontinuation | #286 |
| fatigue crf | #286 |
| weeks patients | #287 |
| function quality | #287 |
| acid adult | #287 |
| colorectal lung | #287 |
| symptoms function | #287 |
| female hormone | #287 |
| paps | #287 |
| aromatase inhibitor therapy | #288 |
| hot flush | #288 |
| life survival | #290 |
| eligible patients | #291 |
| clinical trial participation | #292 |
| treatment target | #292 |
| qualitative approach | #292 |
| common symptom | #292 |
| discouraged | #292 |
| mucositis oral | #293 |
| 1636 | #294 |
| weight gain patients | #294 |
| cbdca | #294 |
| pain symptoms | #294 |
| citalopram | #295 |
| monographs | #295 |
| bone loss patients | #295 |
| testosterone supplementation | #295 |
| vinca alkaloids | #295 |
| toxicity evaluation | #296 |
| primary peritoneal cancer | #297 |
| questionnaires treatment | #298 |
| aspirin placebo | #298 |
| patients entered | #298 |
| neoplasms cyclophosphamide | #299 |
| peripheral nervous | #299 |
| feet | #299 |
| inhibitors ais | #300 |
| hypothetical scenarios | #300 |
| radiation dermatitis | #300 |
| shooting | #301 |
| treated combination | #301 |
| octreotide | #302 |
| nogalamycin | #302 |
| survival trials | #302 |
| stage grade | #303 |
| treatment serum | #303 |
| acute neurotoxicity | #303 |
| nausea vomiting | #304 |
| subscale scores | #304 |
| symptoms pain | #304 |
| complementary therapies | #305 |
| schedule female | #305 |
| placebo groups | #305 |
| prime time | #305 |
| prospective clinical trial | #305 |
| global quality life | #306 |
| factg | #306 |
| placebo treatment | #307 |
| shortread | #307 |
| aromatase inhibitor | #307 |
| inflammatory breast cancer | #307 |
| prochlorperazine | #307 |
| aged cancer | #308 |
| apixaban | #308 |
| neoplasms chemotherapy | #308 |
| drug embryo | #308 |
| darbepoetin alfa | #309 |
| studies double | #310 |
| zoledronic acid | #310 |
| individual subject | #311 |
| cancer receiving | #311 |
| advanced cancer | #311 |
| lung docetaxel | #311 |
| riskstratification | #311 |
| epoetin | #312 |
| placebo‐controlled | #312 |
| testosterone placebo | #312 |
| musculoskeletal symptoms | #313 |
| patients cycle | #313 |
| cancer adjuvant | #314 |
| or10 | #314 |
| syndrome aps | #314 |
| operative chemotherapy | #315 |
| new primary | #315 |
| organoplatinum | #316 |
| article evidence | #316 |
| sesame oil | #317 |
| ambulatory patients | #317 |
| bfi | #317 |
| double‐blind | #317 |
| blinded | #317 |
| symptoms breast | #317 |
| rivaroxaban patients | #318 |
| efficacy treatment | #319 |
| irox | #319 |
| informed decisions | #321 |
| dietary counseling | #322 |
| life differences | #322 |
| thromboembolism anticoagulants | #323 |
| glutamine humans | #324 |
| monthly intervals | #324 |
| smokers nicotine | #324 |
| preventing | #325 |
| nsclc chemotherapy | #326 |
| breast radiotherapy | #326 |
| patients ductal carcinoma | #327 |
| titrate | #327 |
| compared baseline | #327 |
| continuation phase | #328 |
| antagonists female | #329 |
| conducted evaluate | #329 |
| patients resected | #329 |
| vte cancer patients | #329 |
| lymphedema | #329 |
| treatment 1 year | #329 |
| oral nutritional supplements | #329 |
| potential efficacy | #330 |
| patients nasal | #330 |
| future clinical trials | #330 |
| controlled clinical | #330 |
| arms | #330 |
| polymerase inhibitor | #331 |
| diagnosed primary | #332 |
| lozenge | #332 |
| cancer ontario | #332 |
| patients daily | #334 |
| 80 anemia | #334 |
| placebo patients | #334 |
| time disease | #335 |
| paclitaxel therapy | #336 |
| ongoing clinical | #336 |
| 128 patients | #336 |
| relative benefits | #336 |
| pain scale | #336 |
| 5 fluorouracil | #337 |
| adjuvant letrozole | #337 |
| sublingual | #337 |
| surveillance guidelines | #338 |
| survival 5 years | #338 |
| discernible | #339 |
| order entry | #340 |
| flutamide | #340 |
| mastectomy radiotherapy | #341 |
| patients 4 weeks | #341 |
| treatment proportion | #341 |
| eligible participants | #341 |
| cancer cachexia | #342 |
| fallopian tube cancer | #342 |
| osteopenia osteoporosis | #342 |
| tooth disease | #343 |
| society clinical | #343 |
| diseases quality | #343 |
| pilot randomized | #344 |
| clinicians patients | #345 |
| skeletal neoplasms | #345 |
| epha5 | #345 |
| mk2206 | #346 |
| clinical problems | #346 |
| accruing | #346 |
| therapy pain | #347 |
| adverse events groups | #347 |
| coumarin | #347 |
| mucositis patients | #348 |
| antineoplastic therapy | #349 |
| sham acupuncture | #349 |
| adjuvant folfox | #350 |
| vast majority | #350 |
| induced acute | #350 |
| baseline quality | #350 |
| dose schedule | #351 |
| dehydroepiandrosterone dhea | #351 |
| treatment citalopram | #351 |
| study therapy | #352 |
| patientreported outcomes | #353 |
| response letter | #353 |
| endodermal sinus | #353 |
| paclitaxel | #353 |
| risedronate | #355 |
| letrozole | #355 |
| cancer life | #355 |
| pain baseline | #356 |
| adjuvant colonic | #359 |
| skin toxicities | #359 |
| vomiting | #359 |
| clin oncol | #360 |
| potential benefit | #360 |
| wellknown | #360 |
| cryotherapy | #360 |
| ductal situ carcinoma | #360 |
| diaries | #361 |
| began | #361 |
| pelvic radiation | #362 |
| direct oral | #362 |
| calculators | #363 |
| ovarian suppression | #363 |
| nonpharmacological | #363 |
| cancer surveillance | #363 |
| pain measures | #363 |
| flaxseed | #363 |
| docetaxel paclitaxel | #365 |
| cddp | #365 |
| ovarian fallopian | #365 |
| completing | #365 |
| local prognosis receptor | #365 |
| pain cancer | #366 |
| management cancer | #366 |
| optimal frequency | #366 |
| patients delayed | #366 |
| bioavailable testosterone | #366 |
| scalp | #367 |
| weeks study | #368 |
| scale 0 | #368 |
| 5‐year | #368 |
| aged neoplasms | #369 |
| scheduled | #369 |
| hrt risk | #370 |
| skeletalrelated events | #371 |
| cancer received | #371 |
| gamma aminobutyric acid | #372 |
| orally daily | #372 |
| skin toxicity | #373 |
| symptoms patients | #373 |
| 5fluorouracil 5fu | #373 |
| ovarian failure | #374 |
| clinical oncology | #374 |
| ecogps | #374 |
| irreversible damage | #374 |
| paclitaxel dose | #374 |
| resected stage | #374 |
| −005 | #375 |
| women breast | #376 |
| decreasing | #376 |
| therapy based | #376 |
| medroxyprogesterone acetate | #377 |
| blood test | #377 |
| polyneuropathy | #378 |
| week patients | #378 |
| drowsiness | #378 |
| humans specificity | #378 |
| assessable patients | #378 |
| nociceptors | #379 |
| national cancer institute | #380 |
| fura | #381 |
| loss skeletal | #381 |
| telerehabilitation | #381 |
| 4 treatment | #382 |
| leucovorin | #383 |
| organoplatinum compounds | #383 |
| unacceptable toxicity | #383 |
| adverse event | #384 |
| function pain | #384 |
| disputes | #384 |
| target dose | #384 |
| 402 | #384 |
| patients capecitabine | #384 |
| trials involving | #384 |
| conservation agents | #385 |
| leptin patients | #385 |
| 5fluorouracil leucovorin | #385 |
| density conservation | #386 |
| fourths | #386 |
| 2 treatment | #388 |
| androgendeprivation therapy | #389 |
| treatment women | #390 |
| glutathione gsh | #390 |
| advanced adenomas | #391 |
| aromatase inhibitors ais | #392 |
| sexual desire | #392 |
| adjuvant trials | #394 |
| 4 weeks | #394 |
| dying patients | #394 |
| early palliative | #395 |
| discontinuation rates | #396 |
| life breast | #396 |
| humans mastectomy | #397 |
| ring compounds | #397 |
| olanzapine | #397 |
| cytotoxics | #397 |
| performance score | #397 |
| paired tests | #398 |
| 1280 | #398 |
| patients randomly | #398 |
| life data | #399 |
| withdrew | #400 |
| intramuscular | #400 |
| peripheral neurotoxicity | #400 |
| chemotherapy colorectal | #400 |
| questionnaires treatment outcome | #400 |
| fatty acid supplementation | #400 |
| 3 cohorts | #401 |
| assigned | #401 |
| 8090 | #401 |
| estrogen receptors biomarkers | #401 |
| entered | #402 |
| loe | #402 |
| evidencebased | #402 |
| female humans life | #403 |
| sadenosyllmethionine | #403 |
| acid female | #403 |
| 5 weeks | #405 |
| baseline demographics | #406 |
| female fluorouracil | #406 |
| responding patients | #408 |
| cisplatin induced | #409 |
| keratolytic | #410 |
| life aged | #411 |
| patients 5fu | #411 |
| topic neoplasms | #412 |
| female hemorrhage humans | #412 |
| regimens patients | #414 |
| ornithine decarboxylase | #414 |
| oxaliplatin based | #415 |
| based chemotherapy | #415 |
| pain qol | #415 |
| acetate | #415 |
| placebo 2 | #415 |
| patient factors | #416 |
| carboplatin patients | #416 |
| oncology neoplasms | #416 |
| platinum agents | #417 |
| gabapentinoids | #417 |
| delayed | #417 |
| prospective pilot | #417 |
| receiving | #418 |
| nighttime sleep | #419 |
| case series patients | #419 |
| metastatic breast cancer | #419 |
| adjuvant hormonal therapy | #419 |
| 0 4 | #419 |
| antiemetic prophylaxis | #420 |
| tamoxifen women | #421 |
| cancer purpose | #421 |
| controlled pilot | #421 |
| study entry | #421 |
| tcl1a | #421 |
| selfreported symptoms | #422 |
| fourth week | #422 |
| directed therapy | #422 |
| severities | #422 |
| pyridones | #423 |
| arm 2 | #423 |
| 5 trials | #423 |
| adequately | #423 |
| neurophysiologic | #424 |
| anastrozole | #425 |
| androgen ablation | #425 |
| tamoxifen | #425 |
| complementary alternative | #426 |
| ongoing clinical trials | #426 |
| baseline 6 weeks | #427 |
| prevention vte | #427 |
| treating patients | #428 |
| primary peritoneal | #428 |
| gain adult | #428 |
| greater percentage | #429 |
| creatine | #429 |
| adjectives | #430 |
| desipramine | #430 |
| methodsa | #431 |
| hgb | #431 |
| glycitein | #431 |
| fatigue humans | #431 |
| detection colorectal | #431 |
| contraindicated | #431 |
| laser therapy | #431 |
| diploid tumors | #432 |
| symptom management | #432 |
| antiseizure | #433 |
| joint symptoms | #433 |
| sunscreen | #433 |
| resultsone | #434 |
| purpose objectives | #434 |
| 115 patients | #434 |
| cancer tamoxifen | #434 |
| oral calcium | #435 |
| topic treatment | #436 |
| nutrition cancer | #436 |
| olanzapine treatment | #436 |
| pains | #436 |
| 1157 | #436 |
| clinical cancer | #438 |
| absolute terms | #438 |
| anthracyclinebased chemotherapy | #438 |
| nodenegative breast cancer | #439 |
| administration cutaneous | #440 |
| postoperative follow | #440 |
| expected survival | #441 |
| neoplasms cancer | #441 |
| diminish | #441 |
| vasomotor | #442 |
| yoga | #442 |
| hgpin | #444 |
| baseline 1 month | #444 |
| preoperative breast | #445 |
| screening colorectal | #445 |
| loss aged | #445 |
| doxorubicin drug administration | #445 |
| receive | #445 |
| life efficacy | #445 |
| marie | #446 |
| agents antineoplastic | #446 |
| day dexamethasone | #447 |
| acid aged | #447 |
| treatment regimen | #447 |
| european organization | #448 |
| patients qol | #448 |
| 2 months | #448 |
| patients weight | #448 |
| estrogen therapy | #449 |
| climacteric | #449 |
| baseline patient | #450 |
| premature discontinuation | #451 |
| baseline 4 weeks | #452 |
| cancer symptoms | #452 |
| study feasibility | #453 |
| outline | #453 |
| arms arm | #454 |
| nodepositive breast cancer | #454 |
| postmenopause | #455 |
| dhea | #455 |
| 5fu patients | #456 |
| geranium | #456 |
| axillary metastases | #457 |
| diphenhydramine | #458 |
| evaluate efficacy | #459 |
| mucositis | #460 |
| patients venous thromboembolism | #461 |
| questionnaires terminology | #461 |
| enforced | #461 |
| patients baseline | #462 |
| helpful | #462 |
| 6 weeks | #462 |
| cytokines patients | #462 |
| potential interventions | #463 |
| increased weight | #463 |
| therapy stage | #464 |
| cancer institute | #468 |
| clin | #468 |
| asco | #468 |
| radiation enteritis | #469 |
| referral centers | #469 |
| lung humans | #469 |
| sexual distress | #470 |
| consensus guideline | #470 |
| treatment options patients | #471 |
| purposethis | #471 |
| esophagitis patients | #471 |
| chemotherapy regimens | #472 |
| new treatment | #473 |
| 432 | #474 |
| pilocarpine | #474 |
| subscale | #474 |
| groups 6 months | #475 |
| symptoms menopause | #475 |
| hormonal replacement therapy | #475 |
| uncertain | #476 |
| single item | #477 |
| preliminary studies | #477 |
| appears | #477 |
| clinical decision making | #478 |
| placebo 24 weeks | #478 |
| 95 placebo | #479 |
| variables age | #479 |
| iii colon | #479 |
| onco | #479 |
| doubleblind study | #479 |
| enrollment patients | #480 |
| vitamin placebo | #480 |
| alopecia | #480 |
| osteoporosis osteopenia | #481 |
| crc 95 | #482 |
| moderatetosevere | #482 |
| higher dose | #483 |
| reluctance | #484 |
| adjuvant therapy | #484 |
| tpn | #485 |
| neurotoxicity patients | #485 |
| locoregional disease | #485 |
| endpoints included | #485 |
| 655 | #486 |
| cure | #486 |
| blind | #488 |
| taqman pcr | #488 |
| induced neuropathic | #489 |
| estrogen deprivation | #491 |
| pain scores | #491 |
| doselimiting toxicity | #491 |
| cancer cardiovascular disease | #492 |
| primary breast | #493 |
| combined modality treatment | #493 |
| plant preparations | #493 |
| narcotics | #494 |
| patients stage disease | #495 |
| decarboxylase activity | #498 |
| dropout rates | #499 |
| fentanyl humans | #500 |
| patients breast cancer | #500 |
| received placebo | #501 |
| “ ” | #501 |
| life questionnaires survivors | #502 |
| kps | #502 |
| placebo‐controlled study | #502 |
| pilot studies | #502 |
| metastatic cancer | #503 |
| mesonephroma | #504 |
| loss patients | #504 |
| chest ray | #505 |
| awaited | #506 |
| survival chemotherapy | #509 |
| pain inventory | #510 |
| placebo trial | #511 |
| smoking nicotine | #511 |
| preventative | #512 |
| therapy aged | #513 |
| breast diseases | #513 |
| trials data | #513 |
| advance planning acp | #514 |
| nonmetastatic breast cancer | #514 |
| flic | #514 |
| evidencebased interventions | #515 |
| women receiving | #516 |
| premature menopause | #516 |
| letrozole treatment | #516 |
| outcome antineoplastic | #517 |
| serum albumin levels | #517 |
| acute diarrhea | #519 |
| achievements | #520 |
| pain medications | #520 |
| cbcs | #521 |
| eflornithine | #521 |
| gamma aminobutyric | #522 |
| pharmaceutic | #522 |
| poorer quality life | #523 |
| mastectomy middle | #525 |
| symptoms fatigue | #525 |
| chills | #525 |
| resultsto | #527 |
| prophylactic therapy | #528 |
| adverse events placebo | #528 |
| controlled crossover | #528 |
| patients clinical trial | #529 |
| cmf | #529 |
| phytogenic area | #529 |
| abt888 | #529 |
| therapy prostate | #530 |
| radiodermatitis | #531 |
| oncologists | #531 |
| centrally | #531 |
| pregabalin | #531 |
| patients vitamin | #532 |
| iii trial | #533 |
| 30 minutes | #534 |
| genitourinary | #535 |
| medications treatment | #536 |
| patients evaluated | #536 |
| antineoplastic agents | #537 |
| superficial bladder | #538 |
| weeks therapy | #538 |
| agents chemotherapy | #538 |
| study week | #538 |
| patients clinical trials | #539 |
| terminally | #540 |
| patients assigned | #541 |
| pharmacologic | #542 |
| pain patients | #543 |
| dehydroepiandrosterone | #543 |
| topic severity | #543 |
| pain score | #544 |
| risedronic | #544 |
| week 6 | #544 |
| 329 | #545 |
| 592 | #546 |
| patients scheduled | #548 |
| peripheral | #548 |
| unable | #549 |
| receiving adjuvant | #550 |
| bmd baseline | #550 |
| differences study | #551 |
| 3 95 | #552 |
| dabrafenib trametinib | #552 |
| hypesthesia | #553 |
| axonal transport | #553 |
| adenomas patients | #554 |
| leucovorin oxaliplatin | #555 |
| dysplastic lesions | #556 |
| neoplasms drug | #556 |
| evaluable | #556 |
| co2 laser | #556 |
| regular aspirin | #556 |
| 300 day | #557 |
| abh | #557 |
| vasomotor symptoms | #559 |
| emesis | #560 |
| reported outcomes | #560 |
| rbc transfusions | #560 |
| 80000 | #560 |
| methylphenidate | #561 |
| moisturizer | #561 |
| day treatment | #561 |
| mesna | #562 |
| hands | #564 |
| lmwh patients | #564 |
| method drug | #565 |
| time detection | #565 |
| induced cold | #565 |
| treatment periods | #566 |
| trial data | #566 |
| 4 8 | #567 |
| survival stage | #567 |
| supportive cancer | #567 |
| 11 months | #568 |
| calgb | #569 |
| adjuvant clinical trials | #569 |
| scientifically | #569 |
| therapy primary | #569 |
| lower dose | #571 |
| topic treatment outcome | #571 |
| decarboxylase odc | #571 |
| bibliometric analysis | #572 |
| paclitaxel patients | #573 |
| fluorouracil oxaliplatin | #578 |
| topical capsaicin | #578 |
| refute | #580 |
| methods systematic review | #580 |
| patients candidates | #580 |
| hwe | #581 |
| treatment phase | #581 |
| breakthrough pain | #583 |
| paced | #583 |
| life questionnaire | #584 |
| paracentesis | #584 |
| desvenlafaxine | #585 |
| moderate correlation | #585 |
| drug toxicity | #587 |
| neoplasms nutritional | #587 |
| paclitaxel carboplatin | #588 |
| emotional functioning | #589 |
| oxaliplatin patients | #589 |
| muscle cramps | #589 |
| multiple cancers | #589 |
| limited efficacy | #589 |
| aged occult | #589 |
| osteopenia | #590 |
| taxane chemotherapy | #590 |
| aminobutyric | #590 |
| acrin | #591 |
| median time progression | #592 |
| ablation therapy | #592 |
| crossover trial | #592 |
| platinum drugs | #593 |
| chemotherapy benefit | #595 |
| compounded | #596 |
| pentoxifylline | #596 |
| exanthema | #597 |
| sst2 | #597 |
| radiotherapy breast | #597 |
| fatigue female | #597 |
| topic depressive disorder | #598 |
| multisite | #598 |
| initial surgery | #599 |
| publication administration | #599 |
| patients mastectomy | #599 |
| thromboembolism vte | #600 |
| effects breast | #600 |
| patients etanercept | #600 |
| discretion | #601 |
| health providers | #601 |
| statistically differences | #601 |
| patient decision | #601 |
| oral solution | #601 |
| 1093 | #601 |
| prevention measures | #602 |
| vte cancer | #602 |
| cfibers | #603 |
| exposed patients | #604 |
| cancer survivors | #604 |
| anthracycline based | #604 |
| toxicity profile | #605 |
| endoxifen | #607 |
| chemotherapy administration | #608 |
| 16 women | #608 |
| toes | #608 |
| management symptoms | #609 |
| iron supplementation | #609 |
| agents antidepressive | #609 |
| agents tricyclic | #611 |
| topic reproducibility | #612 |
| 2 95 | #613 |
| pilot | #613 |
| updated analysis | #614 |
| montanide | #615 |
| qol baseline | #616 |
| animal data | #616 |
| humans quality | #617 |
| 118 patients | #617 |
| commonly | #618 |
| appetite | #620 |
| antacid | #620 |
| persistent symptoms | #621 |
| aic | #621 |
| urinary frequency | #621 |
| follow median | #622 |
| itching | #625 |
| gangliosides humans | #626 |
| analyzable | #626 |
| cisplatin etoposide | #627 |
| life quality | #630 |
| 1 month | #631 |
| iii patients | #632 |
| authors knowledge | #633 |
| mistletoe | #634 |
| biological targets | #634 |
| month patients | #637 |
| female sexual function | #638 |
| assessment cancer | #640 |
| serum hepcidin | #640 |
| dose placebo | #640 |
| eligible | #641 |
| poorer quality | #642 |
| inhibitors breast | #643 |
| hormonal aromatase | #643 |
| prostatic intraepithelial | #644 |
| placebo time | #645 |
| multiple studies | #646 |
| nasal symptoms | #647 |
| palliative quality | #647 |
| malignant melanomas | #648 |
| 300 patients | #648 |
| syndrome acute | #649 |
| symptoms | #649 |
| flushes | #651 |
| method humans | #651 |
| doses patients | #651 |
| sores | #651 |
| appeared | #652 |
| opioid analgesic | #653 |
| dose limiting | #653 |
| limiting toxicity | #653 |
| patients 16 | #655 |
| poms | #657 |
| prior chemotherapy | #658 |
| complete response patients | #659 |
| grade glioma | #660 |
| twentysix patients | #661 |
| patients chemotherapy | #662 |
| colorectal adenocarcinoma | #662 |
| 62 months | #663 |
| 95 − | #665 |
| active agent | #666 |
| neoplasms patient | #666 |
| alternative treatments | #666 |
| cancer prospective | #666 |
| life radiotherapy | #667 |
| nonparametric surveys | #667 |
| levetiracetam | #668 |
| cancer treatments | #668 |
| treatment trials | #669 |
| women chemotherapy | #670 |
| marie tooth | #671 |
| paclitaxel docetaxel | #671 |
| axonopathy | #674 |
| 1822 | #674 |
| p00004 | #674 |
| pain adult | #674 |
| pharmacologic management | #675 |
| maintenance disorders | #675 |
| racially | #676 |
| induced cognitive | #676 |
| 5 consecutive | #678 |
| patients standard | #678 |
| controlled study | #679 |
| routine follow | #680 |
| diethylstilbestrol | #681 |
| reported outcome | #681 |
| purpose report | #682 |
| study samples | #684 |
| oncology practice | #685 |
| highdose melphalan | #685 |
| popularly | #685 |
| deprivation therapy | #686 |
| fluorouracil leucovorin | #687 |
| therapy cancer | #687 |
| neurologic injury | #688 |
| charcot marie | #688 |
| practice settings | #688 |
| sulindac | #688 |
| life survivors | #692 |
| pharmacological targeting | #692 |
| guideline update | #693 |
| rescue medication | #693 |
| administration schedule | #694 |
| phlebitis | #694 |
| randomized treatment | #695 |
| based testing | #698 |
| desmethyl | #699 |
| potential benefits | #699 |
| descriptive statistics | #700 |
| versa | #701 |
| appearing | #702 |
| postmenopausal | #704 |
| chemopreventive agent | #704 |
| v30 | #705 |
| medical oncologists | #706 |
| effective interventions | #707 |
| tens | #709 |
| locoregionally advanced | #710 |
| capecitabine patients | #711 |
| randomized studies | #712 |
| erythropoiesis stimulating | #712 |
| 160 | #712 |
| newer agents | #714 |
| tube neoplasms | #714 |
| prevention cancer | #715 |
| breast magnetic | #716 |
| lowmolecularweight heparin | #717 |
| inflammatory breast | #717 |
| endorsement | #719 |
| convened | #719 |
| ameliorate | #720 |
| data baseline | #722 |
| erythropoietin female | #722 |
| palliative medicine | #725 |
| humans neoplasms | #725 |
| 6 months 95 | #725 |
| cyclophosphamide methotrexate | #725 |
| therapeutic equivalency | #727 |
| 4 hours | #728 |
| physicians predictive | #728 |
| joint pain | #729 |
| patients radiation therapy | #730 |
| odc activity | #731 |
| induced human | #731 |
| study treatment | #731 |
| charcotmarietooth | #732 |
| women undergoing | #733 |
| nucleotide variants | #734 |
| vinca | #735 |
| medroxyprogesterone | #735 |
| adjuvant clinical | #736 |
| secondary prevention | #737 |
| induced neurotoxicity | #738 |
| chemotherapy women | #738 |
| opd | #739 |
| mirtazapine | #741 |
| locoregional therapy | #742 |
| 4 weeks patients | #742 |
| prescribing practices | #742 |
| fist | #744 |
| baseline 1 year | #745 |
| armamentarium | #745 |
| women placebo | #745 |
| patients breast | #747 |
| bone loss | #748 |
| ecog | #748 |
| trials patients | #749 |
| chemotherapy initiation | #749 |
| alfa | #750 |
| psychostimulant | #750 |
| superficial bladder cancer | #750 |
| 271 | #750 |
| cervical dysplasia | #752 |
| rand | #752 |
| complementary medicine | #753 |
| compared placebo | #753 |
| oct2 | #754 |
| antigen levels | #754 |
| 4·2 | #754 |
| radiation skin | #754 |
| 46 | #755 |
| paclitaxel chemotherapy | #755 |
| secondary points | #755 |
| trouble | #755 |
| patients insomnia | #756 |
| metastatic breast | #757 |
| hepcidin levels | #758 |
| local anesthetics | #759 |
| rifngamma | #759 |
| reduction pain | #759 |
| sulfasalazine | #760 |
| prostate adenocarcinoma | #760 |
| additional data | #762 |
| pain quality | #763 |
| ambulatory setting | #765 |
| 81 patients | #766 |
| occult blood | #766 |
| seventy patients | #766 |
| neoplasms prospective | #768 |
| medroxyprogesterone acetate mpa | #768 |
| acid 4 | #768 |
| baseline pain | #769 |
| humans imidazoles | #769 |
| actual | #770 |
| activity breast | #770 |
| sensory neuropathy | #771 |
| relatedness | #772 |
| modified radical mastectomy | #772 |
| breast carcinoma ductal | #772 |
| sweating | #772 |
| premenopausal women | #773 |
| women enrolled | #773 |
| primary endpoint | #773 |
| keratinocyte growth factor | #773 |
| neoplasms breast | #774 |
| patients colon | #774 |
| 10 day | #774 |
| emla | #774 |
| fifty patients | #774 |
| aged peripheral | #775 |
| acupuncture therapy | #776 |
| octreotide treatment | #776 |
| 257 | #777 |
| oral administration | #777 |
| p00002 | #778 |
| gsm | #778 |
| charcot | #778 |
| 137 patients | #781 |
| severity patients | #782 |
| menopausal symptoms | #783 |
| agents phytogenic | #784 |
| benefits patients | #785 |
| cutaneous administration | #785 |
| skin conductance | #785 |
| prognostic survival | #787 |
| management | #788 |
| enoxaparin | #788 |
| symptom experience | #791 |
| anesthetics local | #792 |
| subsequent cycles | #793 |
| women reported | #793 |
| colon rectal cancer | #796 |
| baseline period | #797 |
| potential treatments | #798 |
| estrogen levels | #798 |
| life outcomes | #801 |
| clinical questions | #801 |
| neuralgia pain | #801 |
| osteoporosis women | #802 |
| erythropoiesisstimulating agents | #802 |
| randomized phase trial | #804 |
| day 3 | #804 |
| lack efficacy | #804 |
| glutathione | #805 |
| primary points | #805 |
| effects patients | #806 |
| double | #806 |
| opioid analgesia | #807 |
| 894 | #807 |
| etoposide cisplatin | #808 |
| placebotreated patients | #808 |
| 3 day | #808 |
| 80 antineoplastic | #808 |
| continue | #808 |
| 0025 | #809 |
| complete response | #811 |
| abrogate | #812 |
| odc | #812 |
| previous reports | #816 |
| mild symptoms | #817 |
| disease genes | #818 |
| lorazepam | #819 |
| eastern cooperative | #820 |
| agents clinical | #820 |
| etoposide patients | #823 |
| randomly | #824 |
| tolerated | #826 |
| statisticians | #826 |
| 148 patients | #827 |
| rasch model | #828 |
| cancer control | #828 |
| suggestive | #830 |
| administration oral | #830 |
| placebo 6 months | #830 |
| cancer phase | #830 |
| dabrafenib | #832 |
| neoplasms bone | #832 |
| subset analysis | #833 |
| humans medical | #833 |
| similarities differences | #835 |
| advanced malignancies | #836 |
| 366 | #836 |
| mandelic | #837 |
| prognosis quality | #837 |
| numeric | #838 |
| eventual | #844 |
| breast neoplasms | #845 |
| adverse events aes | #846 |
| herbal products | #846 |
| p006 | #847 |
| global qol | #848 |
| 142 patients | #848 |
| detection rates | #849 |
| eortc | #850 |
| toxicities | #850 |
| taxol | #851 |
| prostate cancer patients | #852 |
| stage ovarian | #853 |
| oncotype | #853 |
| n55 | #853 |
| palliative services | #855 |
| daily dosing | #858 |
| taxoids | #859 |
| assessment management | #859 |
| vaginal bleeding | #859 |
| published data | #860 |
| stratification patients | #860 |
| strongest | #864 |
| etidronic | #866 |
| unacceptable | #868 |
| patients trial | #868 |
| placebo baseline | #868 |
| jellies | #873 |
| efficacious | #873 |
| peritoneal cancer | #874 |
| treatment completion | #875 |
| timepoints | #878 |
| 5ht3 | #879 |
| symptomatic women | #880 |
| phytogenic carcinoma | #880 |
| nonpharmacological interventions | #880 |
| midlife women | #881 |
| 450 | #883 |
| antineoplastic | #883 |
| study placebo | #883 |
| monoclonal antineoplastic agents | #885 |
| mitigates | #889 |
| neurotoxic | #889 |
| topic female | #890 |
| monoclonal female humans | #891 |
| data article | #892 |
| concomitant chemotherapy | #893 |
| cancer guidelines | #894 |
| caa | #894 |
| control arm | #896 |
| completed | #900 |
| oxy | #901 |
| neoplasms hormone | #901 |
| women hormone | #902 |
| nodal status | #903 |
| percent | #903 |
| inconvenience | #903 |
| nmsc | #904 |
| 00006 | #905 |
| provided | #905 |
| survival surgery | #905 |
| chemotherapy response | #905 |
| hospices | #909 |
| increased risk death | #910 |
| chemotherapeutic | #910 |
| cancer studies | #913 |
| weight maintenance | #914 |
| national cancer | #914 |
| norepinephrine reuptake | #915 |
| life cancer patients | #916 |
| paroxetine | #916 |
| gynecomastia | #918 |
| prospective pilot study | #919 |
| cycle chemotherapy | #920 |
| mouth mucosa | #921 |
| advanced cancer patients | #921 |
| evidence practice | #923 |
| manuscripts | #924 |
| population cohort | #924 |
| illness female humans | #925 |
| primary objectives | #926 |
| chemotherapy study | #927 |
| oral dosing | #929 |
| upper extremities | #929 |
| lasa | #930 |
| oncol | #931 |
| starting | #932 |
| fluoxetine | #933 |
| minocycline | #935 |
| cytotoxic therapy | #937 |
| day placebo | #938 |
| serotonin uptake | #939 |
| electronic health record | #939 |
| visual analogue | #940 |
| treatment symptoms | #940 |
| 138 patients | #942 |
| advanced adenoma | #943 |
| uptake inhibitors | #943 |
| high‐risk | #943 |
| patient population | #944 |
| letter editor | #944 |
| colorectal adenomas | #944 |
| beckman | #945 |
| iii topic | #945 |
| gp100 | #945 |
| 1year survival | #946 |
| fluorouracil | #948 |
| arm patients | #949 |
| natural menopause | #951 |
| recurrence score | #952 |
| compare | #953 |
| orally | #954 |
| jci | #954 |
| participating centers | #955 |
| evaluating | #955 |
| cooperative oncology | #957 |
| hfs | #958 |
| aloe vera | #958 |
| rheumatologic | #958 |
| adjuvant therapies | #958 |
| leukopenia | #959 |
| erythropoietic | #959 |
| moderately | #961 |
| monoclonal carcinoma | #962 |
| trpm8 | #963 |
| pjnk | #963 |
| received adjuvant | #964 |
| serum cytokine | #966 |
| menopause | #968 |
| 1160 | #969 |
| mart1 | #970 |
| earlystage disease | #972 |
| table | #972 |
| randomized pilot | #973 |
| gluconate | #976 |
| restarted | #977 |
| olmsted county | #977 |
| hypercalcemia | #978 |
| 1 10 | #978 |
| mechanical allodynia | #980 |
| 1month | #980 |
| 2700 | #982 |
| 1 week | #984 |
| antidotes | #984 |
| 150 | #984 |
| threequarters | #989 |
| patients venous | #989 |
| adjuvant | #992 |
| pain reduction | #993 |
| multiple logistic regression | #997 |
| analyses data | #998 |
| bother | #1003 |
| mayo | #1003 |
| cancer chemoprevention | #1005 |
| publication analgesics | #1007 |
| 71 | #1010 |
| continued | #1014 |
| patients metastatic disease | #1015 |
| organ systems | #1016 |
| neurocutaneous | #1018 |
| anthraquinones | #1019 |
| patients mri | #1020 |
| reported pain | #1021 |
| life symptoms | #1023 |
| trial participation | #1026 |
| 145 patients | #1027 |
| fatigue patients | #1028 |
| enteritis | #1028 |
| urogenital | #1030 |
| delayed treatment | #1031 |
| alternative treatment | #1031 |
| pill | #1037 |
| evidence treatment | #1037 |
| ” “ | #1038 |
| androgen deprivation therapy | #1042 |
| validity responsiveness | #1043 |
| prx | #1044 |
| postural control | #1044 |
| randomized trial patients | #1046 |
| patients safety | #1047 |
| colorectal tumor | #1047 |
| prevention intervention | #1047 |
| substantial | #1050 |
| nutritional supplementation | #1051 |
| frey | #1051 |
| life | #1053 |
| 30 40 | #1053 |
| postchemotherapy | #1056 |
| doxorubicin female humans | #1056 |
| minority | #1057 |
| osteoporosis treatment | #1059 |
| primary analysis | #1059 |
| feeding eating | #1059 |
| 10 weeks | #1060 |
| tricyclic | #1061 |
| day study | #1061 |
| prospective validation | #1063 |
| oncologist | #1063 |
| fruitful | #1063 |
| endocrine resistance | #1064 |
| 347 | #1064 |
| loss weight | #1066 |
| ongoing studies | #1066 |
| therapy | #1069 |
| disappointing | #1069 |
| suggested | #1069 |
| metastatic lung | #1070 |
| practical guidance | #1070 |
| descriptive | #1073 |
| tobacco dependence | #1075 |
| nccn | #1078 |
| monoclonal humans | #1078 |
| concurrent chemotherapy | #1078 |
| women treatment | #1079 |
| placebo day | #1080 |
| patients bone metastases | #1081 |
| women received | #1083 |
| advance planning | #1084 |
| placebo participants | #1085 |
| breast cancer recurrence | #1089 |
| duloxetine | #1089 |
| prompted | #1089 |
| patients adjuvant therapy | #1090 |
| low intermediate | #1091 |
| prospective multicenter study | #1092 |
| progestogens | #1094 |
| postoperative surveillance | #1095 |
| palonosetron | #1095 |
| adult breast | #1097 |
| 25 day | #1098 |
| favor | #1099 |
| intravenous iron | #1099 |
| agents treatment | #1100 |
| functional ability | #1100 |
| previous chemotherapy | #1100 |
| 54 | #1103 |
| phytoestrogens | #1103 |
| prospective trial | #1106 |
| peripheral neuropathies | #1108 |
| acknowledged | #1110 |
| 3 6 months | #1112 |
| transdermal | #1114 |
| randomized | #1115 |
| 1 year treatment | #1116 |
| prevention trials | #1119 |
| treatment life | #1121 |
| life death | #1122 |
| inhaler | #1124 |
| cancer trials | #1126 |
| interprofessional relations | #1126 |
| prilocaine | #1127 |
| unpleasant | #1127 |
| dmc | #1127 |
| based evidence | #1128 |
| mexiletine | #1129 |
| participants received | #1131 |
| clinician | #1133 |
| patients versus | #1133 |
| sunscreening | #1136 |
| lecithins | #1137 |
| 25 micrograms | #1139 |
| opioid therapy | #1139 |
| hormonal therapy | #1140 |
| practice guideline | #1140 |
| cancer | #1141 |
| inhibit | #1144 |
| purposeto | #1144 |
| cancer pain | #1146 |
| egb | #1146 |
| randomized crossover | #1146 |
| locoregionally | #1147 |
| illness surveys | #1148 |
| taste disorders | #1149 |
| shark | #1150 |
| purpose determine | #1150 |
| premature ovarian failure | #1150 |
| nervousness | #1153 |
| 730 | #1153 |
| smoking prevention | #1154 |
| hormonal | #1154 |
| detrimental | #1154 |
| flecainide | #1157 |
| 325 | #1159 |
| 481 | #1161 |
| 22 | #1162 |
| rinse | #1162 |
| doac | #1163 |
| educate | #1164 |
| purposethis study | #1167 |
| toxicity assessment | #1167 |
| comparative efficacy | #1172 |
| ceramides | #1173 |
| painful | #1174 |
| therapy estrogens | #1174 |
| intervention trials | #1175 |
| receptor modulators | #1176 |
| patients syndrome | #1177 |
| clinical trial | #1178 |
| inadequately | #1179 |
| projects | #1180 |
| lowest risk | #1181 |
| chemotherapy regimen | #1182 |
| chose | #1184 |
| aged prostatic | #1185 |
| growing population | #1186 |
| physician patient | #1187 |
| electrostimulation | #1188 |
| prior treatment | #1189 |
| international consensus | #1189 |
| mastectomy breast | #1190 |
| acetate treatment | #1190 |
| usage | #1193 |
| gained | #1196 |
| diary | #1197 |
| olmsted | #1197 |
| estrogen replacement therapy | #1197 |
| experiencing | #1198 |
| alternative therapies | #1200 |
| caregivers patients | #1202 |
| male smokers | #1204 |
| partial responses | #1204 |
| 552 | #1204 |
| panax | #1205 |
| clinical trials patients | #1207 |
| magnesium | #1208 |
| breast cancer | #1212 |
| satisfied | #1212 |
| induced skin | #1213 |
| 611 | #1215 |
| communication skills | #1215 |
| patients pts | #1215 |
| likert | #1217 |
| adjuvant endocrine | #1218 |
| sexuality | #1219 |
| secondary endpoints | #1219 |
| precludes | #1219 |
| 8 week | #1221 |
| phase clinical trial | #1223 |
| higher numbers | #1223 |
| limiting | #1224 |
| thighs | #1227 |
| editor | #1227 |
| participants reported | #1229 |
| organogel | #1230 |
| 8 weeks | #1232 |
| primary melanomas | #1232 |
| 52 | #1233 |
| n54 | #1234 |
| randomized phase | #1235 |
| discontinue | #1235 |
| clinical syndrome | #1241 |
| tricyclic antidepressants | #1241 |
| baseline values | #1245 |
| day 2 | #1248 |
| review data | #1248 |
| symptoms diagnosis | #1248 |
| decided | #1249 |
| etiologies | #1250 |
| female sexual | #1250 |
| postmenopausal women | #1252 |
| bedtime | #1252 |
| il1β tnfα | #1253 |
| estrogens female | #1255 |
| diarrhea patients | #1257 |
| diphosphonates | #1258 |
| combination docetaxel | #1258 |
| thromboembolism patients | #1258 |
| hypochromic | #1259 |
| trametinib | #1259 |
| patients 4 | #1259 |
| kidney dysfunction | #1260 |
| rasch | #1260 |
| pain medication | #1261 |
| neurologic humans | #1263 |
| doubts | #1263 |
| dna ploidy | #1265 |
| tumor promotion | #1265 |
| esophagitis | #1266 |
| sae | #1266 |
| protocols chemotherapy | #1268 |
| magnesium oxide | #1270 |
| phytotherapy | #1271 |
| drug double | #1272 |
| qol scores | #1272 |
| short form36 | #1273 |
| situ carcinoma ductal | #1273 |
| preoperative chemotherapy | #1274 |
| patients families | #1274 |
| preclude | #1276 |
| cutaneous melanomas | #1278 |
| taxanes | #1279 |
| tamoxifen patients | #1279 |
| median ttp | #1280 |
| dosing interval | #1281 |
| heparin lmwh | #1282 |
| label trial | #1284 |
| male medication adherence | #1285 |
| medical oncology | #1286 |
| adjuvant tamoxifen | #1287 |
| cyclophosphamide doxorubicin | #1289 |
| adjuvant therapy patients | #1289 |
| opposed | #1289 |
| folfox | #1291 |
| 109 patients | #1292 |
| cochran | #1294 |
| acupuncture treatment | #1294 |
| prevalence severity | #1296 |
| data clinical | #1296 |
| antimetabolites antineoplastic | #1297 |
| neurosensory | #1298 |
| neoplasms disease | #1300 |
| emetic | #1301 |
| women cancer | #1303 |
| 8 cycles | #1307 |
| abstinent | #1307 |
| stimulating agents | #1309 |
| motion rom | #1310 |
| survival 5 | #1310 |
| critical review | #1312 |
| sportdiscus | #1313 |
| gynecologic cancers | #1314 |
| biotech | #1315 |
| gsh | #1315 |
| melanoma antigen | #1315 |
| breast biopsy | #1317 |
| durations | #1318 |
| contacted | #1318 |
| etanercept | #1320 |
| health‐related quality | #1320 |
| investigative | #1321 |
| controlled | #1321 |
| oncology patients | #1321 |
| chemotherapeutic agents | #1321 |
| patients quality | #1322 |
| pain interference | #1322 |
| primary outcome measure | #1322 |
| ointments | #1323 |
| nerve damage | #1326 |
| appetite loss | #1327 |
| life scores | #1328 |
| patient physician | #1328 |
| cardiac toxicity | #1329 |
| agents colorectal | #1329 |
| life surveys | #1337 |
| adjuvant breast | #1339 |
| 375 | #1340 |
| published reports | #1341 |
| evenly | #1342 |
| 2 week | #1345 |
| ambulatory monitoring | #1346 |
| breast cancer women | #1347 |
| platinum compounds | #1347 |
| colonoscopic | #1350 |
| experienced | #1350 |
| tibolone | #1351 |
| karnofsky | #1352 |
| benefit patients | #1353 |
| cancer experience | #1353 |
| malignant ascites | #1354 |
| carcinoembryonic | #1356 |
| period patients | #1358 |
| eligibility criteria | #1359 |
| wks | #1360 |
| agents cancer | #1367 |
| effects treatment | #1368 |
| attribution | #1369 |
| postural balance | #1372 |
| continues | #1376 |
| combination female humans | #1377 |
| hopes | #1379 |
| titrated | #1381 |
| n29 | #1382 |
| patients colon cancer | #1382 |
| n32 | #1382 |
| duplicates | #1386 |
| mastectomy | #1387 |
| hydrazines | #1387 |
| snvs | #1388 |
| patients 40 | #1391 |
| femoral neck bmd | #1396 |
| medical literature | #1397 |
| ajcc | #1399 |
| cancer adult | #1400 |
| cancer therapies | #1403 |
| pain neuropathic | #1404 |
| somnolence | #1406 |
| rifn | #1407 |
| polyneuropathies | #1407 |
| replete | #1408 |
| physical activity level | #1410 |
| treats | #1411 |
| integrative medicine | #1412 |
| fisher test | #1415 |
| viscum | #1416 |
| wilcoxon | #1416 |
| combination chemotherapy | #1417 |
| cessation treatment | #1418 |
| quality life | #1420 |
| treatment recommendations | #1423 |
| subjective symptoms | #1424 |
| sleep initiation | #1424 |
| noncompliance | #1424 |
| biloba | #1425 |
| methodsdata | #1426 |
| therapy initiation | #1426 |
| prevent | #1427 |
| cancer quality life | #1427 |
| cytotoxic chemotherapy | #1428 |
| aromatase | #1431 |
| hormonal treatment | #1431 |
| and or | #1432 |
| 5fu | #1433 |
| weight heparin | #1433 |
| radiation injuries | #1434 |
| statistically difference | #1434 |
| daily intake | #1435 |
| primary objective | #1437 |
| caloric intake | #1439 |
| adults cancer | #1440 |
| female humans illness | #1442 |
| proctitis | #1445 |
| goserelin | #1445 |
| aminobutyric acid | #1446 |
| ehrs | #1447 |
| postacute | #1447 |
| cancer clinical trials | #1449 |
| incidences | #1449 |
| assigning | #1450 |
| coulter | #1453 |
| nccn guidelines | #1454 |
| patients ovarian | #1454 |
| treatment pain | #1454 |
| infliximab | #1455 |
| cognitive testing | #1456 |
| bruising | #1457 |
| hrqol | #1458 |
| 63 | #1459 |
| effective management | #1461 |
| dna testing | #1461 |
| individual patients | #1461 |
| adjuvant treatment | #1463 |
| aged quality | #1466 |
| life cancer | #1466 |
| network meta | #1467 |
| discrepancies | #1467 |
| haloperidol humans | #1467 |
| crossover | #1468 |
| nutritional support | #1469 |
| locally advanced head | #1469 |
| physical activity patients | #1470 |
| recurrent vte | #1475 |
| hormone dependent | #1477 |
| life treatment | #1477 |
| substantial proportion | #1479 |
| resultsa | #1479 |
| lower extremities | #1483 |
| oral aged | #1484 |
| tumor promoter | #1484 |
| pik3ca mutation | #1485 |
| aromatase inhibitors | #1492 |
| nrs | #1493 |
| cancer society | #1494 |
| ongoing | #1495 |
| systemic chemotherapy | #1498 |
| mood states | #1499 |
| planned | #1500 |
| resultsafter | #1501 |
| paclitaxel cisplatin | #1501 |
| mpa | #1509 |
| colon cancer patients | #1510 |
| anti anxiety | #1510 |
| gynecologic cancer | #1513 |
| perimenopause | #1513 |
| premalignant | #1514 |
| neuropeptide npy | #1518 |
| bowel function | #1520 |
| hair loss | #1523 |
| biweekly | #1523 |
| efficacy | #1523 |
| p0024 | #1525 |
| diagnosed cancer | #1525 |
| oncology | #1526 |
| root ganglion | #1526 |
| 3 weeks | #1528 |
| interfered | #1530 |
| balanced | #1532 |
| gastrointestinal toxicity | #1533 |
| cytotoxic agents | #1537 |
| cck8 | #1537 |
| survivors | #1538 |
| physical examination | #1542 |
| cycle patients | #1546 |
| warranted | #1548 |
| guideline recommendations | #1549 |
| tamoxifen treatment | #1550 |
| treatment induced | #1556 |
| adult cancer | #1560 |
| male breast | #1562 |
| blind randomized | #1562 |
| pounds | #1567 |
| transfusion requirements | #1568 |
| design considerations | #1569 |
| response rates | #1572 |
| or1 | #1574 |
| iii disease | #1576 |
| pharmacologic treatment | #1576 |
| 5 day | #1579 |
| bibliographies | #1580 |
| patients small | #1583 |
| crushed | #1583 |
| rivaroxaban | #1583 |
| rate survival | #1584 |
| vaginal | #1587 |
| prospective trials | #1588 |
| postmenopausal breast | #1589 |
| updates | #1590 |
| dissent | #1593 |
| image body | #1593 |
| phase iii study | #1595 |
| localized disease | #1599 |
| stratification | #1600 |
| trpa1 | #1600 |
| therapy cyclophosphamide | #1602 |
| aged cross | #1603 |
| completion | #1603 |
| advanced colorectal cancer | #1604 |
| disagreements | #1605 |
| modafinil | #1606 |
| allopurinol | #1608 |
| ≥70 | #1611 |
| bid | #1612 |
| dosing | #1619 |
| aged antineoplastic | #1620 |
| accrual | #1623 |
| oncology nursing | #1624 |
| 970 | #1624 |
| dna markers | #1626 |
| cream | #1627 |
| 176 | #1628 |
| prophylactic treatment | #1629 |
| tumor type | #1633 |
| 227 | #1634 |
| vte | #1636 |
| upfront | #1637 |
| potential channels | #1642 |
| respiratory depression | #1643 |
| combined modality therapy | #1649 |
| cardiovascular toxicity | #1650 |
| 49 | #1651 |
| 2003 | #1652 |
| controlled phase | #1652 |
| monthly | #1656 |
| cancer stage | #1660 |
| current treatment | #1661 |
| limited data | #1663 |
| pelvic radiotherapy | #1664 |
| referencing | #1666 |
| populationbased cohort | #1667 |
| breast cancer patients | #1667 |
| evaluation female | #1670 |
| treated breast | #1676 |
| patient preference | #1679 |
| therapy hrt | #1680 |
| ovid medline | #1682 |
| hb | #1683 |
| agents carcinoma | #1687 |
| blood tests | #1689 |
| publication attitude | #1691 |
| anticancer therapy | #1693 |
| neoplasms practice | #1693 |
| weight patients | #1694 |
| stopping | #1695 |
| percent patients | #1695 |
| ≤2 | #1696 |
| methyldopa | #1696 |
| randomization | #1698 |
| patients bone | #1698 |
| nootropic | #1698 |
| morpholines | #1700 |
| patients control | #1701 |
| symptom distress | #1701 |
| endpoint | #1703 |
| glutamine | #1705 |
| enrolled patients | #1705 |
| reported symptoms | #1706 |
| study groups | #1707 |
| chisquare | #1708 |
| 595 | #1709 |
| chemotherapy patients | #1709 |
| endocrine treatment | #1711 |
| incorrectly | #1714 |
| inhibitor therapy | #1715 |
| crossover study | #1716 |
| hyperalgesia male | #1717 |
| antineoplastic agents carcinoma | #1719 |
| interventions patients | #1720 |
| effects cancer | #1726 |
| human epidermal | #1726 |
| referral consultation | #1728 |
| selective estrogen | #1728 |
| testosterone treatment | #1729 |
| 652 | #1729 |
| nineteen | #1730 |
| orchiectomy | #1731 |
| neuropathic pain | #1731 |
| lmwh | #1738 |
| paucity | #1740 |
| life questionnaires | #1741 |
| p450 cyp2d6 | #1746 |
| topical | #1746 |
| oxcarbazepine | #1749 |
| ≥10 | #1749 |
| scores patients | #1751 |
| fifty | #1752 |
| recommendations patients | #1753 |
| neoplasms early | #1754 |
| unique challenges | #1754 |
| insufficient evidence | #1762 |
| greater reduction | #1762 |
| treatment data | #1762 |
| cramps | #1764 |
| fall risk | #1765 |
| grade 2 | #1766 |
| massage | #1766 |
| progression survival | #1770 |
| anticoagulants doacs | #1772 |
| urinary symptoms | #1775 |
| performance status | #1779 |
| clinical endpoints | #1781 |
| 95 0 | #1781 |
| objective responses | #1784 |
| fingers | #1784 |
| behavioral interventions | #1785 |
| lignans | #1785 |
| pros | #1787 |
| dizziness | #1789 |
| facts | #1790 |
| survival outcomes patients | #1791 |
| anorectic | #1791 |
| life assessment | #1791 |
| drug therapy | #1792 |
| rbc transfusion | #1794 |
| transient receptor | #1795 |
| primary therapy | #1796 |
| alternative medicine | #1796 |
| descriptive analysis | #1798 |
| decision aids | #1800 |
| investigator | #1802 |
| treatment cycles | #1803 |
| acetylcarnitine | #1803 |
| severe toxicity | #1804 |
| median survival time | #1804 |
| supporting | #1805 |
| premenopause | #1807 |
| adjunct | #1808 |
| analgesic efficacy | #1811 |
| topic | #1812 |
| agents female | #1813 |
| 16 patients | #1813 |
| breast surgery | #1816 |
| trpm | #1818 |
| evidencebased recommendations | #1818 |
| ql | #1821 |
| receptor potential | #1822 |
| cancer women | #1823 |
| 327 | #1823 |
| evaluable patients | #1825 |
| effective therapy | #1825 |
| anxiety agents | #1827 |
| humans neoplasm | #1831 |
| ganglion neurons | #1831 |
| longterm survival patients | #1835 |
| neoplasms prognosis | #1835 |
| suffering | #1836 |
| menopausal transition | #1837 |
| administration topical | #1849 |
| active cancer | #1850 |
| comprehensive cancer | #1851 |
| months 12 | #1851 |
| 23 months | #1853 |
| patients prognosis | #1853 |
| neuropathic | #1853 |
| dermatological | #1853 |
| providers patients | #1857 |
| initial dose | #1858 |
| cancer types | #1858 |
| aged postmenopause | #1858 |
| rationale design | #1863 |
| antimitotic | #1864 |
| univariate analyses | #1867 |
| antimetabolites | #1871 |
| europe female humans | #1873 |
| humans pain | #1873 |
| secondary objective | #1876 |
| continuing | #1877 |
| vice | #1878 |
| resultsa total | #1879 |
| induced pain | #1879 |
| musculoskeletal pain | #1881 |
| antigen colorectal | #1881 |
| analysis adult | #1881 |
| leucovorin male | #1886 |
| galvanic | #1887 |
| weeks | #1888 |
| 15 weeks | #1890 |
| schedules | #1891 |
| questionnaires time | #1891 |
| keratinocyte | #1891 |
| mainstay | #1892 |
| sexual functioning | #1893 |
| hospice | #1896 |
| triazoles | #1897 |
| sensory motor | #1898 |
| stellate | #1899 |
| problematic | #1899 |
| psqi | #1903 |
| topic surveys | #1910 |
| treatment modality | #1911 |
| neuropeptide | #1913 |
| evidence recommendations | #1918 |
| serum cortisol | #1922 |
| creams | #1924 |
| unwanted | #1928 |
| symptoms women | #1933 |
| pain | #1940 |
| prematurely | #1946 |
| health personnel attitude | #1946 |
| patients prostate cancer | #1949 |
| 5year followup | #1950 |
| treatment trial | #1951 |
| peritoneal neoplasms | #1952 |
| imidazoles | #1953 |
| cancer survivorship | #1955 |
| diagnosed breast | #1956 |
| cannabidiol | #1964 |
| signed | #1966 |
| nipple | #1969 |
| iii breast | #1971 |
| primary aim | #1971 |
| warrant | #1972 |
| articles | #1974 |
| surveillance colonoscopy | #1974 |
| initiating | #1975 |
| clinical patients | #1978 |
| estrogen replacement | #1978 |
| hand foot | #1979 |
| intravaginal | #1982 |
| collaborative | #1982 |
| dose melphalan | #1983 |
| controlled trial | #1985 |
| wasting syndrome | #1989 |
| androgen antagonists | #1994 |
| cancer patient | #1994 |
| current treatments | #2002 |
| stool samples | #2004 |
| patients dose | #2005 |
| effective therapies | #2011 |
| dose reductions | #2012 |
| gastrointestinal neoplasms | #2017 |
| phytotherapy plant | #2018 |
| form36 | #2018 |
| fallopian tube | #2019 |
| topic clinical trials | #2022 |
| steroidal aspirin | #2023 |
| perimenopausal | #2025 |
| critics | #2025 |
| neuromuscular diseases | #2026 |
| cardiotoxicity | #2029 |
| testing patients | #2031 |
| patients arm | #2032 |
| outpatient visits | #2034 |
| doses | #2036 |
| eortc qlqc30 | #2038 |
| transcutaneous | #2041 |
| exercise interventions | #2042 |
| recurrence survival | #2044 |
| dnr | #2045 |
| functional impairment | #2046 |
| breast cancer treatment | #2047 |
| evidence base | #2056 |
| status patients | #2056 |
| concentration time | #2058 |
| doxorubicin female | #2059 |
| 35 patients | #2063 |
| antibodies monoclonal antibodies | #2064 |
| head neck cancers | #2065 |
| chest | #2066 |
| relaxation therapy | #2069 |
| cancer population | #2069 |
| 120 patients | #2070 |
| contention | #2073 |
| inhibitor treatment | #2074 |
| hb level | #2075 |
| safety pharmacokinetics | #2075 |
| daily | #2075 |
| 50 reduction | #2076 |
| vinblastine | #2076 |
| nk1 | #2077 |
| benefit | #2080 |
| methysergide | #2081 |
| 20 day | #2082 |
| iii | #2087 |
| younger women | #2087 |
| patients caregivers | #2088 |
| advanced cancers | #2090 |
| antidote | #2090 |
| nursing practice | #2090 |
| major bleeding | #2094 |
| cco | #2094 |
| weekly paclitaxel | #2097 |
| 66 years | #2097 |
| anticonvulsants | #2102 |
| density bone | #2103 |
| mcg | #2104 |
| mitomycins | #2107 |
| therapy chemotherapy | #2109 |
| eicosapentaenoic acid | #2110 |
| tmt | #2111 |
| orally administered | #2111 |
| menopausal status | #2113 |
| day 1 | #2114 |
| 65 | #2115 |
| ≥2 | #2121 |
| bmd lumbar spine | #2121 |
| 5fluorouracil | #2122 |
| treatment study | #2124 |
| 96 patients | #2124 |
| journals | #2125 |
| mildly | #2126 |
| hb levels | #2126 |
| ttr | #2127 |
| bpi | #2128 |
| hormone concentrations | #2129 |
| hepcidins | #2130 |
| neoplasms clinical | #2133 |
| osteolytic | #2135 |
| 525 | #2136 |
| egfr inhibitors | #2136 |
| secondary objectives | #2136 |
| concerned | #2136 |
| aggressive disease | #2140 |
| qol | #2142 |
| levamisole | #2150 |
| tolerable | #2153 |
| carcinoembryonic antigen | #2154 |
| regimens | #2157 |
| item | #2158 |
| prt | #2160 |
| preventive strategies | #2161 |
| evidence efficacy | #2166 |
| baseline | #2166 |
| anemic | #2169 |
| treatment acute | #2169 |
| aloe | #2175 |
| women | #2177 |
| pain syndromes | #2179 |
| album | #2179 |
| worst | #2179 |
| tosyl | #2181 |
| physician | #2182 |
| detailed description | #2185 |
| fatigue pain | #2188 |
| 44 patients | #2195 |
| nervous | #2197 |
| severe symptoms | #2204 |
| questionnaires survivors | #2207 |
| 455 | #2208 |
| dose intensity | #2208 |
| age race | #2210 |
| prescription drugs | #2210 |
| female head | #2210 |
| 1 7 | #2212 |
| hypnosis | #2213 |
| ensuing | #2213 |
| weight loss | #2214 |
| 1–4 | #2220 |
| recurrences | #2220 |
| cmt | #2224 |
| adenosyl | #2225 |
| premenopausal | #2226 |
| myalgia | #2233 |
| osteonecrosis jaw | #2235 |
| 9 weeks | #2235 |
| 138 | #2242 |
| 60 minutes | #2243 |
| adrenal axis | #2247 |
| failed | #2247 |
| patient populations | #2251 |
| dermatologic | #2256 |
| life severity | #2257 |
| preliminary evidence | #2262 |
| summarized | #2265 |
| exercise female humans | #2266 |
| clinically meaningful | #2270 |
| patients metastatic melanoma | #2271 |
| 566 | #2272 |
| differences patients | #2273 |
| irritation | #2277 |
| bioelectrical impedance | #2284 |
| oophorectomy | #2285 |
| 1 year patients | #2285 |
| occult | #2288 |
| metastatic melanoma | #2290 |
| osteoporosis postmenopausal | #2291 |
| sloan | #2292 |
| gastrointestinal cancer | #2293 |
| likewise | #2298 |
| 800 | #2299 |
| life illness | #2301 |
| therapy adt | #2301 |
| regular | #2302 |
| dysfunction physiological | #2303 |
| incisional | #2308 |
| future trials | #2309 |
| conclusionthe | #2310 |
| polymerase inhibitors | #2310 |
| recommendation | #2311 |
| patch | #2311 |
| cramp | #2312 |
| genetic variations | #2314 |
| therapeutic strategies | #2320 |
| topic risk | #2326 |
| baclofen | #2327 |
| 74 | #2327 |
| weight breast | #2328 |
| worse | #2329 |
| burning | #2333 |
| mastectomy segmental | #2333 |
| 36 | #2333 |
| toxicity | #2334 |
| modest | #2334 |
| subcutaneously | #2335 |
| receptor positive | #2337 |
| exclusion criteria | #2338 |
| week | #2342 |
| opioid analgesics | #2347 |
| society | #2347 |
| androgen deprivation | #2349 |
| improve quality | #2349 |
| 46 patients | #2352 |
| curve analysis | #2352 |
| endorsed | #2357 |
| adult antineoplastic | #2359 |
| density bmd | #2365 |
| cyp2d6 | #2365 |
| increased risks | #2367 |
| baseline treatment | #2367 |
| nonrandomized | #2371 |
| 669 | #2373 |
| agent | #2374 |
| bibliometric | #2375 |
| rom | #2378 |
| health practice guidelines | #2379 |
| taste | #2389 |
| cancer clinical | #2390 |
| ornithine | #2391 |
| treatment duration | #2393 |
| difference 95 | #2396 |
| justification | #2397 |
| neoplasms survival | #2399 |
| neurological complications | #2400 |
| 266 | #2405 |
| counteract | #2405 |
| titles | #2406 |
| treatment baseline | #2407 |
| inadequate | #2407 |
| remaining patients | #2412 |
| postural | #2418 |
| poor performance | #2419 |
| rectal cancer patients | #2419 |
| ovid | #2420 |
| documenting | #2421 |
| 5 patients | #2425 |
| advanced prostate cancer | #2425 |
| symptom scores | #2426 |
| limited evidence | #2426 |
| debate | #2433 |
| 761 | #2436 |
| practiced | #2437 |
| 71 patients | #2437 |
| estrogen deficiency | #2439 |
| patients crc | #2439 |
| acupuncture | #2442 |
| response evaluation | #2442 |
| outpatient treatment | #2443 |
| phase trials | #2449 |
| 56 years | #2452 |
| chemotherapy adjuvant | #2453 |
| receptor antagonist | #2460 |
| common cancers | #2462 |
| iiic | #2463 |
| common adverse | #2464 |
| assessment scale | #2469 |
| factor inhibitors | #2469 |
| fallopian | #2474 |
| 207 | #2474 |
| patients quality life | #2477 |
| weight gain | #2478 |
| bleomycin | #2480 |
| guidelines patients | #2481 |
| practical approach | #2485 |
| network metaanalysis | #2491 |
| crossed | #2493 |
| approached | #2494 |
| melanomas | #2495 |
| raloxifene | #2496 |
| discontinuing | #2497 |
| 6 patients | #2502 |
| sexual function | #2507 |
| 61 | #2510 |
| ginkgo | #2510 |
| locoregional | #2510 |
| patients colorectal cancer | #2519 |
| children cancer | #2524 |
| topic clinical | #2526 |
| venous thromboembolism | #2527 |
| regimen | #2531 |
| cooperative | #2537 |
| asked | #2542 |
| amitriptyline | #2542 |
| radiation induced | #2544 |
| rescue | #2545 |
| 12 24 | #2556 |
| treatment methods | #2556 |
| carryover | #2557 |
| symptom | #2558 |
| galectin3 | #2562 |
| mandated | #2564 |
| randomised clinical trial | #2567 |
| telopeptide | #2567 |
| nitriles | #2568 |
| reuptake | #2570 |
| treatment selection | #2570 |
| stage small | #2573 |
| earlystage breast cancer | #2573 |
| conjunctivitis | #2574 |
| trials | #2592 |
| secondary analyses | #2592 |
| ideally | #2595 |
| carboplatin | #2597 |
| effects drugs | #2598 |
| 2 cycles | #2602 |
| erbb2 receptors | #2608 |
| parenteral | #2610 |
| arm | #2612 |
| pruritus | #2614 |
| patient education | #2617 |
| outcome united | #2624 |
| antineoplastic combined | #2624 |
| apr | #2626 |
| consented | #2626 |
| suspicious | #2627 |
| dorsal root | #2629 |
| symptoms quality | #2629 |
| life hrqol | #2631 |
| increased likelihood | #2639 |
| managing | #2642 |
| prefer | #2644 |
| remedy | #2648 |
| 55 | #2649 |
| 0001 patients | #2657 |
| thromboembolism | #2657 |
| races | #2657 |
| attenuate | #2662 |
| total parenteral nutrition | #2663 |
| scores | #2663 |
| lasted | #2667 |
| basal cell | #2670 |
| testosterone | #2672 |
| cancer outcomes | #2673 |
| imprecise | #2675 |
| comparable | #2676 |
| poorer survival | #2677 |
| symptoms treatment | #2685 |
| 817 | #2686 |
| prescribed | #2687 |
| prevention interventions | #2692 |
| statistically | #2696 |
| randomized controlled | #2699 |
| direct oral anticoagulants | #2701 |
| prevalence smoking | #2705 |
| impotence | #2707 |
| advanced colorectal | #2711 |
| data synthesis | #2713 |
| primary lung | #2717 |
| myelosuppression | #2724 |
| 1000 | #2735 |
| 01 | #2741 |
| modestly | #2745 |
| chemotherapy protocols | #2745 |
| thermal hyperalgesia | #2748 |
| acp | #2749 |
| multiple factors | #2749 |
| patients pain | #2750 |
| topic drug | #2752 |
| efficacies | #2753 |
| taxane | #2758 |
| advanced breast | #2760 |
| male medical | #2761 |
| ttf | #2762 |
| 250 | #2764 |
| neurotoxicity | #2769 |
| pyrazoles | #2774 |
| 1 4 | #2775 |
| male neoplasms | #2775 |
| 237 | #2776 |
| breast carcinoma | #2777 |
| convenience sample | #2780 |
| selfreport | #2781 |
| syndrome aged | #2788 |
| cryosurgery | #2789 |
| paraneoplastic syndromes | #2790 |
| pooled data | #2790 |
| neoplasia | #2791 |
| undergone | #2792 |
| adverse | #2793 |
| isoflavones | #2794 |
| ascites | #2794 |
| agents | #2797 |
| complete data | #2799 |
| nv | #2801 |
| thrice | #2801 |
| doacs | #2802 |
| acid epa | #2806 |
| cox model | #2812 |
| additional studies | #2813 |
| shortness | #2814 |
| continuous infusion | #2815 |
| preferred | #2817 |
| neurofeedback | #2823 |
| 750 | #2827 |
| breast | #2834 |
| sexual health | #2837 |
| muscle weakness | #2840 |
| 1 3 | #2842 |
| opioids | #2844 |
| meeting | #2844 |
| 38 | #2845 |
| primary outcomes | #2845 |
| cancer aged | #2854 |
| n31 | #2857 |
| cohen | #2857 |
| linseed | #2859 |
| breakthrough | #2859 |
| pharmacogenomic | #2860 |
| neoplasms | #2860 |
| sham | #2861 |
| statistical methods | #2866 |
| activity level | #2867 |
| breaths | #2867 |
| purposethe | #2869 |
| anticipate | #2869 |
| covariate | #2870 |
| fertility preservation | #2875 |
| surveillance patients | #2876 |
| task force | #2886 |
| 5 years patients | #2886 |
| ellipse | #2893 |
| survival dose | #2895 |
| p04 | #2895 |
| decarboxylase | #2912 |
| functional assessment | #2915 |
| endodermal | #2917 |
| packyears | #2918 |
| screening tests | #2920 |
| measurable | #2922 |
| p0002 | #2927 |
| placebo response | #2930 |
| prior | #2931 |
| condylomata | #2931 |
| phase clinical | #2933 |
| p008 | #2941 |
| topic design | #2945 |
| identifier | #2949 |
| dosing regimens | #2949 |
| review articles | #2949 |
| colonoscopy colorectal | #2951 |
| auc | #2954 |
| laser treatment | #2955 |
| utility | #2956 |
| week 12 | #2961 |
| 2 groups | #2962 |
| humans infusions | #2963 |
| hirsutism | #2966 |
| combined chemotherapy | #2969 |
| search terms | #2971 |
| curable | #2974 |
| chest wall | #2975 |
| intraepithelial neoplasia | #2977 |
| prophylactic | #2982 |
| placebo difference | #2983 |
| questionnaires | #2985 |
| eicosapentaenoic | #2986 |
| calculator | #2988 |
| testimony | #2989 |
| stopped | #2990 |
| calories | #2991 |
| started | #2991 |
| severity symptoms | #2995 |
| positive breast | #2998 |
| fatigue | #3000 |
| resected | #3004 |
| long acting | #3010 |
| n5 | #3012 |
| objective response | #3012 |
| topically | #3013 |
| discomfort | #3014 |
| time progression | #3014 |
| pathologic complete response | #3019 |
| patients 5 | #3022 |
| mianserin | #3026 |
| bone fractures | #3029 |
| ifosfamide | #3033 |
| nci | #3034 |
| skeletal muscle mass | #3038 |
| her2 status | #3041 |
| reuptake inhibitors | #3041 |
| dermatoses | #3042 |
| placebo week | #3052 |
| sided | #3053 |
| relief | #3058 |
| dukes | #3058 |
| risk colorectal | #3058 |
| tumor activity | #3066 |
| outcome measure | #3067 |
| curve auc | #3067 |
| 264 | #3068 |
| clonidine | #3069 |
| malignancy | #3071 |
| hyperhidrosis | #3072 |
| ctx | #3074 |
| sternal | #3076 |
| histograms | #3092 |
| sexual dysfunction | #3097 |
| nicotine dependence | #3098 |
| loss adult | #3099 |
| intergroup | #3103 |
| patients day | #3107 |
| tumor grade | #3108 |
| vera | #3111 |
| bmd | #3111 |
| cancer female humans | #3111 |
| 66 | #3116 |
| 26 | #3121 |
| neurokinin1 | #3121 |
| reversing | #3135 |
| cognitive dysfunction | #3139 |
| schedule | #3143 |
| 12 weeks | #3144 |
| treatment oral | #3146 |
| life measures | #3147 |
| clinical stage | #3150 |
| trpv1 | #3154 |
| infusions intravenous | #3155 |
| randomized controlled study | #3161 |
| χ2 | #3165 |
| subsequent development | #3166 |
| strongest association | #3168 |
| lifestyle factors | #3178 |
| phase 3 | #3180 |
| reasonable | #3181 |
| systematic literature search | #3183 |
| current approaches | #3185 |
| supportive | #3185 |
| leuprolide | #3186 |
| relevant articles | #3188 |
| 617 | #3189 |
| intravenous | #3190 |
| wore | #3192 |
| cannabinoids | #3193 |
| 64 | #3196 |
| podophyllotoxin | #3197 |
| abstracted | #3201 |
| menopausal | #3208 |
| case reports | #3210 |
| constellation | #3218 |
| 42 | #3222 |
| intervention trial | #3225 |
| joint committee | #3225 |
| nonsmallcell lung cancer | #3226 |
| 39 | #3226 |
| cochrane central register | #3231 |
| pain perception | #3235 |
| enrolled | #3238 |
| breathing | #3239 |
| medical record | #3240 |
| paraneoplastic | #3245 |
| itch | #3260 |
| therapy combination | #3260 |
| intervention patients | #3263 |
| oral mucosa | #3264 |
| designed | #3264 |
| 236 | #3266 |
| prior studies | #3269 |
| disagree | #3269 |
| treatment efficacy | #3270 |
| n30 | #3271 |
| 5 10 | #3272 |
| skin biopsies | #3278 |
| supplementary | #3279 |
| finished | #3282 |
| expert panel | #3284 |
| root ganglia | #3287 |
| 2030 | #3287 |
| 80 antibodies | #3288 |
| 885 | #3290 |
| 695 | #3290 |
| lymphoma patients | #3290 |
| previous analyses | #3291 |
| 576 | #3294 |
| understudied | #3296 |
| 0026 | #3303 |
| neuralgia | #3313 |
| suffer | #3314 |
| undertook | #3316 |
| resection colorectal | #3319 |
| impression | #3320 |
| treatment placebo | #3320 |
| electronic health | #3321 |
| chlorhexidine | #3322 |
| prostate cancer risk | #3328 |
| 171 | #3334 |
| acuminata | #3334 |
| risk vte | #3339 |
| systemically | #3350 |
| platinum based | #3352 |
| terminology | #3356 |
| erythema | #3358 |
| historic | #3360 |
| female breast | #3365 |
| breast prostate | #3368 |
| doubt | #3370 |
| bone metastases | #3370 |
| thirty | #3374 |
| preclinical studies | #3375 |
| relapse free | #3380 |
| chemoprevention | #3386 |
| acute chronic | #3392 |
| equivalency | #3395 |
| advanced prostate | #3396 |
| iii trials | #3399 |
| answers | #3400 |
| preceding | #3406 |
| oral | #3408 |
| lymph node excision | #3411 |
| prostatic neoplasms | #3415 |
| delaying | #3417 |
| anilides | #3418 |
| severity | #3422 |
| delineated | #3425 |
| axillary lymph | #3426 |
| administering | #3437 |
| npy | #3438 |
| higher scores | #3444 |
| screening methods | #3446 |
| 012 | #3446 |
| subsequent | #3452 |
| aminoquinolines | #3460 |
| 64 patients | #3463 |
| utilizing | #3463 |
| sprays | #3464 |
| pts | #3468 |
| survival benefits | #3468 |
| listed | #3468 |
| chemotherapy radiation | #3471 |
| anthracyclines | #3471 |
| multicenter randomized | #3473 |
| lidocaine | #3475 |
| lower rate | #3477 |
| mailed | #3479 |
| cross validation | #3480 |
| cessation smoking | #3481 |
| 3 6 | #3484 |
| attempt | #3489 |
| antidepressants | #3490 |
| intent | #3495 |
| reviewing | #3499 |
| ctc | #3500 |
| malignant disease | #3501 |
| — | #3505 |
| chemotherapeutic agent | #3512 |
| recommend | #3524 |
| allodynia | #3529 |
| carries | #3539 |
| metastatic disease | #3544 |
| points | #3545 |
| opiates | #3559 |
| stage breast | #3561 |
| 148 | #3565 |
| faced | #3566 |
| patients metastatic | #3574 |
| correlational | #3583 |
| phase topic | #3583 |
| survival women | #3583 |
| carboplatin paclitaxel | #3586 |
| 135 | #3586 |
| oestrogen | #3587 |
| patients experiences | #3588 |
| chemotherapy cycles | #3588 |
| treatment decisions | #3595 |
| 211 | #3596 |
| gold standard | #3607 |
| life qol | #3608 |
| objective measures | #3608 |
| periodically | #3610 |
| thiotepa | #3615 |
| stage iiia | #3618 |
| oral adult | #3619 |
| ≥30 | #3620 |
| benefits risks | #3620 |
| survival cancer | #3620 |
| therapeutic benefit | #3623 |
| improvement quality | #3629 |
| antacids | #3630 |
| 29 patients | #3631 |
| survivals | #3634 |
| racial differences | #3639 |
| complete responses | #3648 |
| colon cancer | #3650 |
| ordinal | #3650 |
| patients adjuvant chemotherapy | #3650 |
| adjuvant chemotherapy patients | #3652 |
| ≥18 years | #3655 |
| parp inhibitor | #3660 |
| bodymass | #3661 |
| 34 patients | #3666 |
| acid antagonists | #3674 |
| 673 | #3682 |
| sigmoidoscopy | #3682 |
| preceded | #3685 |
| proportion | #3686 |
| 580 | #3686 |
| aps | #3688 |
| thirty patients | #3689 |
| cardio | #3690 |
| chemotherapies | #3695 |
| redness | #3700 |
| moxibustion | #3702 |
| options | #3705 |
| electron rats | #3706 |
| relapsefree survival | #3707 |
| study evidence | #3708 |
| cancer chemotherapy | #3712 |
| annually | #3714 |
| instructed | #3716 |
| adjuvant chemotherapy | #3718 |
| 5000 | #3719 |
| exception | #3721 |
| 911 | #3725 |
| breast tissue | #3731 |
| impressive | #3738 |
| combination female | #3741 |
| foams | #3742 |
| randomized clinical trial | #3742 |
| practicing | #3743 |
| anabolic | #3746 |
| late effects | #3752 |
| lymphatic vessels | #3754 |
| weight status | #3758 |
| longterm survival | #3768 |
| menopausal women | #3774 |
| symptom severity | #3782 |
| vertigo | #3788 |
| adversely | #3789 |
| cancer drugs | #3795 |
| compassionate | #3800 |
| 567 | #3801 |
| hormone replacement therapy | #3804 |
| external beam | #3805 |
| sixth | #3806 |
| 600 | #3807 |
| terminal | #3811 |
| hormone replacement | #3811 |
| anesthetics | #3811 |
| colchicine | #3815 |
| phase trial | #3816 |
| centric | #3817 |
| etoposide | #3822 |
| pain control | #3825 |
| cancer prostate | #3830 |
| ploidies | #3831 |
| intramuscularly | #3834 |
| patients experienced | #3834 |
| 136 | #3839 |
| 16 weeks | #3839 |
| patients moderate | #3843 |
| cutaneous | #3846 |
| trpv | #3847 |
| contraindications | #3847 |
| seventy | #3854 |
| blinding | #3854 |
| sharks | #3855 |
| patients grade | #3855 |
| internally | #3858 |
| 23 | #3861 |
| treatment metastatic | #3861 |
| 04 | #3866 |
| futility | #3867 |
| 786 | #3875 |
| individually | #3880 |
| queried | #3882 |
| flushing | #3886 |
| midwestern | #3888 |
| adenomas | #3895 |
| compelling | #3897 |
| dfs survival | #3905 |
| modulators | #3906 |
| received chemotherapy | #3909 |
| sponsored | #3917 |
| bone turnover | #3919 |
| 24 weeks | #3921 |
| hyperactivation | #3922 |
| keywords | #3927 |
| vte patients | #3928 |
| therapies | #3933 |
| myoclonus | #3940 |
| publication clinical trials | #3940 |
| discontinued | #3942 |
| grade 1 | #3945 |
| 61 patients | #3947 |
| bf | #3950 |
| food drug administration | #3951 |
| difficulty | #3953 |
| colorectal | #3955 |
| inhibitors female | #3956 |
| prostate carcinoma | #3961 |
| capsaicin | #3969 |
| manifested | #3970 |
| study drug | #3973 |
| 25 | #3975 |
| accidental | #3976 |
| pain severity | #3977 |
| adenosine triphosphate | #3980 |
| pluronic | #3983 |
| 20 | #3988 |
| 30 years | #3991 |
| toxic effects | #3993 |
| 449 | #3994 |
| weight | #4002 |
| lasting | #4002 |
| 370 | #4004 |
| gait | #4005 |
| sideeffects | #4006 |
| 692 | #4008 |
| kras mutations | #4014 |
| surgery radiation | #4018 |
| estrogenic | #4023 |
| patients intervention | #4034 |
| audio | #4034 |
| year patients | #4039 |
| lumbar spine | #4044 |
| thirteen patients | #4047 |
| tid | #4052 |
| prostatic | #4062 |
| erythropoietin | #4062 |
| nonusers | #4066 |
| flax | #4068 |
| conjunction | #4069 |
| cancer therapy | #4069 |
| 516 | #4075 |
| intravenously | #4077 |
| extremities | #4084 |
| strong evidence | #4087 |
| meaningful | #4099 |
| revisions | #4102 |
| rose | #4108 |
| 2–4 | #4116 |
| iii study | #4120 |
| bone neoplasms | #4124 |
| dermatitis | #4125 |
| noninfiltrating | #4126 |
| favoring | #4126 |
| sphase | #4131 |
| documentation | #4132 |
| 7 months | #4134 |
| topic practice patterns | #4138 |
| tablets | #4138 |
| definitions | #4138 |
| femoral neck | #4139 |
| malignant melanoma | #4139 |
| 269 | #4143 |
| combination therapy | #4144 |
| mbc | #4157 |
| interleukin6 il6 | #4159 |
| 4 months | #4164 |
| 326 | #4175 |
| effective | #4194 |
| noxious | #4196 |
| 10 months | #4199 |
| calcium vitamin | #4201 |
| cancer bone | #4210 |
| depressants | #4210 |
| undertaken | #4211 |
| 2006 | #4220 |
| treatment option | #4223 |
| twothirds | #4232 |
| 18 months | #4236 |
| platinumbased chemotherapy | #4238 |
| drug response | #4250 |
| quinazolines | #4254 |
| anemia patients | #4256 |
| contraindication | #4258 |
| neoplasms colorectal | #4258 |
| serially | #4268 |
| treatment discontinuation | #4268 |
| cation channels | #4271 |
| 58 patients | #4278 |
| 2 4 | #4283 |
| survival quality | #4284 |
| bone density | #4284 |
| day | #4285 |
| utilized | #4289 |
| inconsistencies | #4289 |
| colorectal neoplasms | #4297 |
| rheumatism | #4301 |
| node negative | #4307 |
| aged breast | #4313 |
| bioavailable | #4314 |
| chemotherapy treatment | #4323 |
| prednisolone | #4326 |
| reductions | #4326 |
| vast | #4327 |
| bone diseases | #4330 |
| healthy women | #4331 |
| primary endpoints | #4331 |
| reply | #4340 |
| firstline chemotherapy | #4343 |
| treatment studies | #4355 |
| equally | #4357 |
| neoplasms combined | #4359 |
| institute | #4359 |
| participated | #4360 |
| detrimental effects | #4367 |
| outcome data | #4368 |
| 3 months | #4373 |
| sleeping | #4376 |
| discontinuation | #4381 |
| preliminary | #4385 |
| carcinoma ductal | #4389 |
| time surgery | #4393 |
| therapies patients | #4394 |
| judgment | #4395 |
| 12 week | #4396 |
| drug combinations | #4402 |
| repeatedly | #4402 |
| hyperalgesia | #4411 |
| grouping | #4414 |
| minnesota | #4415 |
| purpose | #4417 |
| “ | #4424 |
| evaluate | #4425 |
| 1015 | #4427 |
| 14 months | #4429 |
| balance | #4430 |
| 80 breast | #4431 |
| studies colorectal | #4431 |
| low doses | #4436 |
| drg neurons | #4437 |
| pain relief | #4438 |
| documented | #4440 |
| relevant studies | #4445 |
| day patients | #4446 |
| improve patient | #4446 |
| summarize | #4450 |
| clinical predictors | #4455 |
| clinical parameters | #4460 |
| humanized antineoplastic | #4464 |
| 80 | #4465 |
| pain measurement | #4465 |
| fecal | #4466 |
| clinical practice guidelines | #4490 |
| 05 | #4494 |
| risk breast cancer | #4499 |
| humans lymph | #4501 |
| received | #4504 |
| drug administration | #4505 |
| stimulants | #4510 |
| axillary | #4521 |
| 5 | #4523 |
| daily activities | #4523 |
| sedation | #4529 |
| ganglion | #4530 |
| gynecologic | #4530 |
| ductal breast | #4530 |
| disease recurrence | #4531 |
| cancer methods | #4534 |
| hematology | #4535 |
| disabling | #4536 |
| stimulant | #4536 |
| natural | #4537 |
| sphingolipids | #4537 |
| diarrhea | #4540 |
| drug effects | #4540 |
| journal | #4544 |
| impairments | #4546 |
| 3 4 | #4550 |
| ganglia spinal | #4552 |
| continuation | #4558 |
| outcome measures | #4561 |
| financial | #4562 |
| rescue therapy | #4564 |
| clinical | #4564 |
| 376 | #4567 |
| rbc | #4569 |
| 4 | #4575 |
| reliability validity | #4575 |
| successes | #4577 |
| single blind | #4583 |
| tumor regression | #4587 |
| explore | #4588 |
| risk bleeding | #4591 |
| hydroxytryptamine | #4591 |
| mmf | #4592 |
| cumulative | #4604 |
| tenderness | #4606 |
| 115 | #4609 |
| longer duration | #4612 |
| chemopreventive | #4617 |
| emphasizes | #4620 |
| neoplasms dna | #4626 |
| throat | #4633 |
| caf | #4636 |
| patients increase | #4642 |
| 6 12 | #4647 |
| daily dose | #4647 |
| neuropathies | #4647 |
| tumor recurrence | #4653 |
| 1 study | #4661 |
| data studies | #4662 |
| 96 | #4664 |
| dose chemotherapy | #4665 |
| adpribose | #4665 |
| increased incidence | #4669 |
| treatments | #4674 |
| qol patients | #4679 |
| vitality | #4683 |
| peaked | #4684 |
| hazards | #4689 |
| deprivation | #4691 |
| 29 | #4693 |
| secondary analysis | #4699 |
| treatment survival | #4701 |
| dose | #4704 |
| low dose | #4708 |
| dose reduction | #4712 |
| reference lists | #4722 |
| preliminary study | #4733 |
| ” | #4734 |
| mediastinum | #4734 |
| assessment tool | #4740 |
| phase 2 trial | #4741 |
| vigor | #4751 |
| percentage patients | #4752 |
| cgy | #4762 |
| efficacy tolerability | #4773 |
| analysis neoplasm | #4783 |
| recommended | #4785 |
| adt | #4790 |
| invasive breast cancer | #4792 |
| 353 | #4795 |
| proven | #4798 |
| 009 | #4806 |
| corticosteroid | #4806 |
| 538 | #4810 |
| tears | #4810 |
| evaluations | #4813 |
| circulating concentrations | #4817 |
| improved quality | #4818 |
| cancer compared | #4818 |
| acetylcysteine | #4821 |
| capecitabine | #4829 |
| musculoskeletal | #4830 |
| multicenter | #4836 |
| symptom burden | #4836 |
| carcinoma small | #4837 |
| bridged | #4837 |
| seer program | #4841 |
| tubulin | #4841 |
| aes | #4846 |
| 60 | #4848 |
| 55 patients | #4854 |
| receipt | #4857 |
| 381 | #4861 |
| patients recurrence | #4868 |
| patients prostate | #4870 |
| individual patient data | #4876 |
| amines | #4886 |
| neck neoplasms humans | #4890 |
| 048 | #4901 |
| receptor egfr | #4904 |
| fisher | #4910 |
| crc patients | #4911 |
| lastly | #4917 |
| systemic therapy | #4921 |
| harms | #4922 |
| platinum | #4924 |
| stage iiib | #4925 |
| abstinence | #4926 |
| unfavorable | #4927 |
| existed | #4928 |
| basal cell carcinoma | #4933 |
| ≥1 | #4937 |
| 727 | #4942 |
| coadministration | #4946 |
| sensitization | #4956 |
| screening tool | #4956 |
| 9 months | #4960 |
| plethora | #4970 |
| subsequently | #4974 |
| eligibility | #4975 |
| equivocal | #4980 |
| cancer background | #4981 |
| optimal management | #4983 |
| depot | #4989 |
| deep vein thrombosis | #4992 |
| cumulative dose | #4996 |
| recurrence free | #4997 |
| exercise intervention | #5003 |
| lessons | #5005 |
| metastatic prostate | #5016 |
| situ carcinoma | #5017 |
| based cohort | #5018 |
| combined treatment | #5027 |
| routine clinical | #5028 |
| biphasic | #5029 |
| multicenter trial | #5039 |
| initiate | #5045 |
| sedative | #5055 |
| actively | #5058 |
| missing data | #5060 |
| favorably | #5071 |
| osteoporosis | #5073 |
| physical symptoms | #5075 |
| 3 trials | #5076 |
| methotrexate | #5077 |
| karnofsky performance | #5084 |
| genistein | #5084 |
| study incidence | #5086 |
| phenobarbital | #5091 |
| 100 patients | #5098 |
| 342 | #5099 |
| pyrimidinones | #5104 |
| version | #5104 |
| bortezomib | #5105 |
| cisplatin treatment | #5106 |
| published | #5116 |
| skin neoplasms | #5121 |
| ntprobnp | #5124 |
| conventional chemotherapy | #5126 |
| reducing | #5131 |
| physical therapy | #5131 |
| 120 | #5141 |
| topical application | #5142 |
| indomethacin | #5143 |
| medicine humans | #5149 |
| higher rate | #5154 |
| women early | #5155 |
| lower rates | #5157 |
| bisphosphonates | #5165 |
| resolve | #5169 |
| prognostic | #5176 |
| analysis randomized | #5177 |
| compiled | #5181 |
| cycle | #5186 |
| antiinflammatory agents | #5187 |
| supplement | #5201 |
| thalidomide | #5207 |
| 30 patients | #5214 |
| references | #5218 |
| cisplatin | #5225 |
| april | #5231 |
| medications | #5239 |
| identical | #5243 |
| dying | #5243 |
| randomised controlled trial | #5244 |
| humans lung | #5249 |
| article | #5249 |
| insomnia | #5255 |
| patients time | #5257 |
| conventionally | #5257 |
| mitoxantrone | #5265 |
| progestins | #5266 |
| resectable | #5269 |
| low molecular | #5270 |
| caring | #5270 |
| negative impact | #5277 |
| health disparities | #5278 |
| sed | #5291 |
| undergo | #5306 |
| gynecology | #5309 |
| parenteral nutrition | #5310 |
| vaporizers | #5317 |
| cancer prevention | #5319 |
| conflicting | #5325 |
| pelvic | #5326 |
| ineligible | #5327 |
| 404 | #5333 |
| anticipated | #5335 |
| alkaloids | #5335 |
| administered | #5339 |
| methods design | #5344 |
| patient data | #5349 |
| monophenol | #5351 |
| perceived | #5359 |
| sensation | #5359 |
| current practice | #5361 |
| colorectal cancers | #5362 |
| answered | #5376 |
| neurologists | #5377 |
| 346 | #5385 |
| adenosylmethionine | #5393 |
| isotretinoin | #5394 |
| declining | #5396 |
| judged | #5403 |
| responding | #5412 |
| study women | #5421 |
| officinalis | #5423 |
| stage iii | #5423 |
| 33 | #5425 |
| colonic polyps | #5444 |
| axilla | #5468 |
| 57 | #5470 |
| manner | #5473 |
| p0006 | #5481 |
| minutes | #5482 |
| baseline characteristics | #5486 |
| health records | #5490 |
| pufas | #5492 |
| based interventions | #5496 |
| 167 | #5504 |
| preclinical models | #5506 |
| methylases | #5508 |
| ovary | #5512 |
| thromboembolic events | #5518 |
| patient demographics | #5521 |
| neoplasms humans | #5525 |
| 410 | #5535 |
| pooled | #5548 |
| medical conditions | #5556 |
| 03 | #5571 |
| cancer center | #5573 |
| ready | #5580 |
| acne | #5582 |
| routine clinical practice | #5583 |
| stage patients | #5590 |
| dropped | #5593 |
| 002 | #5594 |
| current literature | #5598 |
| patient quality | #5604 |
| woman | #5605 |
| 41 | #5611 |
| polyps | #5620 |
| carnitine | #5623 |
| enteral | #5633 |
| treatment approaches | #5638 |
| sensory | #5638 |
| new therapies | #5642 |
| lung carcinoma | #5642 |
| 0007 | #5648 |
| concurrent | #5672 |
| treatment regimens | #5676 |
| guideline | #5679 |
| constipation | #5683 |
| sf36 | #5684 |
| n6 | #5687 |
| standard chemotherapy | #5688 |
| neuromodulation | #5689 |
| 50 | #5693 |
| renewed | #5694 |
| dexamethasone | #5694 |
| desire | #5695 |
| preserve | #5696 |
| online | #5699 |
| patients therapy | #5701 |
| nonsignificant | #5703 |
| multiplied | #5704 |
| raise | #5705 |
| cancer type | #5708 |
| androgen | #5716 |
| trials rcts | #5722 |
| specialist | #5730 |
| complete | #5730 |
| dna content | #5733 |
| serial | #5736 |
| provider | #5761 |
| tumor breast | #5762 |
| interruption | #5762 |
| tumor stage | #5762 |
| total score | #5766 |
| impair | #5770 |
| versus | #5773 |
| chance | #5779 |
| nicotine | #5783 |
| mucous | #5783 |
| carcinoma situ | #5783 |
| exploratory study | #5790 |
| node excision | #5795 |
| 345 | #5805 |
| higher doses | #5806 |
| 395 | #5814 |
| vitamin | #5817 |
| systemic effects | #5827 |
| patients aspirin | #5828 |
| patient experience | #5830 |
| 4 5 | #5837 |
| cancer breast | #5842 |
| leukocyte count | #5850 |
| intermediate risk | #5852 |
| selfreported | #5855 |
| patients survival | #5857 |
| stools | #5858 |
| subgroups patients | #5873 |
| interfere | #5877 |
| 405 | #5877 |
| excitatory amino | #5883 |
| enrollment | #5886 |
| neoplasm recurrence | #5887 |
| exercises | #5888 |
| totally | #5898 |
| response relationship | #5899 |
| potential mechanisms | #5909 |
| 3 | #5910 |
| 0 1 | #5917 |
| trastuzumab | #5925 |
| alternating | #5926 |
| gel | #5930 |
| acids omega3 | #5935 |
| humans injections | #5940 |
| pooled analysis | #5946 |
| dysplastic | #5947 |
| questionnaires adult | #5952 |
| treatment toxicity | #5954 |
| previous | #5955 |
| treatment failure | #5964 |
| symptoms depression | #5967 |
| returned | #5979 |
| confounding | #5990 |
| analogue | #5995 |
| devoted | #5996 |
| 239 | #5997 |
| evaluation studies | #5997 |
| icd9 | #6000 |
| sectional survey | #6002 |
| validated | #6007 |
| serum patients | #6010 |
| 1977 | #6013 |
| insulinlike growth factor | #6013 |
| prognostic indicator | #6018 |
| minute | #6019 |
| descriptions | #6019 |
| worsened | #6026 |
| sentinel node | #6028 |
| 0013 | #6041 |
| chemotherapy radiotherapy | #6041 |
| grade 3 | #6042 |
| 243 | #6045 |
| new evidence | #6049 |
| month | #6052 |
| institutional | #6061 |
| syndrome | #6065 |
| protective agents | #6066 |
| caution | #6067 |
| stool | #6070 |
| 480 | #6082 |
| subscales | #6083 |
| approved | #6097 |
| aspect | #6098 |
| 20 years | #6102 |
| 43 | #6104 |
| hormone therapy | #6108 |
| increment | #6109 |
| tests prognosis | #6116 |
| spitzer | #6118 |
| conducted | #6120 |
| randomized controlled trial | #6125 |
| routes | #6128 |
| surviving | #6156 |
| antiepileptic | #6164 |
| kilogram | #6167 |
| endpoints | #6173 |
| inception | #6184 |
| skin diseases | #6188 |
| 241 | #6189 |
| omega3 | #6193 |
| selective serotonin | #6195 |
| boronic | #6199 |
| intraepithelial | #6204 |
| 16 | #6215 |
| 900 | #6218 |
| female | #6221 |
| central venous | #6229 |
| combination treatment | #6232 |
| 62 | #6234 |
| epa | #6239 |
| randomized clinical trials | #6242 |
| invasive breast | #6249 |
| patients colorectal | #6253 |
| treated mice | #6255 |
| exploratory | #6257 |
| 58 | #6258 |
| asymptomatic patients | #6260 |
| metastasis neoplasm | #6261 |
| receptors progesterone | #6265 |
| historically | #6269 |
| palliative | #6270 |
| protocols | #6275 |
| psychotropic drugs | #6280 |
| disclosure | #6280 |
| ease | #6282 |
| 2000 | #6283 |
| xerostomia | #6284 |
| followup patients | #6293 |
| innovations | #6299 |
| scopus | #6300 |
| benzhydryl | #6302 |
| insignificant | #6302 |
| survival female | #6312 |
| 328 | #6314 |
| chi2 | #6320 |
| prospective | #6330 |
| lobular | #6343 |
| counseling | #6344 |
| 59 | #6346 |
| rigorous | #6347 |
| clinically | #6350 |
| endocrine therapy | #6365 |
| fentanyl | #6372 |
| aged | #6372 |
| venous thromboembolism vte | #6385 |
| 2007 | #6385 |
| infusions | #6393 |
| epidermal growth | #6393 |
| breadth | #6395 |
| physicians | #6402 |
| cronbach | #6404 |
| narcotic | #6407 |
| vitro model | #6413 |
| early intervention | #6424 |
| sexes | #6425 |
| initial treatment | #6426 |
| endocrinology | #6432 |
| 2 3 | #6433 |
| psychotropic | #6439 |
| pittsburgh | #6439 |
| entire | #6440 |
| multinational | #6440 |
| 361 | #6445 |
| counts | #6446 |
| soybeans | #6449 |
| sex hormones | #6452 |
| logs | #6453 |
| congeners | #6455 |
| quality | #6458 |
| termed | #6470 |
| intraluminal | #6471 |
| 75 | #6471 |
| life health | #6478 |
| n16 | #6481 |
| treatment guidelines | #6482 |
| patients 2 | #6485 |
| time diagnosis | #6486 |
| mcf7 cells | #6496 |
| records | #6498 |
| abcb1 | #6499 |
| ≥18 | #6501 |
| usual patients | #6512 |
| disease stage | #6515 |
| adenoma | #6520 |
| complementary | #6521 |
| consultation | #6524 |
| guidance | #6531 |
| iu | #6533 |
| ranked | #6536 |
| developments | #6540 |
| transfusions | #6551 |
| 004 | #6552 |
| tumor location | #6554 |
| 86 | #6567 |
| 0004 | #6575 |
| analog | #6576 |
| 53 | #6591 |
| abstracts | #6593 |
| baseline patients | #6598 |
| initiated | #6602 |
| acting | #6604 |
| colonic neoplasms | #6605 |
| pyrazines | #6608 |
| l3 | #6612 |
| hemoglobins | #6612 |
| decisions | #6614 |
| 287 | #6614 |
| fourth | #6615 |
| phase | #6617 |
| 02 | #6618 |
| surveys questionnaires | #6621 |
| hrt | #6622 |
| curative resection | #6623 |
| familiar | #6641 |
| pellet | #6646 |
| guidelines | #6646 |
| crf | #6648 |
| hormone receptor | #6651 |
| patients health | #6651 |
| courses | #6664 |
| randomized controlled trials | #6666 |
| emerging evidence | #6681 |
| osseous | #6682 |
| physical health | #6683 |
| tools | #6685 |
| figure | #6689 |
| dex | #6691 |
| caloric | #6694 |
| erectile dysfunction | #6694 |
| develops | #6696 |
| neoplasm metastasis | #6699 |
| radiotherapy chemotherapy | #6702 |
| hypothesized | #6702 |
| ketamine | #6710 |
| colorectal cancer patients | #6717 |
| consecutive | #6717 |
| interprofessional | #6728 |
| detailed | #6731 |
| testicular cancer | #6743 |
| score | #6745 |
| 295 | #6750 |
| quit | #6751 |
| replacement therapy | #6751 |
| difference | #6763 |
| grade | #6770 |
| lower incidence | #6773 |
| true | #6776 |
| ocular | #6783 |
| prevents | #6784 |
| titration | #6787 |
| pain management | #6793 |
| longest | #6801 |
| search strategy | #6801 |
| frequently | #6801 |
| chart review | #6802 |
| rounds | #6804 |
| 344 | #6806 |
| hepcidin | #6809 |
| fulfilled | #6810 |
| controlled studies | #6810 |
| participating | #6811 |
| mice treated | #6818 |
| detect | #6826 |
| ovarian function | #6841 |
| treatment advanced | #6842 |
| integrative | #6851 |
| early treatment | #6853 |
| exercise therapy | #6861 |
| classification | #6874 |
| inventory | #6877 |
| narrative | #6879 |
| drg | #6883 |
| routinely | #6887 |
| new drugs | #6889 |
| secondary | #6891 |
| concerns | #6896 |
| strength muscle | #6898 |
| differ | #6903 |
| 277 | #6904 |
| serum concentrations | #6912 |
| tumor formation | #6917 |
| 5 ht | #6918 |
| controversial | #6930 |
| summarizes | #6932 |
| mass loss | #6941 |
| cbd | #6942 |
| factors breast | #6942 |
| iiib | #6944 |
| laparotomy | #6953 |
| diarrhoea | #6955 |
| tartrate | #6960 |
| quarter | #6970 |
| regressions | #6981 |
| skin temperature | #6981 |
| ais | #6986 |
| calorie | #6990 |
| wearing | #6990 |
| quiet | #6990 |
| definition | #6994 |
| 35 | #6994 |
| seer | #7001 |
| promise | #7002 |
| patients developed | #7006 |
| 1 year | #7011 |
| initially | #7015 |
| women study | #7019 |
| hemorrhage humans | #7020 |
| breast cancers | #7030 |
| 051 | #7045 |
| metaanalyses | #7049 |
| animal doseresponse relationship | #7050 |
| neoplasms risk | #7063 |
| patients 1 | #7067 |
| interested | #7067 |
| 50 patients | #7068 |
| 31 | #7083 |
| screening middle | #7089 |
| total | #7097 |
| overview | #7098 |
| asian patients | #7111 |
| neu | #7113 |
| approval | #7114 |
| 97 | #7121 |
| neoplasms treatment | #7122 |
| polyadp | #7124 |
| neoplasms female | #7130 |
| prostate cancer | #7130 |
| 261 | #7131 |
| female gastrointestinal | #7143 |
| strengthened | #7144 |
| neuroprotection | #7147 |
| 833 | #7154 |
| therapy humans | #7165 |
| estrogens | #7171 |
| appropriateness | #7179 |
| breast cancer risk | #7187 |
| expect | #7188 |
| pik3ca | #7201 |
| confirm | #7211 |
| uncontrolled | #7220 |
| estrogen | #7228 |
| entity | #7234 |
| discusses | #7238 |
| agents steroidal | #7255 |
| 203 | #7262 |
| questionnaire | #7264 |
| ameliorates | #7264 |
| chosen | #7266 |
| popularity | #7283 |
| additionally | #7295 |
| neoplasms primary | #7296 |
| outpatients | #7296 |
| cinahl | #7333 |
| node biopsy | #7334 |
| increased survival | #7336 |
| 10 | #7340 |
| aged anti | #7343 |
| stages | #7347 |
| evaluates | #7353 |
| superficial | #7353 |
| radiotherapy adjuvant | #7358 |
| prognosis prospective | #7361 |
| firstline therapy | #7376 |
| epo | #7378 |
| eating | #7379 |
| short | #7384 |
| square distribution | #7390 |
| 47 | #7393 |
| noradrenergic | #7407 |
| rfs | #7416 |
| curative | #7416 |
| esr1 | #7417 |
| radiotherapy | #7433 |
| genital | #7435 |
| receptor agonists | #7436 |
| emphasis | #7436 |
| confirmatory | #7436 |
| naphthalenes | #7437 |
| cancer treated | #7438 |
| established | #7449 |
| 25 patients | #7456 |
| clinical evaluation | #7467 |
| 199 | #7478 |
| 1st | #7482 |
| 058 | #7484 |
| wasting | #7488 |
| prognosis proportional | #7488 |
| treatment strategy | #7489 |
| bolus | #7496 |
| genetic factors | #7499 |
| metastatic colorectal | #7501 |
| gonadotropin | #7504 |
| 259 | #7507 |
| november | #7509 |
| dysplasia | #7523 |
| transaminases | #7524 |
| objectively | #7526 |
| melanoma patients | #7528 |
| cancer vaccines | #7531 |
| infertility | #7534 |
| investigators | #7534 |
| october | #7539 |
| tumor colorectal | #7541 |
| local neoplasm | #7543 |
| 315 | #7558 |
| primary treatment | #7559 |
| adequacy | #7564 |
| concurrently | #7578 |
| kaplanmeier method | #7583 |
| intraductal | #7586 |
| 00001 | #7589 |
| patients head | #7594 |
| grades | #7605 |
| single dose | #7607 |
| tretinoin | #7608 |
| discussions | #7609 |
| chronic pain | #7615 |
| coumarins | #7616 |
| gain | #7620 |
| opinions | #7621 |
| ploidy | #7624 |
| interval | #7624 |
| receptor antagonists | #7632 |
| receptor erbb2 | #7633 |
| pharmacists | #7641 |
| local neoplasms | #7642 |
| sequelae | #7645 |
| metastatic colorectal cancer | #7656 |
| clinical benefit | #7666 |
| retinoids | #7678 |
| corticosteroids | #7684 |
| visits | #7691 |
| longterm effects | #7695 |
| evident | #7696 |
| monitored | #7699 |
| 1 day | #7699 |
| 026 | #7710 |
| publication biomarkers | #7713 |
| 021 | #7725 |
| surveys | #7725 |
| recurrence | #7726 |
| risk breast | #7728 |
| thrombophilia | #7734 |
| administration | #7744 |
| washout | #7744 |
| onethird | #7749 |
| nicotinic | #7751 |
| rank | #7758 |
| cancer recurrence | #7763 |
| independent predictors | #7776 |
| omega3 fatty | #7779 |
| treatment time | #7780 |
| serotonergic | #7785 |
| pathophysiology | #7796 |
| negative effects | #7805 |
| 14 | #7807 |
| ovarian neoplasms | #7811 |
| erectile | #7812 |
| clinicians | #7820 |
| gonadal | #7839 |
| 12 months | #7842 |
| swallowing | #7843 |
| subcutaneous | #7855 |
| pain intensity | #7856 |
| patient centered | #7866 |
| thiophenes | #7869 |
| 0 | #7876 |
| hemoglobins humans | #7892 |
| statistic | #7900 |
| physical function | #7917 |
| ago | #7927 |
| impacted | #7927 |
| 40 | #7933 |
| dysfunctions | #7950 |
| androgens | #7955 |
| comparing | #7956 |
| 5year survival | #7956 |
| advanced | #7957 |
| generally | #7963 |
| 305 | #7965 |
| ductal carcinoma | #7968 |
| ≤ | #7972 |
| actuarial | #7973 |
| 055 | #7975 |
| individualized | #7981 |
| collect | #7982 |
| situation | #7983 |
| female genital | #7985 |
| 062 | #8006 |
| 278 | #8020 |
| noninferiority | #8032 |
| powered | #8051 |
| preclinical | #8062 |
| genders | #8063 |
| intractable | #8063 |
| colorectal cancer crc | #8064 |
| 45 | #8065 |
| 208 | #8069 |
| 105 | #8086 |
| sixteen | #8088 |
| humans longitudinal | #8090 |
| relating | #8096 |
| expand | #8099 |
| resultant | #8100 |
| trial background | #8102 |
| occurred | #8107 |
| irrespective | #8127 |
| analgesics opioid | #8128 |
| 5 years | #8132 |
| reduce | #8141 |
| receptors estrogen | #8142 |
| methodswe | #8150 |
| entering | #8154 |
| translational | #8164 |
| facilitating | #8173 |
| dose escalation | #8185 |
| specific antigen | #8189 |
| edetic | #8191 |
| ondansetron | #8204 |
| withdrawal | #8206 |
| tnf alpha | #8213 |
| cancer detection | #8218 |
| popular | #8220 |
| b4 | #8224 |
| mild | #8234 |
| spearman | #8242 |
| patients adult | #8249 |
| regard | #8249 |
| committees | #8252 |
| stage | #8255 |
| parp | #8258 |
| dietary supplements | #8265 |
| treated | #8266 |
| modalities | #8269 |
| tobramycin | #8285 |
| antitumor activity | #8287 |
| neoplasms male | #8289 |
| patient groups | #8315 |
| 201 | #8324 |
| estradiol | #8325 |
| risk cancer | #8327 |
| triazines | #8331 |
| wellbeing | #8341 |
| sertraline | #8344 |
| concern | #8345 |
| cell lung | #8349 |
| pubmed | #8352 |
| patient treatment | #8362 |
| pharmacogenetics | #8372 |
| year follow | #8372 |
| calcium | #8389 |
| clinical activity | #8395 |
| choose | #8397 |
| 6 cycles | #8403 |
| predisposing | #8405 |
| costly | #8417 |
| undergoing | #8422 |
| preparations | #8422 |
| neck neoplasms | #8435 |
| expense | #8447 |
| married | #8448 |
| detecting | #8460 |
| testing | #8465 |
| underestimate | #8466 |
| composition body | #8478 |
| 3 trial | #8482 |
| 37 | #8482 |
| eruptions | #8486 |
| oncologic | #8488 |
| neuromuscular | #8489 |
| clinical experience | #8509 |
| 39 patients | #8527 |
| respond | #8553 |
| cyclophosphamide | #8562 |
| 253 | #8570 |
| average | #8576 |
| 020 | #8587 |
| stratified | #8596 |
| exists | #8598 |
| ttp | #8610 |
| standard therapy | #8620 |
| 81 | #8624 |
| 015 | #8629 |
| morphine | #8637 |
| estrogen receptors | #8637 |
| cancer female | #8639 |
| remain | #8643 |
| fda | #8646 |
| legs | #8657 |
| initial | #8658 |
| relative risks | #8659 |
| practitioners | #8676 |
| functional status | #8679 |
| syndrome patients | #8684 |
| 6 months | #8685 |
| egfr | #8692 |
| grip | #8695 |
| notable | #8700 |
| single nucleotide polymorphisms | #8700 |
| threatening | #8705 |
| molecular markers | #8705 |
| loss | #8714 |
| aged 80 | #8715 |
| selfreports | #8722 |
| leptin | #8728 |
| 32 patients | #8731 |
| colorectal cancer | #8743 |
| drug | #8748 |
| perspectives | #8751 |
| majority | #8756 |
| illustrates | #8757 |
| inhibitors | #8764 |
| repeated | #8765 |
| 123 | #8769 |
| 2001 | #8774 |
| survivorship | #8779 |
| 066 | #8786 |
| aged models | #8792 |
| real | #8800 |
| mouth | #8800 |
| prospective randomized | #8808 |
| providers | #8813 |
| question | #8814 |
| advanced stage | #8823 |
| accumulating | #8842 |
| groups patients | #8847 |
| ferric | #8858 |
| uremic | #8865 |
| concomitant | #8886 |
| highrisk | #8893 |
| enteral nutrition | #8908 |
| publication aged aged | #8919 |
| predefined | #8929 |
| supplemental | #8938 |
| negatively | #8961 |
| 017 | #8966 |
| 145 | #8971 |
| ovaries | #8984 |
| demographics | #8989 |
| ribose | #8990 |
| 28 patients | #8996 |
| 2 study | #9000 |
| acceptability | #9006 |
| dna neoplasm | #9008 |
| 304 | #9013 |
| lung neoplasms | #9014 |
| analyses | #9017 |
| bivariate | #9019 |
| favored | #9020 |
| longer | #9020 |
| 300 | #9035 |
| 18 | #9037 |
| literature | #9043 |
| 223 | #9060 |
| vagina | #9062 |
| analgesics | #9073 |
| women risk | #9074 |
| 116 | #9084 |
| venous | #9089 |
| 275 | #9107 |
| consisted | #9112 |
| medical treatment | #9114 |
| 70 | #9117 |
| instability | #9124 |
| oral anticoagulants | #9131 |
| referred | #9132 |
| 286 | #9133 |
| gene expression profiling | #9135 |
| rated | #9162 |
| 232 | #9167 |
| 1987 | #9170 |
| 103 | #9180 |
| germ cell | #9183 |
| erbb receptors | #9195 |
| feeling | #9196 |
| moderate | #9197 |
| embryonal | #9202 |
| erythropoiesis | #9216 |
| 12 patients | #9228 |
| predict | #9230 |
| approaches | #9232 |
| 320 | #9249 |
| psycinfo | #9250 |
| update | #9253 |
| incidence | #9265 |
| eighteen | #9277 |
| stimulate | #9281 |
| manifestation | #9291 |
| primary | #9292 |
| administrative | #9293 |
| greater risk | #9301 |
| favorable | #9308 |
| hypnotics | #9310 |
| 94 | #9317 |
| systematic literature | #9317 |
| 15 | #9332 |
| possess | #9332 |
| participant | #9336 |
| grip strength | #9341 |
| metastatic | #9361 |
| lives | #9367 |
| cycles | #9371 |
| acceptable | #9383 |
| mechanisms action | #9383 |
| drug female | #9385 |
| ambulatory | #9385 |
| postulated | #9389 |
| 177 | #9431 |
| 82 | #9435 |
| 28 | #9436 |
| consisting | #9437 |
| neurologic | #9443 |
| definitive | #9454 |
| partial response | #9454 |
| abdomen | #9468 |
| 3 groups | #9499 |
| death patients | #9509 |
| ophthalmic | #9514 |
| recurrence patients | #9518 |
| serving | #9539 |
| 500 | #9542 |
| cancer crc | #9542 |
| 006 | #9545 |
| 065 | #9547 |
| jaw | #9565 |
| decisionmaking | #9568 |
| imbalance | #9575 |
| melphalan | #9579 |
| similarities | #9580 |
| add | #9583 |
| sentinel lymph | #9619 |
| 68 | #9624 |
| progesterone receptor | #9627 |
| addressed | #9641 |
| oral cavity | #9657 |
| prednisone | #9662 |
| electroacupuncture | #9668 |
| publications | #9669 |
| referrals | #9677 |
| items | #9695 |
| p0004 | #9696 |
| fell | #9698 |
| 149 | #9702 |
| nerve injury | #9707 |
| adenocarcinoma aged | #9733 |
| logistic regression analysis | #9737 |
| smokers | #9746 |
| cope | #9749 |
| erbb | #9762 |
| experts | #9767 |
| carcinoma patients | #9777 |
| sleep disorders | #9784 |
| food intake | #9785 |
| priority | #9791 |
| monoclonal humanized | #9791 |
| 0002 | #9797 |
| remission induction | #9812 |
| exercise female | #9831 |
| trends | #9835 |
| 7 | #9836 |
| patient age | #9855 |
| saponins | #9856 |
| palliation | #9857 |
| neuroprotective agents | #9871 |
| clinical outcomes patients | #9872 |
| avoid | #9872 |
| 95ci | #9875 |
| goals | #9882 |
| bleeding | #9884 |
| axonal | #9897 |
| illness | #9909 |
| 89 | #9921 |
| injections | #9941 |
| zinc | #9942 |
| mitigate | #9952 |
| provision | #9954 |
| variety | #9963 |
| telephone | #9968 |
| recurrence rates | #9969 |
| education topic | #9980 |
| 88 | #9985 |
| behavioral therapy | #9988 |
| ethics | #9991 |
| 400 | #9997 |
| growing | #9999 |
| square | #10005 |
| reactions female | #10007 |
| prescribing | #10007 |
| advanced disease | #10009 |
| dosedependent manner | #10013 |
| exist | #10016 |
| art | #10020 |
| bone resorption | #10023 |
| progressed | #10053 |
| women health | #10061 |
| autonomic | #10070 |
| ortho | #10071 |
| reason | #10076 |
| percentages | #10095 |
| candidates | #10096 |
| exceptions | #10097 |
| 76 | #10099 |
| node dissection | #10100 |
| il1β | #10101 |
| criterion | #10109 |
| disease adult | #10113 |
| 56 | #10120 |
| predictive factors | #10154 |
| preference | #10168 |
| micronutrients | #10188 |
| categorized | #10215 |
| measures | #10218 |
| monoamine | #10221 |
| 12 | #10224 |
| 40 patients | #10233 |
| demonstrate | #10251 |
| lack | #10261 |
| curve | #10266 |
| guideline adherence | #10267 |
| 256 | #10271 |
| developed | #10274 |
| achieving | #10279 |
| caused | #10317 |
| higher incidence | #10325 |
| sarcomas | #10341 |
| epidermal | #10345 |
| variables | #10354 |
| bone mineral density | #10369 |
| anemia | #10385 |
| cell transplant | #10386 |
| morning | #10392 |
| changed | #10400 |
| survival dfs | #10400 |
| 3 5 | #10407 |
| 142 | #10413 |
| 141 | #10436 |
| smoking cessation | #10437 |
| chart | #10440 |
| 041 | #10450 |
| revised | #10485 |
| 24 hours | #10489 |
| lvef | #10497 |
| masked | #10500 |
| syndromes | #10508 |
| mineral density | #10522 |
| longitudinal studies | #10522 |
| effort | #10550 |
| instruments | #10555 |
| 154 | #10558 |
| define | #10560 |
| 650 | #10565 |
| surveillance | #10571 |
| persisted | #10581 |
| elucidate | #10582 |
| informed | #10584 |
| trend | #10585 |
| months 95 | #10586 |
| encountered | #10600 |
| 667 | #10608 |
| fewer | #10613 |
| counselling | #10617 |
| doxorubicin | #10617 |
| academic | #10623 |
| include | #10636 |
| concert | #10640 |
| european society | #10663 |
| histories | #10672 |
| curative intent | #10673 |
| upper extremity | #10688 |
| vitamins | #10697 |
| examinations | #10703 |
| treatment chronic | #10721 |
| prognostic significance | #10733 |
| median followup | #10743 |
| tests | #10751 |
| edema | #10753 |
| enter | #10757 |
| anticoagulants | #10757 |
| fat mass | #10763 |
| median duration | #10779 |
| iiia | #10779 |
| patients response | #10788 |
| induction chemotherapy | #10795 |
| 60 years | #10802 |
| 182 | #10803 |
| clinic | #10803 |
| columbia | #10805 |
| 73 | #10812 |
| insufficient | #10814 |
| rcts | #10818 |
| internal consistency | #10826 |
| 21 | #10828 |
| advisory | #10839 |
| noradrenaline | #10843 |
| recurrent | #10863 |
| randomised controlled | #10873 |
| determine | #10873 |
| hydroxy | #10874 |
| neck cancer | #10884 |
| clinicaltrialsgov | #10885 |
| nighttime | #10888 |
| felt | #10892 |
| held | #10899 |
| 1 patient | #10911 |
| 9 patients | #10922 |
| limited | #10928 |
| occurring | #10934 |
| supplements | #10937 |
| kits | #10950 |
| head neck cancer | #10956 |
| cognition disorders | #10958 |
| start | #10961 |
| retrospective review | #10966 |
| failure | #10978 |
| needed | #10981 |
| squamous cell carcinoma | #10982 |
| registry | #10999 |
| physiology | #11017 |
| 155 | #11028 |
| 030 | #11031 |
| agents drug | #11051 |
| rationale | #11080 |
| ascertained | #11084 |
| interventions | #11094 |
| soft tissue | #11097 |
| international society | #11105 |
| smoking | #11105 |
| 3 years | #11121 |
| 043 | #11122 |
| editorial | #11123 |
| years diagnosis | #11128 |
| sleep wake | #11133 |
| sick | #11135 |
| practice guidelines | #11135 |
| 091 | #11146 |
| decrease | #11150 |
| extensive | #11160 |
| head neck | #11164 |
| reduces | #11166 |
| 127 | #11168 |
| subclinical | #11185 |
| decreases | #11199 |
| progesterone | #11207 |
| facilitate | #11216 |
| gamma | #11222 |
| 2004 | #11246 |
| secondary outcome | #11250 |
| anticoagulation | #11251 |
| 1983 | #11257 |
| survival | #11259 |
| prostate | #11267 |
| contributed | #11278 |
| cognitive behavioral | #11279 |
| diploid | #11281 |
| therapy neoplasm | #11287 |
| snps | #11295 |
| closer | #11307 |
| reviews | #11329 |
| benzimidazoles | #11334 |
| vincristine | #11361 |
| 168 | #11373 |
| thrombocytopenia | #11377 |
| 129 | #11387 |
| affect | #11397 |
| radiation therapy | #11423 |
| subgroup analyses | #11428 |
| clinical signs | #11439 |
| apparent | #11439 |
| point | #11449 |
| rating scale | #11457 |
| 78 | #11468 |
| 092 | #11469 |
| label | #11482 |
| 2 trial | #11486 |
| patients patient | #11493 |
| multidimensional | #11498 |
| alive | #11501 |
| 235 | #11509 |
| caregivers | #11509 |
| recombinant human | #11530 |
| 6 | #11541 |
| 130 | #11548 |
| lymphatic metastasis | #11549 |
| 040 | #11553 |
| helps | #11582 |
| computerized | #11583 |
| 109 | #11585 |
| enhancing | #11586 |
| 20 patients | #11588 |
| analgesic | #11591 |
| humans mass | #11616 |
| incontinence | #11617 |
| opioid | #11645 |
| benefits | #11651 |
| pulmonary embolism | #11652 |
| minimal | #11660 |
| peritoneal | #11670 |
| 028 | #11674 |
| gefitinib | #11675 |
| adenocarcinoma adult | #11688 |
| camptothecin | #11691 |
| body image | #11717 |
| docetaxel | #11732 |
| sarcopenia | #11745 |
| lumbar | #11751 |
| small cell | #11764 |
| rheumatic | #11765 |
| comparisons | #11767 |
| nerves | #11789 |
| reduction | #11791 |
| oxidative damage | #11822 |
| aged postoperative | #11823 |
| 128 | #11825 |
| resultsthe | #11835 |
| risk recurrence | #11837 |
| definite | #11855 |
| 024 | #11855 |
| neoplasms cell | #11862 |
| interim | #11864 |
| hematologic | #11897 |
| investigation | #11910 |
| testicular | #11913 |
| cured | #11926 |
| haloperidol | #11938 |
| pelvis | #11956 |
| thirteen | #11969 |
| humanized | #11970 |
| ≥3 | #11995 |
| 1998 | #11997 |
| referral | #11997 |
| involving | #11999 |
| 90 patients | #12014 |
| 24 patients | #12015 |
| humans | #12017 |
| negative breast | #12030 |
| effectively | #12047 |
| thirds | #12053 |
| single nucleotide | #12063 |
| muscarinic | #12067 |
| triphosphate | #12068 |
| committee | #12069 |
| rating | #12071 |
| bone mineral | #12074 |
| − | #12078 |
| toxic | #12079 |
| cumulative incidence | #12103 |
| greater | #12144 |
| expectancy | #12147 |
| dosage | #12148 |
| rectal cancer | #12163 |
| 119 | #12183 |
| 104 | #12187 |
| unadjusted | #12191 |
| validity | #12205 |
| aspirin | #12207 |
| deoxycytidine | #12226 |
| alternatively | #12248 |
| believed | #12251 |
| malignant | #12268 |
| sodium channel | #12270 |
| peri | #12270 |
| 2 weeks | #12279 |
| disease specific | #12302 |
| igf | #12308 |
| compliance | #12317 |
| categories | #12322 |
| cognitive | #12338 |
| terms | #12340 |
| grading | #12342 |
| classic | #12345 |
| tolerability | #12360 |
| sexual | #12361 |
| psychometrics | #12376 |
| 27 | #12378 |
| adjuvants | #12396 |
| falls | #12402 |
| searched | #12414 |
| relapse | #12415 |
| qualitative study | #12416 |
| sentinel | #12421 |
| p21ras | #12426 |
| 1 2 | #12446 |
| anticancer drugs | #12449 |
| science | #12462 |
| drug humans | #12482 |
| 90 | #12485 |
| predictive | #12492 |
| 194 | #12495 |
| embase | #12496 |
| transfusion | #12502 |
| consistency | #12511 |
| reasons | #12523 |
| prognostic factor | #12536 |
| mitomycin | #12540 |
| 010 | #12573 |
| predictors | #12577 |
| bladder cancer | #12581 |
| explored | #12591 |
| bioavailability | #12611 |
| sleep | #12615 |
| attempts | #12621 |
| test | #12626 |
| psychometric | #12641 |
| therapeutic approaches | #12642 |
| supports | #12643 |
| rank test | #12657 |
| fourteen | #12657 |
| recommendations | #12691 |
| problem | #12710 |
| 2013 | #12714 |
| patient outcome | #12719 |
| reliability | #12747 |
| translated | #12749 |
| stiffness | #12752 |
| crc | #12777 |
| missed | #12783 |
| develop | #12817 |
| 023 | #12853 |
| segmental | #12865 |
| cancer nsclc | #12868 |
| patients surgery | #12874 |
| statistics | #12876 |
| subject | #12882 |
| ice | #12886 |
| normal tissue | #12931 |
| interviewed | #12944 |
| inform | #12945 |
| irreversible | #12946 |
| poorer | #12947 |
| coded | #12950 |
| 184 | #12952 |
| single agent | #12954 |
| scale | #12961 |
| univariate | #12983 |
| monoclonal antibodies monoclonal | #13009 |
| 193 | #13020 |
| n4 | #13025 |
| defining | #13026 |
| cancers | #13041 |
| ovariectomy | #13045 |
| paired | #13049 |
| humans logistic | #13082 |
| future | #13082 |
| suggests | #13099 |
| longterm followup | #13101 |
| pharmacotherapy | #13121 |
| trial comparing | #13126 |
| gains | #13129 |
| alter | #13132 |
| aged neoadjuvant | #13151 |
| inflammatory cytokines | #13153 |
| demographic | #13159 |
| originally | #13160 |
| cox regression | #13163 |
| responsiveness | #13183 |
| 44 | #13192 |
| tpa | #13230 |
| multiple myeloma | #13238 |
| humans lymphatic | #13262 |
| epidemiologic | #13262 |
| 21 patients | #13267 |
| longitudinal data | #13270 |
| myeloma | #13286 |
| racial | #13299 |
| requiring | #13322 |
| outpatient | #13334 |
| symptomatic | #13346 |
| cognitive function | #13351 |
| hours | #13376 |
| steroidal | #13380 |
| pg | #13393 |
| measure | #13408 |
| formal | #13409 |
| therapeutic potential | #13414 |
| intermediate | #13433 |
| muscle mass | #13492 |
| ductal | #13505 |
| eventually | #13506 |
| randomised trial | #13513 |
| attending | #13528 |
| psychometric properties | #13563 |
| discriminate | #13564 |
| pharmacological | #13578 |
| typically | #13588 |
| diminished | #13609 |
| improves | #13630 |
| agonists | #13630 |
| 196 | #13634 |
| skin cancer | #13649 |
| tended | #13650 |
| frequency | #13652 |
| participants | #13674 |
| infective | #13701 |
| hypothesis | #13703 |
| tested | #13723 |
| attempted | #13739 |
| initiation | #13758 |
| distress | #13778 |
| foods | #13785 |
| severe | #13795 |
| 192 | #13800 |
| clinical manifestations | #13803 |
| marked | #13813 |
| 18 years | #13813 |
| conditional | #13831 |
| 018 | #13858 |
| colonic | #13890 |
| solid tumors | #13891 |
| negative patients | #13900 |
| march | #13918 |
| lymphatic | #13928 |
| sleep quality | #13935 |
| mechanisms underlying | #13938 |
| 102 | #13944 |
| p00001 | #13946 |
| focus | #13988 |
| aged muscle | #13991 |
| conducting | #13996 |
| estimate male | #13999 |
| igf1 | #14032 |
| calcitonin | #14038 |
| head | #14056 |
| eastern | #14057 |
| lung cancer | #14080 |
| substances | #14080 |
| 0001 | #14090 |
| respondents | #14106 |
| skin | #14109 |
| 169 | #14117 |
| breast cancer cells | #14121 |
| physiologic | #14122 |
| antagonist | #14137 |
| led | #14139 |
| risk death | #14180 |
| her2 | #14186 |
| protective | #14195 |
| modality | #14195 |
| risk developing | #14199 |
| etiology | #14201 |
| 189 | #14202 |
| cytotoxic | #14234 |
| demonstrating | #14236 |
| 124 | #14251 |
| life style | #14259 |
| suboptimal | #14279 |
| states aged | #14282 |
| careful | #14282 |
| cetuximab | #14293 |
| hypothesize | #14318 |
| efficacy safety | #14319 |
| 32 | #14329 |
| recurrence risk | #14331 |
| instance | #14341 |
| analysis performed | #14341 |
| virtually | #14371 |
| 188 | #14375 |
| clinical impact | #14379 |
| cessation | #14403 |
| alpha2 | #14412 |
| 144 | #14420 |
| produces | #14420 |
| 4 patients | #14436 |
| nodal | #14440 |
| extremity | #14440 |
| transitional | #14454 |
| stat | #14456 |
| 178 | #14484 |
| 1997 | #14487 |
| distant metastases | #14504 |
| trial registration | #14517 |
| 2008 | #14518 |
| 8 | #14521 |
| univariate multivariate | #14524 |
| nsclc | #14525 |
| erbb2 | #14544 |
| gm | #14553 |
| 035 | #14567 |
| year survival | #14570 |
| heavily | #14577 |
| iron | #14583 |
| 34 | #14587 |
| prospectively | #14607 |
| episodes | #14626 |
| 09 | #14626 |
| 007 | #14634 |
| tumor response | #14639 |
| hypothetical | #14647 |
| additional | #14648 |
| initial diagnosis | #14674 |
| estrogen receptor | #14679 |
| prophylaxis | #14686 |
| 5 year | #14689 |
| dermal | #14710 |
| 008 | #14729 |
| adult | #14729 |
| menstrual | #14740 |
| examine | #14743 |
| practice | #14751 |
| reflecting | #14758 |
| neoplasm | #14762 |
| 15 years | #14762 |
| neoplasm staging | #14774 |
| interferons | #14781 |
| clarify | #14785 |
| health professionals | #14804 |
| erlotinib | #14821 |
| asian | #14838 |
| relevant | #14863 |
| peer | #14921 |
| 1990 | #14930 |
| cancer cases | #14942 |
| incorporate | #14956 |
| emerged | #14959 |
| cancer diagnosis | #14977 |
| median | #15008 |
| colorectal carcinoma | #15030 |
| cognitive decline | #15047 |
| 07 | #15052 |
| premature | #15064 |
| overexpressing | #15067 |
| expected | #15111 |
| september | #15115 |
| proportions | #15119 |
| 011 | #15123 |
| medical | #15125 |
| 2 | #15153 |
| clear | #15163 |
| p004 | #15169 |
| colonoscopy | #15187 |
| assessments | #15187 |
| odds ratios | #15193 |
| replacement | #15198 |
| ganglia | #15220 |
| specific | #15227 |
| portion | #15240 |
| intervals | #15241 |
| acute | #15247 |
| agreed | #15266 |
| subjective | #15290 |
| area | #15293 |
| subgroups | #15325 |
| achieved | #15344 |
| proliferative | #15352 |
| routine | #15362 |
| releasing hormone | #15390 |
| 131 | #15404 |
| 197 | #15404 |
| 072 | #15431 |
| 070 | #15436 |
| december | #15459 |
| investigate | #15464 |
| reports | #15470 |
| 51 | #15487 |
| race | #15509 |
| education | #15510 |
| 1 | #15515 |
| medication | #15554 |
| basis | #15598 |
| standard | #15614 |
| life expectancy | #15626 |
| ranging | #15639 |
| safely | #15648 |
| estimate | #15652 |
| male | #15673 |
| survival benefit | #15674 |
| 24 months | #15681 |
| criteria | #15693 |
| 502 | #15702 |
| measuring | #15712 |
| animals antineoplastic | #15714 |
| individual | #15716 |
| offered | #15728 |
| option | #15749 |
| updated | #15749 |
| colon | #15751 |
| period | #15756 |
| nutrition | #15780 |
| antagonists | #15789 |
| globulin | #15792 |
| quartile | #15810 |
| nonparametric | #15815 |
| kappa | #15831 |
| rate treatment | #15867 |
| societies medical | #15873 |
| local | #15882 |
| glandular | #15882 |
| 87 | #15905 |
| focused | #15931 |
| pharmacokinetics | #15932 |
| longitudinally | #15937 |
| dfs | #15988 |
| phenomenon | #16013 |
| usa | #16013 |
| roughly | #16039 |
| distant metastasis | #16044 |
| squared | #16045 |
| improvement | #16107 |
| 118 | #16114 |
| 079 | #16120 |
| february | #16127 |
| naïve | #16154 |
| decision | #16179 |
| 95 patients | #16188 |
| 161 | #16209 |
| analysis survival | #16209 |
| drug interactions | #16211 |
| lung | #16212 |
| 081 | #16213 |
| supported | #16222 |
| neoadjuvant | #16222 |
| 162 | #16223 |
| serotonin | #16242 |
| cold | #16243 |
| cation | #16245 |
| cochrane library | #16265 |
| 93 | #16278 |
| alternatives | #16284 |
| exceeded | #16313 |
| colleagues | #16319 |
| neurotransmitter | #16320 |
| detection cancer | #16320 |
| channel blockers | #16348 |
| supplemented | #16355 |
| papillomavirus | #16362 |
| 14 patients | #16380 |
| excision | #16385 |
| releasing | #16393 |
| kras | #16396 |
| neoplasm grading | #16407 |
| progressively | #16413 |
| 0006 | #16416 |
| diagnostic imaging | #16418 |
| improvements | #16418 |
| osteonecrosis | #16452 |
| scales | #16460 |
| 30 | #16525 |
| protect | #16536 |
| declined | #16537 |
| ranged | #16562 |
| black | #16565 |
| support | #16576 |
| population surveillance | #16580 |
| improving | #16587 |
| 13 patients | #16588 |
| condition | #16625 |
| systematic review metaanalysis | #16649 |
| radiation | #16657 |
| understand | #16705 |
| male neoplasm | #16705 |
| tumor size | #16709 |
| treat | #16715 |
| mucosa | #16717 |
| broader | #16719 |
| broadly | #16748 |
| 082 | #16750 |
| 106 | #16760 |
| 10 years | #16780 |
| post operative | #16791 |
| mimic | #16818 |
| studying | #16832 |
| demonstrated | #16842 |
| bayes | #16878 |
| safety | #16885 |
| rarely | #16886 |
| major | #16886 |
| maintained | #16890 |
| inpatient | #16921 |
| aware | #16924 |
| drugs | #16939 |
| 67 | #16962 |
| depletion | #16977 |
| sex | #16982 |
| hormone | #16988 |
| confer | #16998 |
| hemoglobin | #17005 |
| 125 | #17019 |
| maximum | #17031 |
| muscles | #17039 |
| investigating | #17045 |
| issues | #17053 |
| neoadjuvant therapy | #17063 |
| genotype humans | #17068 |
| publication adaptation | #17073 |
| 84 | #17091 |
| directed | #17099 |
| iron deficiency | #17162 |
| diseasefree survival | #17162 |
| disseminated | #17164 |
| utilize | #17166 |
| feasible | #17197 |
| energy intake | #17217 |
| inconsistent | #17247 |
| mineral | #17315 |
| 088 | #17335 |
| valid | #17344 |
| tnfα | #17364 |
| percentage | #17396 |
| interleukin6 | #17416 |
| raf | #17421 |
| describing | #17520 |
| centered | #17529 |
| neck | #17557 |
| functioning | #17582 |
| locally | #17585 |
| physical activity | #17586 |
| survival outcomes | #17596 |
| traditional | #17602 |
| fact | #17609 |
| original | #17648 |
| 080 | #17655 |
| 2019 | #17720 |
| current evidence | #17735 |
| log | #17761 |
| adding | #17766 |
| unrelated | #17776 |
| carcinogenesis | #17789 |
| lactic | #17816 |
| impairment | #17825 |
| assayed | #17837 |
| decreased | #17874 |
| confirms | #17879 |
| 094 | #17886 |
| examination | #17892 |
| graded | #17909 |
| meta | #17936 |
| monoclonal antibodies | #17955 |
| 200 | #17981 |
| minimum | #18048 |
| clinical presentation | #18052 |
| structured | #18083 |
| primary prevention | #18124 |
| 48 | #18131 |
| primary tumors | #18132 |
| formulated | #18148 |
| il6 | #18159 |
| metastasis male | #18162 |
| bone | #18174 |
| medline | #18185 |
| uncommon | #18193 |
| mass screening | #18244 |
| 80 biomarkers | #18256 |
| critically | #18295 |
| assessing | #18322 |
| retinoic | #18359 |
| hazards models | #18394 |
| reporting | #18396 |
| healthrelated quality | #18416 |
| relationships | #18418 |
| respective | #18423 |
| carry | #18439 |
| humans intestinal | #18447 |
| 096 | #18450 |
| 83 | #18485 |
| staging prognosis | #18489 |
| consistently | #18499 |
| akt | #18504 |
| adjustment | #18519 |
| equal | #18526 |
| 2 years | #18534 |
| maintain | #18583 |
| negligible | #18617 |
| nutritional | #18643 |
| 003 | #18655 |
| address | #18711 |
| raised | #18739 |
| 3 patients | #18741 |
| meier estimate | #18762 |
| kaplan meier | #18769 |
| mucosal | #18825 |
| promising | #18832 |
| highlighted | #18856 |
| includes | #18858 |
| 098 | #18862 |
| chronic diseases | #18875 |
| poor | #18878 |
| hormones | #18887 |
| tailored | #18923 |
| status | #18942 |
| united states | #18948 |
| pyridines | #18950 |
| serum | #18956 |
| orr | #18990 |
| histologic | #19009 |
| stimulating | #19056 |
| dysfunction | #19111 |
| meier | #19125 |
| cohort | #19137 |
| inhibitor | #19177 |
| mood | #19177 |
| ≥ | #19195 |
| excessive | #19215 |
| irinotecan | #19250 |
| agents apoptosis | #19258 |
| consensus | #19281 |
| accepted | #19282 |
| candidate | #19292 |
| recombinant proteins | #19298 |
| recorded | #19302 |
| ovarian | #19337 |
| metaanalysis | #19377 |
| newly | #19381 |
| staging | #19391 |
| global | #19431 |
| evidenced | #19433 |
| fats | #19483 |
| inflammatory agents | #19496 |
| proportional hazards | #19507 |
| prone | #19520 |
| asymptomatic | #19544 |
| surgically | #19614 |
| hospitalized | #19617 |
| pretreated | #19680 |
| degree | #19687 |
| predicted | #19728 |
| adaptation psychological | #19769 |
| emotional | #19779 |
| making | #19782 |
| humans kaplan | #19803 |
| scored | #19840 |
| kaplan | #19866 |
| neoplasms carcinoma | #19874 |
| 3 year | #19944 |
| 1995 | #19991 |
| procedures | #20019 |
| 2002 | #20057 |
| cervical | #20082 |
| tumor necrosis factor | #20104 |
| observational studies | #20128 |
| randomised | #20168 |
| mediator | #20189 |
| beneficial | #20254 |
| 24 | #20258 |
| patients risk | #20262 |
| maximal | #20273 |
| log rank | #20282 |
| small | #20300 |
| endocrine | #20301 |
| rates | #20333 |
| involves | #20398 |
| allcause mortality | #20422 |
| exploring | #20500 |
| assess | #20503 |
| adjusting | #20553 |
| successful | #20677 |
| usual | #20690 |
| women aged | #20722 |
| 95 confidence interval | #20729 |
| invasiveness neoplasm | #20747 |
| addressing | #20782 |
| 19 | #20821 |
| concluded | #20831 |
| july | #20847 |
| node | #20854 |
| finding | #21019 |
| remaining | #21031 |
| relationship | #21070 |
| collected | #21085 |
| male mass | #21107 |
| reliable | #21137 |
| year | #21139 |
| january | #21202 |
| statistical | #21265 |
| 1999 | #21287 |
| absence | #21319 |
| mri | #21400 |
| comparison | #21403 |
| extended | #21420 |
| proportional | #21490 |
| feasibility | #21521 |
| rectal | #21541 |
| prognosis | #21551 |
| gradually | #21576 |
| implementing | #21589 |
| models male | #21936 |
| improved | #21939 |
| death | #21941 |
| apply | #21969 |
| morbidity | #22004 |
| intervention | #22038 |
| insulin growth | #22054 |
| verbal | #22139 |
| 10 patients | #22157 |
| urinary | #22186 |
| combination | #22213 |
| authors | #22223 |
| 2005 | #22223 |
| alterations | #22302 |
| aimed | #22386 |
| predictive tests | #22416 |
| event | #22426 |
| fibroblast | #22446 |
| reviewed | #22573 |
| status humans | #22597 |
| elevated | #22633 |
| frequent | #22673 |
| setting | #22759 |
| cox proportional | #22797 |
| malignancies | #22798 |
| allocated | #22808 |
| 95 | #22862 |
| imaging mri | #23033 |
| diverse | #23033 |
| superior | #23111 |
| post | #23144 |
| selected | #23153 |
| june | #23240 |
| surgical resection | #23266 |
| aged neoplasm | #23452 |
| persistent | #23460 |
| term | #23463 |
| represent | #23526 |
| antibodies monoclonal | #23543 |
| comprehensive | #23553 |
| continuously | #23560 |
| remained | #23674 |
| classified | #23739 |
| body | #23757 |
| strong | #23813 |
| monoclonal | #23861 |
| physical | #23883 |
| gastrointestinal | #23900 |
| exclude | #23924 |
| 2011 | #23997 |
| 2017 | #23997 |
| severely | #24141 |
| median follow | #24342 |
| partial | #24353 |
| abnormal | #24383 |
| systemic | #24466 |
| recruited | #24477 |
| general | #24560 |
| dietary | #24683 |
| 1996 | #24713 |
| carcinoma | #24787 |
| susceptible | #24878 |
| providing | #25068 |
| acids | #25078 |
| consistent | #25119 |
| implemented | #25293 |
| attributed | #25373 |
| 17 | #25476 |
| early | #25506 |
| markedly | #25526 |
| inhibition | #25536 |
| free | #25571 |
| lymph | #25627 |
| international | #25729 |
| regional | #25737 |
| sought | #25746 |
| selective | #25748 |
| 0003 | #25751 |
| single | #25859 |
| mechanism | #26084 |
| unclear | #26339 |
| putative | #26419 |
| surgery | #26438 |
| 13 | #26589 |
| unknown | #26785 |
| electronic | #26810 |
| predisposition disease | #26997 |
| accompanied | #26998 |
| multiple | #27050 |
| follow studies | #27065 |
| polymorphism single | #27142 |
| united | #27151 |
| histologically | #27323 |
| inherited | #27404 |
| neoplasm proteins | #27717 |
| prognosis retrospective | #27768 |
| systematic | #27775 |
| functional | #27808 |
| 0005 | #28001 |
| predisposition | #28007 |
| preoperative | #28036 |
| skeletal | #28185 |
| longitudinal | #28189 |
| estimated | #28229 |
| leads | #28238 |
| missing | #28264 |
| acid | #28356 |
| anti inflammatory | #28360 |
| correlate | #28365 |
| larger | #28581 |
| sex factors | #28629 |
| causing | #28688 |
| sensitivity | #28740 |
| vary | #28851 |
| 11 | #28869 |
| matched | #28979 |
| represents | #29258 |
| detection | #29343 |
| active | #29413 |
| differentiate | #29510 |
| objectives | #29543 |
| completely | #29721 |
| factual | #29750 |
| databases factual | #29793 |
| varied | #30036 |
| excluded | #30077 |
| quantified | #30091 |
| occurs | #30143 |
| adjusted | #30189 |
| logistic | #30241 |
| underlying | #30508 |
| allowed | #30520 |
| national | #30765 |
| odds | #30909 |
| 001 | #30996 |
| regression | #31005 |
| unchanged | #31053 |
| separately | #31068 |
| characterize | #31283 |
| recombinant | #31415 |
| adolescent | #31473 |
| dose dependent | #31787 |
| age | #31875 |
| lacking | #31939 |
| attenuated | #31971 |
| lower | #32078 |
| correlated | #32273 |
| postoperative | #32309 |
| negative | #32666 |
| growth factor | #33089 |
| positive | #33861 |
| understood | #33957 |
| confirmed | #33982 |
| reduced | #34048 |
| implicated | #34054 |
| confidence | #34153 |
| defined | #34517 |
| occur | #34659 |
| requires | #35112 |
| directly | #35347 |
| followup | #36532 |
| diagnosed | #36787 |
| suggesting | #37604 |
| remains | #37899 |
| multivariate | #38132 |
| independent | #38886 |
| measured | #38991 |
| proto oncogene | #39186 |
| proto | #39814 |
| biomarkers tumor | #39899 |
| examined | #40295 |
| retrospective studies | #42973 |
| underwent | #43365 |
| 95 confidence | #44196 |
运行报告 | |
Prominent publications by Charles L Loprinzi
KOL-Index: 16482
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.
Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.
Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United ...
| 闻名 Zoledronic Acid | Bone Metastases | 2 Years | Patients Breast Cancer | Skeletal Events |
KOL-Index: 16399
Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized ...
| 闻名 Postmenopausal Women | Bone Loss | Zoledronic Acid | Breast Cancer | Versus Delayed |
KOL-Index: 13693
PURPOSE: Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer.
PATIENTS AND METHODS: Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the ...
| 闻名 Bone Loss | Premenopausal Women | Breast Cancer | 1 Year | Bmd Baseline |
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
[ PUBLICATION ]
BACKGROUND: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have ...
| 闻名 Trpv1 Trpa1 | Transient Receptor | Cisplatin Oxaliplatin | Mechanical Allodynia | Treated Mice |
KOL-Index: 13187
PURPOSE: Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA.
PATIENTS AND METHODS: This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received ...
| 闻名 Oral Iron | Darbepoetin Alfa | Erythropoietic Response | Phase Iii | Ferric Gluconate |
KOL-Index: 12870
To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a ...
| 闻名 Cancer Cachexia | International Consensus | Definition Classification | Weight Loss | Reduced Food Intake |
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
[ PUBLICATION ]
PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain.
PATIENTS AND METHODS: Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis ...
| 闻名 Adjuvant Therapy | Nodal Status | Colon Cancer | Survival Stage | Pooled Analysis |
Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention
[ PUBLICATION ]
OBJECTIVE: To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention.
METHODS: Smokers were randomized to receive a nicotine inhaler, bupropion, or both for 3 months. At 3 months, smoking-abstinent study participants were randomized to their initial medications or placebo. Participants who were smoking at 3 months were randomized to an alternative treatment regimen or placebo. This study was conducted ...
| 闻名 Relapse Prevention | Nicotine Inhaler | Bupropion Placebo | Smoking Abstinence | Treatment Phase |
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
[ PUBLICATION ]
BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers.
METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of ...
| 闻名 Colorectal Adenomas | Patients Aspirin | Observational Studies | Relative Risks | Cancer Adenoma |
KOL-Index: 12619
BACKGROUND: Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting.
OBJECTIVE: To compare stool DNA and fecal blood testing for detection of screen-relevant neoplasia (curable-stage cancer, high-grade dysplasia, or adenomas >1 cm).
DESIGN: Blinded, multicenter, cross-sectional study.
SETTING: Communities surrounding 22 participating academic and regional health care systems in the United States.
PARTICIPANTS: 4482 ...
| 闻名 Stool Dna | Blood Test | Screen Detection | Colorectal Neoplasia | Humans Specificity |
Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging
[ PUBLICATION ]
PURPOSE: Recent changes have occurred in the presurgical planning for breast cancer, including the introduction of preoperative breast magnetic resonance imaging (MRI). We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN.
PATIENTS AND METHODS: We identified 5,405 patients who underwent surgery between 1997 and 2006. Patients undergoing MRI were identified from a prospective database. Trends in ...
| 闻名 Mastectomy Rates | Magnetic Resonance | Patients Mri | Surgery Type | Surgical Year |
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
[ PUBLICATION ]
PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer ...
| 闻名 Cancer Anorexia | Megestrol Acetate | Cachexia Patients | Progestational Agents | Corticosteroid Treatment |
KOL-Index: 12321
BACKGROUND: Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of ...
| 闻名 Megestrol Acetate | Hot Flashes | Women Breast Cancer | Deprivation Therapy | Weeks Placebo |
关键人物 Hot Flashes
世界顶级科尔斯
选择一个搜索短语 hot flashes , hot flashes women , hot flashes sweats , hot flashes patients , hot flashes hfs
Charles L Loprinzi:专家影响
哪个概念Charles L Loprinzi具有直接影响:Hot flashes, Breast cancer, Megestrol acetate, Peripheral neuropathy, Scrambler therapy, Phase iii, Newer antidepressants, Hot flash.
Charles L Loprinzi:KOL的影响
与其他作者的工作有关的概念for which Charles L Loprinzi 有影响力:Breast cancer, Hot flashes, Adjuvant chemotherapy, Quality life, Weight loss, Oral mucositis, Neuropathic pain.
Tools
这是您的个人资料吗？ 要求您的个人资料 复制URL 嵌入到您的个人资料的链接 |